<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006640.pub3" GROUP_ID="UPPERGI" ID="367006061511562198" MERGED_FROM="" MODIFIED="2014-11-14 14:04:10 +0000" MODIFIED_BY="Karin Dearness" REVIEW_NO="61" REVMAN_SUB_VERSION="5.3.4 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-11-14 14:04:10 +0000" MODIFIED_BY="Karin Dearness">
<TITLE>Tranexamic acid for upper gastrointestinal bleeding</TITLE>
<CONTACT MODIFIED="2014-11-14 14:04:10 +0000" MODIFIED_BY="Karin Dearness"><PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR"><FIRST_NAME>Lise Lotte</FIRST_NAME><LAST_NAME>Gluud</LAST_NAME><SUFFIX>M.D., Dr.Med.Sci.</SUFFIX><EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1><ADDRESS><DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT><ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION><ADDRESS_1>Kettegaards Alle</ADDRESS_1><CITY>Hvidovre</CITY><ZIP>2650</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>31353212</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-11-14 14:04:10 +0000" MODIFIED_BY="Karin Dearness"><PERSON ID="828110F882E26AA200E51E67E25FC1CF" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Cathy</FIRST_NAME><LAST_NAME>Bennett</LAST_NAME><POSITION>Visiting Professor</POSITION><EMAIL_1>info@systematicresearch.co.uk</EMAIL_1><EMAIL_2>info@systematicresearch.co.uk</EMAIL_2><ADDRESS><DEPARTMENT>Centre for Technology Enabled Health Research (CTEHR)</DEPARTMENT><ORGANISATION>Coventry University</ORGANISATION><ADDRESS_1>Priory Street</ADDRESS_1><CITY>Coventry</CITY><ZIP>CV1 5FB</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="13999" ROLE="AUTHOR"><FIRST_NAME>Sarah Louise</FIRST_NAME><LAST_NAME>Klingenberg</LAST_NAME><SUFFIX>Cand. scient.</SUFFIX><POSITION>Trials Search Coordinator</POSITION><EMAIL_1>slk@ctu.dk</EMAIL_1><ADDRESS><DEPARTMENT>Cochrane Hepato-Biliary Group</DEPARTMENT><ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION><ADDRESS_1>Blegdamsvej 9</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7168</PHONE_1><FAX_1>+45 3545 7101</FAX_1></ADDRESS></PERSON><PERSON ID="A71B94EE82E26AA20078D4E646E8A109" ROLE="AUTHOR"><FIRST_NAME>Ebbe</FIRST_NAME><LAST_NAME>Langholz</LAST_NAME><EMAIL_1>ebla@geh.regionh.dk</EMAIL_1><EMAIL_2>ebbe.langholz@regionh.dk</EMAIL_2><ADDRESS><DEPARTMENT>Department F, Gastroenterology Section</DEPARTMENT><ORGANISATION>Gentofte University Hospital</ORGANISATION><ADDRESS_1>Niels Andersensvej 65</ADDRESS_1><CITY>Hellerup</CITY><ZIP>2900</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 39773993</PHONE_1></ADDRESS></PERSON><PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR"><FIRST_NAME>Lise Lotte</FIRST_NAME><LAST_NAME>Gluud</LAST_NAME><SUFFIX>M.D., Dr.Med.Sci.</SUFFIX><EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1><ADDRESS><DEPARTMENT>Gastrounit, Medical Division</DEPARTMENT><ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION><ADDRESS_1>Kettegaards Alle</ADDRESS_1><CITY>Hvidovre</CITY><ZIP>2650</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>31353212</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-11-05 14:52:16 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="29" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="7" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2012"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>We originally planned to perform separate analyses on continued bleeding and rebleeding, but we were unable to extract the necessary data from the included trials</P>
<P>We have updated the assessment of bias according to the recommendations provided in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> of The Cochrane Collaboration</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>One additional randomised controlled trial has been included in the analyses. The addition of this trial has not changed our conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-07-01 15:06:02 +0100" MODIFIED_BY="Karin L Dearness"/>
<SOURCES_OF_SUPPORT MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<NAME>The present review did not receive funding</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-11-13 11:48:33 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">Tranexamic acid, an agent that promotes blood clotting, for serious or uncontrolled upper gastrointestinal bleeding</TITLE>
<SUMMARY_BODY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Upper gastrointestinal bleeding is a common reason for emergency hospital admission. The prognosis is serious. Some patients may die as the result of uncontrolled bleeding.</P>
<P>
<B>Review question</B>
</P>
<P>Tranexamic acid is an antifibrinolytic agent. This drug reduces the breakdown of fibrin; fibrin provides the framework for the formation of a blood clot, which is needed to stop the bleeding. Clinical trials suggest that tranexamic acid could reduce mortality in upper gastrointestinal bleeding.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This review includes data from eight randomised trials on tranexamic acid. Two trials also assessed antiulcer drugs. Only one trial used additional endoscopic therapy, as the remaining trials were performed before this intervention was introduced into clinical practice.</P>
<P>
<B>Key results</B>
</P>
<P>These trials found that tranexamic acid appears to have a beneficial effect on mortality, but a high dropout rate in some trials means that we cannot be sure of these findings until additional research is published . Tranexamic acid did not reduce mortality in the trials that included antiulcer drugs or endoscopic therapy. Additional randomised controlled trials are needed before we can determine whether tranexamic acid has a beneficial effect on serious or uncontrolled upper gastrointestinal bleeding.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Many patients who were randomly assigned were subsequently excluded from the assessment. The main source of bias was therefore attrition. The overall quality of the evidence was moderate to low.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-11-13 11:36:38 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-08-06 15:45:18 +0100" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid reduces haemorrhage through its antifibrinolytic effects. In a previous version of the present review, we found that tranexamic acid may reduce mortality. This review includes updated searches and new trials.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of tranexamic acid versus no intervention, placebo or other antiulcer drugs for upper gastrointestinal bleeding.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We updated the review by performing electronic database searches (Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Science Citation Index) and manual searches in July 2014.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials, irrespective of language or publication status.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We used the standard methodological procedures of the The Cochrane Collaboration. All-cause mortality, bleeding and adverse events were the primary outcome measures. We performed fixed-effect and random-effects model meta-analyses and presented results as risk ratios (RRs) with 95% confidence intervals (CIs) and used I² as a measure of between-trial heterogeneity. We analysed tranexamic acid versus placebo or no intervention and tranexamic acid versus antiulcer drugs separately. To analyse sources of heterogeneity and robustness of the overall results, we performed subgroup, sensitivity and sequential analyses.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-11-13 11:36:38 +0000" MODIFIED_BY="[Empty name]">
<P>We included eight randomised controlled trials on tranexamic acid for upper gastrointestinal bleeding. Additionally, we identified one large ongoing pragmatic randomised controlled trial from which data are not yet available. Control groups were randomly assigned to placebo (seven trials) or no intervention (one trial). Two trials also included a control group randomly assigned to antiulcer drugs (lansoprazole or cimetidine). The included studies were published from 1973 to 2011. The number of participants randomly assigned ranged from 47 to 216 (median 204). All trials reported mortality. In total, 42 of 851 participants randomly assigned to tranexamic acid and 71 of 850 in the control group died (RR 0.60, 95% CI 0.42 to 0.87; P value 0.007; I² = 0%). The analysis was not confirmed when all participants in the intervention group with missing outcome data were included as treatment failures, or when the analysis was limited to trials with low risk of attrition bias. Rebleeding was diagnosed for 117 of 826 participants in the tranexamic acid group and for 146 of 825 participants in the control group (RR 0.80, 95% CI 0.64 to 1.00; P value 0.07; I² = 49%). We were able to evaluate the risk of serious adverse events on the basis of only four trials. Our analyses showed 'no evidence of a difference between tranexamic acid and control interventions regarding the risk of thromboembolic events.' Tranexamic acid appeared to reduce the risk of surgery in a fixed-effect meta-analysis (RR 0.73, 95% CI 0.56 to 0.95), but this result was no longer statistically significant in a random-effects meta-analysis (RR 0.61, 95% CI 0.35 to 1.04; P value 0.07). No difference was apparent between tranexamic acid and placebo in the assessment of transfusion (RR 1.02, 95% CI 0.94 to 1.11; I² = 0%), and meta-analyses that compared tranexamic acid versus antiulcer drugs did not identify beneficial or detrimental effects of tranexamic acid for any of the outcomes assessed.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>This review found that tranexamic acid appears to have a beneficial effect on mortality, but a high dropout rate in some trials means that we cannot be sure of this until the findings of additional research are published. At the time of this update in 2014, one large study (8000 participants) is in progress, so this review will be much more informative in a few years. Further examination of tranexamic acid would require inclusion of high-quality randomised controlled trials. Timing of randomisation is essential to avoid attrition bias and to limit the number of withdrawals. Future trials may use a pragmatic design and should include all participants with suspected bleeding or with endoscopically verified bleeding, as well as a tranexamic placebo arm and co-administration of pump inhibitors and endoscopic therapy. Assessment of outcome measures in such studies should be clearly defined. Endoscopic examination with appropriate control of severe bleeding should be performed, as should endoscopic verification of clinically significant rebleeding. In addition, clinical measures of rebleeding should be included. Other important outcome measures include mortality (30-day or in-hospital), need for emergency surgery or blood transfusion and adverse events (major or minor).</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-11-13 11:48:33 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Upper gastrointestinal bleeding is a common reason for emergency hospital admission and a common complication in hospitalised patients (<LINK REF="REF-Rockall-1995" TYPE="REFERENCE">Rockall 1995</LINK>; <LINK REF="REF-Blatchford-1997" TYPE="REFERENCE">Blatchford 1997</LINK>). A systematic review of general, population-based epidemiological studies found that the incidence of upper gastrointestinal bleeding among patients treated with non-steroidal anti-inflammatory drugs was 0.8 per 1000 (<LINK REF="REF-Hernandez-2002" TYPE="REFERENCE">Hernandez 2002</LINK>). The risk of upper gastrointestinal bleeding has been found to increase significantly with age, co-morbidity and use of non-steroidal anti-inflammatory drugs (<LINK REF="REF-Yavorski-1995" TYPE="REFERENCE">Yavorski 1995</LINK>; <LINK REF="REF-Paspatis-2000" TYPE="REFERENCE">Paspatis 2000</LINK>; <LINK REF="REF-Ng-2006" TYPE="REFERENCE">Ng 2006</LINK>). About 80% of patients with upper gastrointestinal bleeding will spontaneously stop bleeding, without recurrence (<LINK REF="REF-Laine-1994" TYPE="REFERENCE">Laine 1994</LINK>). The highest mortality and morbidity rates are seen in the remaining 20%, who experience recurrent or continued bleeding. Among patients referred to endoscopy for suspected upper gastrointestinal bleeding, 30-day mortality is 10% to 14% (<LINK REF="REF-van-Leerdam-2003" TYPE="REFERENCE">van Leerdam 2003</LINK>; <LINK REF="REF-Barkun-2004" TYPE="REFERENCE">Barkun 2004</LINK>; <LINK REF="REF-Barkun-2010" TYPE="REFERENCE">Barkun 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Several endoscopic therapies have been found to be effective in clinical trials (<LINK REF="REF-Kahi-2005" TYPE="REFERENCE">Kahi 2005</LINK>). However, some hospital departments may not have access to acute endoscopy. In other cases, patients may refuse to undergo endoscopy. Identification of drugs that may achieve haemostasis, stabilising patients until endoscopy can be performed, is therefore essential.</P>
</INTERVENTION>
<THEORY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid reduces fibrinolysis by slowing down the conversion of plasminogen to plasmin. The resulting reduction in fibrinolysis prevents the breakdown of blood clots, which may result in haemostasis but increased risk of thromboembolic complications. This drug was introduced for menorrhagia in 1968 (<LINK REF="REF-Vermylen-1968" TYPE="REFERENCE">Vermylen 1968</LINK>) and is used to reduce blood loss during surgery (<LINK REF="REF-Laupacis-1997" TYPE="REFERENCE">Laupacis 1997</LINK>; <LINK REF="REF-Cid-2005" TYPE="REFERENCE">Cid 2005</LINK>). A large multi-centre trial found that tranexamic acid reduces mortality in individuals with bleeding trauma by 9% and results in no apparent increase in thromboembolic events (<LINK REF="REF-CRASH_x002d_2" TYPE="REFERENCE">CRASH-2</LINK>). It is possible that a similar effect can be achieved in cases of upper gastrointestinal bleeding.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Endoscopic therapy and proton pump inhibitors serve as the cornerstone in the treatment of bleeding from peptic ulcers (<LINK REF="REF-Lau-2013" TYPE="REFERENCE">Lau 2013</LINK>). These treatments are highlighted in recent evidence-based guidelines (<LINK REF="REF-Dworzynski-2012" TYPE="REFERENCE">Dworzynski 2012</LINK>), which do not recommend tranexamic acid for the management of upper gastrointestinal bleeding. Randomised trials have assessed the effects of tranexamic acid among patients with suspected or verified upper gastrointestinal bleeding (<LINK REF="STD-Cormack-1973" TYPE="STUDY">Cormack 1973</LINK>; <LINK REF="STD-Biggs-1976" TYPE="STUDY">Biggs 1976</LINK>; <LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>; <LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>; <LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). A meta-analysis of these trials revealed that tranexamic acid reduces the risks of rebleeding and mortality (<LINK REF="REF-Henry-1989" TYPE="REFERENCE">Henry 1989</LINK>). However, results of individual trials varied considerably. Furthermore, the overall result has been characterised as disproportionately skewed by inclusion of a trial in which mortality in the control group was surprisingly high (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="REF-Palmer-2002" TYPE="REFERENCE">Palmer 2002</LINK>). We have previously published a systematic review on tranexamic acid versus placebo (<LINK REF="REF-Gluud-2008" TYPE="REFERENCE">Gluud 2008</LINK>). A randomised trial on tranexamic acid for upper gastrointestinal bleeding was published after our previous meta-analysis had been completed (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). This trial was included in a recent review, which determined that we still have insufficient evidence for definitive conclusions (<LINK REF="REF-Manno-2014" TYPE="REFERENCE">Manno 2014</LINK>). We performed this updated systematic review on tranexamic acid versus placebo, cimetidine or lansoprazole for upper gastrointestinal bleeding.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of tranexamic acid versus no intervention, placebo or other antiulcer drugs for upper gastrointestinal bleeding.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-11-13 11:41:22 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trials, irrespective of language, blinding, length of follow-up or publication status.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Individuals with suspected or endoscopically verified upper gastrointestinal bleeding, irrespective of the bleeding source.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Primary analyses included trials on tranexamic acid versus placebo or no intervention. Secondary analyses compared tranexamic acid versus any other antiulcer drug.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Mortality.</LI>
<LI>Adverse events. We defined serious adverse events as all adverse events considered serious by study participants or investigators.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Rebleeding.</LI>
<LI>Surgery.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Electronic searches of the following were performed July 2014.</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) <B>(</B>
<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
<LI>MEDLINE via Ovid SP (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</LI>
<LI>EMBASE via Ovid SP (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</LI>
<LI>Science Citation Index Expanded (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</LI>
</UL>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We scanned conference proceedings and reference lists from relevant trials, wrote to authors of included trials and searched the International Clinical Trials Registry Platform (ICTRP) to identify trials on tranexamic acid (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-11-13 11:41:22 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Three review authors (LLG, SLK and CB) screened search results for potentially eligible trials and identified trials that were eligible for inclusion. Excluded trials were listed together with the reasons for exclusion. At each stage of the selection process, at least two review authors independently reviewed search results and selected trials for inclusion. Three review authors (LLG, SLK and CB) agreed on the final list.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors (LLG and SLK) independently extracted data using data collection forms designed to capture information specific to this review. CB verified the extracted data at this update. Disagreements were resolved through discussion before analyses were performed. Data on baseline participant characteristics (inclusion criteria, mean age, proportion of men and source of bleeding), dose and duration of treatment, country of origin, publication status, funding, duration of follow-up and risk of bias were gathered from the included trials and from correspondence with study authors. For trials published in Russian, two review authors (LLG and CB) extracted data obtained by machine translation (Google translate). Dimitrinka Nikolova from the Cochrane Hepato-Biliary Group read the original Russian language publication and verified the extracted data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>At least two review authors (LLG and SLK or CB) independently assessed risk of bias in the included studies by using the risk of bias assessment tool provided in Chapter 8 of the<I> Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We compared these evaluations and discussed and resolved inconsistencies.</P>
<P>We rated the following domains separately for each of the included studies as 'low risk of bias,' 'high risk of bias' or 'unclear risk of bias' if the risk of bias was uncertain or unknown. These assessments are reported in the 'Risk of bias' table for each individual study included in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section of the review.</P>
<UL>
<LI>Allocation sequence was adequately generated ('sequence generation').</LI>
<LI>Allocation was adequately concealed ('allocation concealment').</LI>
<LI>Knowledge of allocated interventions was adequately prevented during the study ('blinding') (whether the trial was described as double-blind or single-blind, and whether blinding involved healthcare providers, outcome assessors or those performing data extraction or data analysis).</LI>
<LI>Incomplete outcome data were adequately addressed.</LI>
<LI>Reports of the study were free of suggestions of selective outcome reporting (whether clinically relevant outcome measures were defined and reported).</LI>
<LI>The study was apparently free of other sources of bias that could put it at high risk of bias (e.g. potential conflicts of interest, pharmaceutical funding/support, or both).</LI>
<LI>Other biases (sample size calculations and registration in clinical trial databases).</LI>
</UL>
<P>We categorised and reported the overall risk of bias of each of the included studies according to the following.</P>
<UL>
<LI>Low risk of bias (plausible bias unlikely to seriously alter the results) if all criteria were met.</LI>
<LI>Unclear risk of bias (plausible bias that raises some doubt about the results) if one or more criteria were assessed as unclear.</LI>
<LI>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more criteria were not met.</LI>
</UL>
<P>We reported these assessments in the <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> section of this review.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>The effect measure consisted of risk ratios (RRs) with 95% confidence intervals (CIs).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>As the primary outcome measure was mortality, only trials using a parallel-group design were included. Data on all intervention groups were analysed separately for all trials, including those with more than two parallel arms. Risk of selection bias was noted in the allocation of participants to intervention or control groups and in the administration of collateral interventions; therefore we did not include cluster-randomised trials.</P>
<SUBSECTION>
<HEADING LEVEL="4">Multi-armed trials</HEADING>
<P>For trials with multiple intervention groups, we partitioned participants into individual allocation arms to perform pair-wise comparisons. For example, a three-arm trial with 30 participants (10 in each arm) allocated to tranexamic acid versus placebo versus antiulcer drugs would allow two pair-wise comparisons of tranexamic acid versus placebo (10 vs 10 participants) and tranexamic acid versus antiulcer drugs (10 vs 10 participants).</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We contacted study investigators to request data on all randomly assigned participants to perform intention-to-treat analyses. We used simple imputation to evaluate the potential influence of missing data: imputing failures, imputing successes and worst- and best-case scenarios (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed clinical heterogeneity by examining trial conditions on the basis of characteristics of included trials, participants and interventions. We assessed statistical heterogeneity by using I<SUP>2</SUP> statistical values and reported heterogeneity as important when the I² statistic was &gt; 60% (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We attempted to obtain trial protocols to compare reported outcome measures in the protocol versus those in the published trial. For analyses with at least 10 trials, we planned to assess reporting biases and other dissemination biases by using funnel plots (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and to perform regression analyses by using Harbord's modified test (<LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>). Our analyses included only eight trials; therefore we did not carry out a statistical analysis of reporting bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We performed analyses in <LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK> (The Nordic Cochrane Centre, Copenhagen, Denmark), STATA version 13 (Stata Corp., Texas, USA) and Trial Sequential Analysis (The Cochrane Hepato-Biliary Group, Copenhagen, Denmark). We performed all meta-analyses using both random-effects and fixed-effect models. Fixed-effect model meta-analyses are reported only when the results of the two models differ (e.g. one model shows no difference between interventions and the other shows an intervention effect).</P>
<P>We report the results of analyses with the total number of participants. When it was possible to calculate an effect size, we report this with 95% confidence intervals. When the calculated effect size was statistically significant (defined as P value &lt; 0.05), we state whether the result favoured the intervention or control condition.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We performed separate analyses of trials on tranexamic acid versus placebo or no intervention and trials on tranexamic acid versus antiulcer drugs, as well as subgroup analyses of trials with low risk of bias based on assessment of the separate domains. We also analysed subgroups of trials that used endoscopic therapy and trials published in English or Russian.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-11-13 11:41:22 +0000" MODIFIED_BY="[Empty name]">
<P>We performed two further analyses to determine the effects of missing outcome data and a per-protocol analysis to evaluate the influence of missing data. In the first scenario, all participants in the intervention arm with missing outcome data were included as treatment failures and participants in the control group with missing outcome data were considered as treatment successes. In the per-protocol analyses, we excluded participants with missing outcome data. We performed a post hoc analysis that excluded a trial with a very high event rate in the control group (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>We performed a post hoc trial sequential analysis to determine the risk of bias associated with cumulative testing and to evaluate futility in the assessment of mortality and bleeding (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). We performed the analysis with power set to 80%, alpha to 5% and model-based diversity and with relative risk reduction (RRR) to 30%. We set the control incidence to 10% for the analysis of mortality and to 30% for the analysis of bleeding.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' tables</HEADING>
<P>We prepared a 'Summary of findings' table (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) using GRADEpro software (<LINK REF="REF-Gradepro-3.6" TYPE="REFERENCE">Gradepro 3.6</LINK>) and we included information on the results of our primary outcomes in relation to risk of heterogeneity, duration of follow-up and quality of the evidence.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>The original electronic searches identified 84 hits, and the updated search 37 hits (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>). The manual search identified one additional record. After reading the titles and abstracts, we retrieved 15 records for further assessment. One record referred to an ongoing trial (<LINK REF="STD-ISRCTN11225767" TYPE="STUDY">ISRCTN11225767</LINK>) on tranexamic acid for gastrointestinal bleeding (<LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>). We will include this trial in future updates if the results become available (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We excluded four records that did not assess tranexamic acid for upper gastrointestinal bleeding. In total, we included eight randomised controlled trials in our analyses (<LINK REF="STD-Cormack-1973" TYPE="STUDY">Cormack 1973</LINK>; <LINK REF="STD-Biggs-1976" TYPE="STUDY">Biggs 1976</LINK>; <LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>; <LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>; <LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). We received additional information about study design and outcomes from the primary investigators of one of the included trials (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). For the remaining trials, we had access only to published data. The included trials were published as full paper articles, from 1973 to 2011. One trial was published in Russian (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>), and the remaining in English.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All trials were randomised, parallel arm. One trial was open (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>), and the remaining trials were double blind with a placebo control.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>The numbers of participants randomly assigned ranged from 47 to 216 (median 204).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>All trials were performed at hospitals.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The trials included participants admitted with suspected upper gastrointestinal bleeding confirmed by endoscopy or clinically through gastric lavage, hematemesis or melena. Participants with previous or ongoing thromboembolic disease or renal disease and pregnant women were excluded from the trials. Three trials included only participants with severe bleeding (<LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>; <LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>; <LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). In the remaining trials, proportions of participants with circulatory involvement ranged from 1% to 21%. Mean participant age ranged from 56 to 62 years in the tranexamic acid groups and from 56 to 65 years in the control groups. Five trials reported that a proportion of participants had oesophageal varices (mean proportion 8%, range 5% to 16%). In four trials (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>), participants underwent endoscopy within 24 hours after admission. One trial reported that 12% of included participants did not undergo the planned endoscopy. Two trials evaluated participants with endoscopy but did not specify the time frame (<LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>; <LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>). The remaining two trials did not include an endoscopic evaluation (<LINK REF="STD-Cormack-1973" TYPE="STUDY">Cormack 1973</LINK>) or had access to endoscopy only during a portion of the trial (<LINK REF="STD-Biggs-1976" TYPE="STUDY">Biggs 1976</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Tranexamic acid was administered intravenously in one trial (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>) and orally in three trials (<LINK REF="STD-Cormack-1973" TYPE="STUDY">Cormack 1973</LINK>; <LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). The remaining trials used intravenous followed by oral administration. The total daily dose of tranexamic acid ranged from 4 to 8 g. Duration of therapy ranged from two to seven days.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<P>One trial included a no intervention control group (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>), and the remaining trials included a placebo control. Two trials were multi-armed and included control groups randomly assigned to the histamine receptor (H2) agonist cimetidine (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>) or the proton pump inhibitor lansoprazole alone or with tranexamic acid (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). One trial allowed co-intervention with the histamine receptor agonist famotidine (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). In five trials, a variety of co-interventions, including novaluzide and cimetidine or ranitidine, were administered to participants in both treatment arms (<LINK REF="STD-Cormack-1973" TYPE="STUDY">Cormack 1973</LINK>; <LINK REF="STD-Biggs-1976" TYPE="STUDY">Biggs 1976</LINK>; <LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>; <LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>; <LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>). Two trials used endoscopic therapy to control bleeding (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>One trial reported endoscopically verified rebleeding (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). Another trial reported rebleeding as assessed by hematemesis, melena or hypotension plus a drop in haemoglobin or rebleeding seen at endoscopy (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). Two trials defined rebleeding on the basis of a drop in haemoglobin (<LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>) or a drop in haemoglobin, hematemesis or melena (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>). The remaining trials did not define rebleeding.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded four trials that were published as full paper articles (<LINK REF="STD-Hollanders-1982" TYPE="STUDY">Hollanders 1982</LINK>; <LINK REF="STD-Tam-1989" TYPE="STUDY">Tam 1989</LINK>; <LINK REF="STD-Adachi-2001" TYPE="STUDY">Adachi 2001</LINK>; <LINK REF="STD-Sabovic-2003" TYPE="STUDY">Sabovic 2003</LINK>). These trials were excluded because they were observational, assessed certrexate or did not include participants with upper gastrointestinal bleeding (<LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>One trial (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>) reported an adequate method for allocation sequence generation (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). The remaining trials did not describe how the allocation sequence was generated. One trial did not describe how allocation was concealed (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). In the remaining trials, allocation was adequately concealed through double-blind administration of the intervention or placebo.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-08-06 08:47:51 +0100" MODIFIED_BY="[Empty name]">
<P>One trial was open (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). The remaining trials were double blind with a placebo control.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Attrition was one of the main sources of bias. Five trials reported losses to follow-up (<LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>; <LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>; <LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). Three trials gave the impression that no dropouts or withdrawals had occurred, although this was not specifically reported (<LINK REF="STD-Cormack-1973" TYPE="STUDY">Cormack 1973</LINK>; <LINK REF="STD-Biggs-1976" TYPE="STUDY">Biggs 1976</LINK>; <LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). One in five participants (20%) were withdrawn or excluded after randomisation. Reasons for exclusion included lack of verified bleeding, malignant disease and terminal illness, or the treatment was administered too late.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>One trial did not report bleeding and was classed as having high risk of reporting bias (<LINK REF="STD-Bergqvist-1980" TYPE="STUDY">Bergqvist 1980</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-07-29 14:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>None of the trials had other potential sources of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1. Tranexamic acid versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality</HEADING>
<P>All trials reported mortality (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Forty-two of 851 participants randomly assigned to tranexamic acid and 71 of 850 in the control group died. The fixed-effect meta-analysis showed that tranexamic acid reduced mortality (RR 0.60, 95% CI 0.42 to 0.87; P value 0.007). No statistical heterogeneity was noted between trials (I² = 0%).</P>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity analyses and trial sequential analysis</HEADING>
<P>The analysis was not confirmed in a scenario analysis in which all participants with missing outcome data were included as treatment failures (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), but it was confirmed in a per-protocol analysis (data not shown).</P>
<P>Analyses of studies with low risk of bias confirmed that attrition was the main source of bias (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). The single remaining trial with low risk of attrition bias (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) found no effects of the intervention. A similar result was seen when trials that used endoscopic therapy to control bleeding were analysed (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). No difference (test for subgroup differences P value 0.67) was noted between trials published in English and those translated from Russian (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>One of the trials has been criticised for reporting a high control group event rate (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="REF-Palmer-2002" TYPE="REFERENCE">Palmer 2002</LINK>). This trial included 516 participants and reported a large weight in the analysis (49%). In a post hoc analysis that excluded this trial, tranexamic acid was seen to have no effect on mortality (RR 0.73, 95% CI 0.45 to 1.19; analysis not shown). In our post hoc trial sequential analysis (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), the required information size was not met, suggesting that the meta-analysis is inconclusive.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Bleeding</HEADING>
<P>Seven trials reported rebleeding (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). In total, rebleeding was diagnosed for 117 of 826 participants in the tranexamic acid group and for 146 of 825 participants in the control group.</P>
<SUBSECTION>
<HEADING LEVEL="6">Sensitivity analyses and trial sequential analysis</HEADING>
<P>The difference was not statistically significant (RR 0.72, 95% CI 0.50 to 1.03; P value 0.07). A similar conclusion was reached in worst-case scenario analysis (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>) and per-protocol analysis (data not shown). Analyses of trials with low risk of bias found no effects of tranexamic acid on bleeding (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), and no differences were noted between trials stratified according to use of endoscopic therapy (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) or language (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). In the trial sequential analysis (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), 95% of the required information size was reached. This analysis suggested that the meta-analysis was inconclusive.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Several participants randomly assigned to tranexamic acid experienced abdominal pain, nausea, vomiting and thrombophlebitis at the injection site (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). We were unable to perform meta-analyses on these adverse events because data were not provided for both treatment and control groups.</P>
<P>Three trials (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>) on 1048 participants reported thromboembolic events (<LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>; <LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>). Among participants randomly assigned to tranexamic acid, two cases of myocardial infarction, two cases of pulmonary embolism and one case of cerebral infarction occurred. In the placebo group, two cases of myocardial infarction and two cases of cerebral infarction were recorded. When data on these serious thromboembolic events were combined, the difference was not statistically significant (RR 1.37, 95% CI 0.36 to 5.28; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). Six cases of deep venous thrombosis occurred among participants randomly assigned to tranexamic acid compared with two cases in the placebo group (RR 2.32, 95% CI 0.60 to 8.89; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>). The numbers of participants with any thrombotic event were not significantly different between treatment and control groups (RR 1.86, 95% CI 0.66 to 5.24; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Surgery</HEADING>
<P>Seven studies with 1551 participants reported the numbers of participants who required surgery (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). Between-trial heterogeneity was important (I² = 63%). Tranexamic acid appeared to reduce the risk of surgery in a fixed-effect meta-analysis (RR 0.73, 95% CI 0.56 to 0.95), but this result was no longer statistically significant at the 5% level, when a random-effects meta-analysis was used (RR 0.61, 95% CI 0.35 to 1.04; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Transfusions</HEADING>
<P>We planned to analyse the transfusion requirements of included participants, but we did not identify the necessary data. We therefore performed a post hoc analysis of the total numbers of participants who needed at least one blood transfusion (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>) and found no apparent differences between tranexamic acid and placebo (RR 1.02, 95% CI 0.94 to 1.11 in 931 participants; five studies; I² = 0%).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2. Tranexamic acid versus antiulcer drugs (cimetidine or lansoprazole)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Mortality and rebleeding</HEADING>
<P>Two trials compared tranexamic acid with cimetidine (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>) or lansoprazole (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). These trials found no significant effects of tranexamic acid on mortality (RR 0.91, 95% CI 0.50 to 1.64; 720 participants; I² = 0%; <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) or bleeding (RR 0.87, 95% CI 0.64 to 1.20; I² = 0%; <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>We were unable to perform meta-analyses on adverse events (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). <LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK> reported one case of fatal stroke in the tranexamic acid group and two cases of confusion in the control group. <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK> reported no adverse events in the tranexamic acid or control groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Surgery and transfusions</HEADING>
<P>Trials comparing tranexamic acid versus cimetidine or lansoprazole (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) found no differences between allocation groups regarding the need for surgery (RR 0.83, 95% CI 0.54 to 1.26; 720 participants; two studies; I² = 3%; <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) or blood transfusion (RR 0.97, 95% CI 0.78 to 1.22; 720 participants; two studies; I² = 64%; <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">'Summary of findings' tables</HEADING>
<P>As shown in the 'Summary of findings' tables on tranexamic acid versus placebo (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) or cimetidine or lansoprazole (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>), the quality of the evidence was downgraded to moderate or low because of risk of bias.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-11-13 11:46:54 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2014-11-13 11:43:07 +0000" MODIFIED_BY="[Empty name]">
<P>This review includes eight randomised controlled trials and a total of 1701 participants with acute upper gastrointestinal bleeding. The meta-analyses found that tranexamic acid appears to have a beneficial effect on mortality, but a high dropout rate in some trials means that we cannot be sure of this until additional research is published. Reduced mortality did not clearly reflect reduced bleeding or surgery. The result of the primary meta-analysis was not stable in analyses that adjusted for risk of attrition bias or in trial sequential analyses. When trials with high risk of attrition bias were removed, only one trial was left (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) in the analysis, so although we may need to be cautious about the potential effects of dropouts, the evidence is still fairly strong in favour of tranexamic acid. Likewise, only two of the included trials used endoscopic therapy (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>; <LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). These trials found no clear effects of tranexamic acid on bleeding was noted and that attrition bias may affect the assessment of mortality, therefore the combined evidence does not allow any recommendations to be made. Additional randomised controlled trials are needed to determine the effects of tranexamic acid. A large randomised double-blind trial on tranexamic acid for gastrointestinal bleeding is ongoing (<LINK REF="STD-ISRCTN11225767" TYPE="STUDY">ISRCTN11225767</LINK>). This trial has started to randomly assign the first participants. Results of this trial are expected to finally confirm or refute the effects of tranexamic acid for individuals with upper gastrointestinal bleeding.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>During recent years, standard care and assessment of outcomes have changed considerably (<LINK REF="REF-Dworzynski-2012" TYPE="REFERENCE">Dworzynski 2012</LINK>). Previously, patients were not offered full diagnostic endoscopy or endoscopic interventions that are used as standard care today. It is noteworthy that the trial that is the most favourable towards tranexamic acid was published in 1983 (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>). The clinical question today is not whether tranexamic acid is better than placebo, but whether tranexamic acid is better than or may be used in combination with current treatments. One of the included trials found no significant difference between tranexamic acid and lansoprazole when used alone, or when the two treatments were combined (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). This trial was not designed to assess clinical outcomes, and its statistical power may well have been too small to detect clinically relevant effects. On the other hand, this trial does suggest that additional research is necessary.</P>
<P>Several reasons may explain why we found that tranexamic acid reduces mortality but not bleeding. One possible explanation is that tranexamic acid may be effective in subgroups of patients with a serious prognosis. One of the included trials assessed the influence of the severity of bleeding on the intervention effect (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). This trial included 414 participants with suspected upper gastrointestinal bleeding and asked admitting investigators to classify participant risk as high or low on the basis of their presentation. No specific criteria were used. Overall, high-risk participants were more likely to die or need surgery. The effect of tranexamic acid was not related to risk stratification.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-11-13 11:46:08 +0000" MODIFIED_BY="[Empty name]">
<P>In clinical guidelines on the management of upper gastrointestinal non-variceal bleeding, tranexamic acid may be considered, but it is not recommended as routine therapy (<LINK REF="REF-Palmer-2002" TYPE="REFERENCE">Palmer 2002</LINK>; <LINK REF="REF-Barkun-2003" TYPE="REFERENCE">Barkun 2003</LINK>). This treatment generally is not recommended for variceal bleeding, and in several trials, participants with varices were excluded after randomisation. However, meta-analyses in the present review include participants with upper gastrointestinal bleeding due to oesophageal varices. No significant association was found between treatment effect and the proportion of participants with varices. These analyses are only hypothesis generating but suggest that the effects of tranexamic acid on mortality may also be seen in this patient group. Likewise, we found no significant differences between trials in which participants received tranexamic acid in a daily dose of 12 g for two days and those in which the dose was 4 g for seven days. It may be interesting to determine whether dose or treatment duration is related to the risk of thromboembolic events, but we did not have sufficient data to analyse this question.</P>
<P>Vested interests were reported in some of the included trials. We were unable to identify specific design features that introduced bias due to vested interests and the fact that we included only eight trials limited the possibility of further analyses. Nevertheless, we cannot exclude that this factor can lead to bias. On the other hand, the trial that received full funding (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>) found no effect of tranexamic acid on any of the outcomes assessed.The largest trials received tranexamic acid and placebo from pharmaceutical companies (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>; <LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>). The trial with the most positive assessment of tranexamic acid received only medications (<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>).</P>
<P>Mortality is an outcome measure that is relatively stable in relation to performance and ascertainment bias, but not to attrition bias. We found that attrition was the main source of bias. Included trials randomly assigned participants early, and many excluded participants after the source of bleeding had been identified by endoscopy. Exclusion of participants appeared to be done before blinding was broken, although this is not specifically stated. As the result of risk of bias and clinical heterogeneity between trials, which is inevitable given that trials were conducted over several decades, the overall quality of the evidence was deemed moderate or low (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-11-13 11:46:54 +0000" MODIFIED_BY="[Empty name]">
<P>Potential biases in the review process are limited. In particular, we attempted to avoid bias in identification and selection of trials, but one possible limitation is that despite exhaustive searching, it is possible that other trials have been conducted, and although we searched extensively, we did not identify unpublished trials or trials published in abstract form. We included only one paper that was published in Russian (<LINK REF="STD-Bagnenko-2011" TYPE="STUDY">Bagnenko 2011</LINK>). Remaining trials were published in English. Because the number of identified trials was limited, we were not able to analyse the risk of publication bias. In theory, meta-analyses are observational, which may lead to biases. A written protocol is necessary to determine biases in the review process and in general, the original protocol must be followed. However, we made methodological changes to our protocol that were based on recent evidence and guidelines (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>; <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). These changes were mainly related to assessment of risk of bias. We also performed post hoc sequential analyses to improve assessment of biases.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Although our review methods did include assessment of all reported adverse events, we did not carry out a separate search for adverse effects; therefore one of the most important limitations of the present review is the fact that information about adverse events was limited. The recent debate on the use of antifibrinolytic drugs highlights the need for valid safety data. In 2006, an observational study of patients undergoing revascularisation was reported (<LINK REF="REF-Mangano-2006" TYPE="REFERENCE">Mangano 2006</LINK>). This study included 1295 participants who received aprotinin and 822 who received tranexamic acid. Multi-variable analyses found that aprotinin, but not tranexamic acid, significantly increased the risk of renal failure and cardiovascular or cerebral adverse events. Although results support the safety of tranexamic acid, the participant cohort was considerably different from that included in the present review. In particular, the trials included in the present review excluded participants with previous thromboembolic or renal disease. Therefore, it may be argued that one of the most important limitations of the present review is that limited information about adverse events was available. Although we found no significant association between tranexamic acid and risk of thromboembolic events, our analyses did not have sufficient statistical power to allow clear inferences. Theoretically, tranexamic acid increases the risk of thrombosis due to unopposed fibrin generation. Case reports have associated tranexamic acid with thromboembolic events, which may be fatal (<LINK REF="REF-Rydin-1976" TYPE="REFERENCE">Rydin 1976</LINK>; <LINK REF="REF-Agnelli-1982" TYPE="REFERENCE">Agnelli 1982</LINK>; <LINK REF="REF-Endo-1988" TYPE="REFERENCE">Endo 1988</LINK>; <LINK REF="REF-Woo-1989" TYPE="REFERENCE">Woo 1989</LINK>; <LINK REF="REF-Taparia-2002" TYPE="REFERENCE">Taparia 2002</LINK>). The trials in the present review excluded participants with previous thromboembolic events, although this is not generally accepted as a contraindication in clinical practice. Likewise these trials excluded participants with renal disease. One observational study has assessed the effects of tranexamic acid on patients undergoing dialysis. Tranexamic acid seems relatively safe to use in this patient group. However, the study included only 20 participants, so additional evidence is needed (<LINK REF="STD-Sabovic-2003" TYPE="STUDY">Sabovic 2003</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-11-13 11:48:33 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>This review found no evidence to support or refute the use of tranexamic acid for upper gastrointestinal bleeding, in terms of mortality, bleeding, surgery or transfusion requirements. We found limited information about adverse events. At present, tranexamic acid cannot be recommended for routine clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-11-13 11:48:33 +0000" MODIFIED_BY="[Empty name]">
<P>This review found no evidence that tranexamic acid offers benefit to patients with upper gastrointestinal bleeding in terms of mortality, bleeding, surgery or requirement for blood transfusion. At the time of this update in 2014, additional large pragmatic randomised trials seem warranted. We are aware of one large study (8000 participants) that is in progress, so this review will be much more informative in a few years. However, proton pump inhibitors and endoscopic interventions for severe gastrointestinal bleeding, including injection and thermal and mechanical methods such as haemoclips, may serve as alternative effective interventions (<LINK REF="REF-Dworzynski-2012" TYPE="REFERENCE">Dworzynski 2012</LINK>).</P>
<P>Further examination of the efficacy and safety of tranexamic acid would involve high-quality randomised controlled trials. The timing of randomisation is essential in avoiding attrition bias and limiting the number of withdrawals. The trial may use a pragmatic design and include all participants with suspected bleeding based on haemoglobin levels, gastric lavage, hematemesis or melena. Alternatively, only participants with endoscopically verified bleeding may be randomly assigned. The pragmatic approach could mean inclusion of participants with concomitant disease who may have higher risk of bleeding. When such participants are excluded from trials, we may overestimate benefits and underestimate adverse events. Therefore the advantage of a pragmatic approach would be that investigators could assess whether the intervention works in these patients, that is, such trials would have high external validity.</P>
<P>Future trials should assess tranexamic acid delivered orally or intravenously over an appropriate length of time. The trials included in this review assessed a daily dose of up to 16 to 42 g. A placebo arm (for comparison with tranexamic acid) should be included, and interventions should be administered in accordance with current treatment recommendations. Accordingly, co-interventions such as proton pump inhibitors and endoscopic therapy must be offered. Assessment of outcome measures should be clearly defined, and reports of adverse events should be included. Endoscopic examination with appropriate control of severe bleeding should be included, and endoscopic verification of clinically significant rebleeding should be performed. In addition, clinical measures of rebleeding should be included. Other important outcome measures include mortality (30-day or in-hospital), along with need for emergency surgery, blood transfusion and adverse events (major or minor).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-11-13 11:40:46 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Dr GM Hawkey (<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>), who responded to our request for additional data and Dimitrinka Nikolova of the Cochrane Hepato-Biliary Group for translations.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>None of the review authors has reported any conflicts of interest with regard to the present work.</P>
<P>CB is the proprietor of Systematic Research Ltd and was paid by the CUGPD Editorial Group for her contributions to this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>LLG drafted the review and performed the statistical analyses. SLK and ELA participated in interpretation of the results and revision of the review. All review authors have approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>We updated the review in 2014 to comply with MECIR standards for the conduct and reporting of systematic reviews. We updated the format of the review for clarity and provided the following information about our methods.</P>
<UL>
<LI>We included adverse effects as a primary outcome (formerly a secondary outcome) to comply with recent guidance on conduct and presentation of the systematic review.</LI>
<LI>We clarified that because of the risk of selection bias in the allocation of participants to intervention or control groups and bias in the administration of collateral interventions, we did not include cluster-randomised trials.</LI>
<LI>For trials with multiple intervention groups, we partitioned the numbers of participants in individual allocation arms into pair-wise comparisons.</LI>
<LI>We used simple imputation to evaluate the potential influence of missing data: imputing failures, imputing successes, worst- and best-case.</LI>
<LI>We provided additional explanations of our assessment and reporting of heterogeneity for clarity; our methods remain unchanged.</LI>
<LI>We performed all meta-analyses using both random-effects and fixed-effect models. Fixed-effect meta-analyses are reported only when results of the two models differ (e.g. one model shows no difference between interventions and the other shows an intervention effect).</LI>
<LI>We performed separate analyses of trials on tranexamic acid versus placebo or no intervention and trials on tranexamic acid versus antiulcer drugs. We performed subgroup analyses of trials with low risk of bias based on assessment of the separate domains. We also analysed subgroups of trials that used endoscopic therapy and trials published in English or Russian.</LI>
<LI>We performed an analysis when all participants with missing outcome data were included as treatment failures, and we used a per-protocol analysis to evaluate the influence of missing data when we excluded participants with missing outcome data.</LI>
<LI>For analyses with at least 10 trials, we planned to assess reporting biases and other dissemination biases on the basis of funnel plots (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and regression analyses by using Harbord's modified test (<LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>). Our analyses included only eight trials; therefore we did not carry out statistical analysis of reporting bias.</LI>
<LI>We performed a post hoc trial sequential analysis to evaluate the risk of bias associated with cumulative testing and to evaluate futility in assessment of mortality and bleeding (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). We performed the analysis with power set to 80%, alpha to 5%, model-based diversity and relative risk reduction (RRR) to 25%. We set the control group incidence to 8% in our analysis of mortality and to 18% in our analysis of bleeding.</LI>
<LI>We prepared a 'Summary of findings' table (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>) using GRADEpro software (<LINK REF="REF-Gradepro-3.6" TYPE="REFERENCE">Gradepro 3.6</LINK>) and included information on results of our primary outcomes in relation to risk of heterogeneity, duration of follow-up and quality of the evidence.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-08-06 16:11:14 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-08-06 16:11:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bagnenko-2011" MODIFIED="2014-08-06 16:11:14 +0100" MODIFIED_BY="[Empty name]" NAME="Bagnenko 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-08-06 16:11:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bagnenko SF, Verbitskii VG</AU>
<TI>[Antifibrinolitic therapy for the treatment of massive ulcerative gastro-intestinal bleedings]</TI>
<SO>Khirurgiia</SO>
<YR>2011</YR>
<VL>4</VL>
<PG>42-6</PG>
<IDENTIFIERS MODIFIED="2014-07-29 08:36:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21721282"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barer-1983" MODIFIED="2009-07-13 10:32:19 +0100" MODIFIED_BY="[Empty name]" NAME="Barer 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-07-13 10:32:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barer D, Ogilvie A, Henry D, Dronfield M, Coggon D, French S, et al</AU>
<TI>Cimetidine and tranexamic acid in the treatment of acute upper-gastrointestinal-tract bleeding</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>308</VL>
<PG>1571-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogilvie AL, Barer D, Dronfield MW</AU>
<TI>Trial of cimetidine, tranexamic acid and placebo in the management of acute upper gastrointestinal haemorrhage [abstract]</TI>
<SO>Gut</SO>
<YR>1981</YR>
<VL>22</VL>
<PG>F20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1980" NAME="Bergqvist 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Dahlgren S, Hessman Y</AU>
<TI>Local inhibition of the fibrinolytic system in patients with massive upper gastrointestinal hemorrhage</TI>
<SO>Uppsala Journal of Medical Sciences</SO>
<YR>1980</YR>
<VL>85</VL>
<PG>173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biggs-1976" NAME="Biggs 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biggs JC, Hugh TB, Dodds AJ</AU>
<TI>Tranexamic acid and upper gastrointestinal haemorrhage - a double-blind trial</TI>
<SO>Gut</SO>
<YR>1976</YR>
<VL>17</VL>
<PG>729-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cormack-1973" NAME="Cormack 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cormack F, Chakrabarti RR, Jouhar AJ, Fearnley GR</AU>
<TI>Tranexamic acid in upper gastrointestinal haemorrhage</TI>
<SO>Lancet</SO>
<YR>1973</YR>
<VL>1</VL>
<PG>1207-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Engquist-1979" NAME="Engquist 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Engqvist A, Brostrom O, von Feilitzen F, Halldin M, Nystrom B, Ost A, et al</AU>
<TI>Tranexamic acid in massive haemorrhage from the upper gastrointestinal tract: a double-blind study</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>1979</YR>
<VL>14</VL>
<PG>839-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawkey-2001" NAME="Hawkey 2001" YEAR="49">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawkey GM, Cole AT, McIntyre AS, Long RG, Hawkey CJ</AU>
<TI>Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points</TI>
<SO>Gut</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>372-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holstein-1987" MODIFIED="2011-11-30 02:46:23 +0000" MODIFIED_BY="Karin L Dearness" NAME="Holstein 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-11-30 02:46:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>von Holstein CC, Eriksson SB, Kallen R</AU>
<TI>Tranexamic acid as an aid to reducing blood transfusion requirements in gastric and duodenal bleeding</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>1987</YR>
<VL>294</VL>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-07-01 14:59:23 +0100" MODIFIED_BY="Karin L Dearness" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Holstein CC, Eriksson SB, Kallen R</AU>
<TI>Tranexamic acid in gastric and duodenal bleeding</TI>
<SO>Scandinavian Journal of Gastroenterology. Supplement</SO>
<YR>1987</YR>
<VL>137</VL>
<PG>71-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-07-27 12:28:01 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adachi-2001" NAME="Adachi 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;BACKGROUND AND AIM: Helicobacter pylori (H. pylori) infection is known to affect&lt;br&gt;the gastric microcirculation, and cetraxate is reported to accelerate gastric&lt;br&gt;ulcer healing, possibly by augmenting gastric mucosal blood flow (MBF). The aim&lt;br&gt;of this study is to clarify the effect of H. pylori infection and cetraxate on&lt;br&gt;MBF during gastric ulcer healing. METHODS: Forty-two patients who had undergone endoscopic mucosal resection (EMR) were studied. Mucosal blood flow was measured by the use of a laser Doppler flowmeter in the surrounding mucosa and at the ulcer margin, before, 1 day, 1 week and 4 weeks after EMR. Helicobacter pylori infection was confirmed by the use of bacterial culture and histology. After EMR, patients were randomly assigned to receive 30 mg lansoprazole (u.i.d; L-regimen) or 30 mg lansoprazole (u.i.d.) with 200 mg cetraxate (q.i.d; LC-regimen) for 4 weeks. RESULTS: The MBF ratio (MBF at ulcer margin/MBF in surrounding mucosa) 1 week after EMR was significantly lower than that before or 4 weeks after EMR only in H. pylori-positive patients treated with the L-regimen. No such decrease in MBF was observed after 1 week in H.&lt;br&gt;pylori-positive patients treated with the LC-regimen or in H. pylori-negative&lt;br&gt;patients. CONCLUSION: A transient decrease in MBF was detected at the ulcer&lt;br&gt;margin during healing of EMR-induced ulcers in H. pylori-infected patients.&lt;br&gt;Cetraxate seemed to prevent this decrease in MBF.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adachi K, Suetsugu H, Moriyama N, Kazumori H, Kawamura A, Fujishiro H, et al</AU>
<TI>Influence of Helicobacter pylori infection and cetraxate on gastric mucosal blood flow during healing of endoscopic mucosal resection-induced ulcers</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>1211-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hollanders-1982" MODIFIED="2009-07-01 09:46:12 +0100" MODIFIED_BY="[Empty name]" NAME="Hollanders 1982" YEAR="1982">
<REFERENCE MODIFIED="2009-07-01 09:46:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hollanders D, Thomson JM, Schofield PF</AU>
<TI>Tranexamic acid therapy in ulcerative colitis</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1982</YR>
<VL>58</VL>
<NO>676</NO>
<PG>87-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sabovic-2003" MODIFIED="2011-11-30 02:48:29 +0000" MODIFIED_BY="[Empty name]" NAME="Sabovic 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-11-30 02:48:29 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;BACKGROUND: In a pilot, non-randomized trial we tested the efficacy of&lt;br&gt;tranexamic acid (TXA), a potent fibrinolytic inhibitor, as adjunctive therapy in&lt;br&gt;standard treatment of major upper gastrointestinal bleeding in dialysis&lt;br&gt;patients. METHODS: Twenty consecutive patients (12 male, eight female; 63+/-8&lt;br&gt;years) with 36 episodes of major upper gastrointestinal bleeding were included&lt;br&gt;in the study. In 16 episodes of bleeding TXA was used (in a dosage of 20 mg&lt;br&gt;intravenously, followed for the next 4 weeks by 10 mg/kg/48 h orally), whereas&lt;br&gt;in 20 other cases of bleeding, TXA was not used. The decision to use TXA was&lt;br&gt;left to the attending physician's clinical judgement, resulting in all the more&lt;br&gt;severe cases of bleeding being treated with TXA. RESULTS: Treatment including&lt;br&gt;TXA was shown to be beneficial (relative to cases not treated with TXA) in terms&lt;br&gt;of decreasing the rate of early re-bleeding (in the first week, 0 vs 6, P&amp;lt;0.05),&lt;br&gt;the rate of early and late re-bleeding (in the first month, 1 vs 8, P&amp;lt;0.05), the&lt;br&gt;rate of repeated endoscopic procedures (in the first month, 1 vs 8, P&amp;lt;0.05) and&lt;br&gt;the number of blood transfusions needed (in the first month, 1.4+/-1.3 vs&lt;br&gt;2.6+/-1.5 units, P&amp;lt;0.05). CONCLUSIONS: The results of this pilot study suggest&lt;br&gt;that TXA can be beneficial in the treatment of major upper gastrointestinal&lt;br&gt;bleeding in dialysis patients. This remains to be definitely confirmed in a&lt;br&gt;randomized study.&lt;/p&gt;" NOTES_MODIFIED="2011-11-30 02:48:29 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sabovic M, Lavre J, Vujkovac B</AU>
<TI>Tranexamic acid is beneficial as adjunctive therapy in treating major upper gastrointestinal bleeding in dialysis patients</TI>
<SO>Nephrology, Dialysis, Transplantation</SO>
<YR>2003</YR>
<VL>18</VL>
<PG>1388-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tam-1989" NAME="Tam 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Forty-nine Chinese patients, ages 65 years or over, with endoscopically and&lt;br&gt;pathologically diagnosed benign gastric ulcer, completed a randomized&lt;br&gt;double-blind double dummy trial in treatment with either cetraxate 200 mg four&lt;br&gt;times daily or ranitidine 150 mg two times daily for 12 weeks or less if the&lt;br&gt;gastric ulcer had completely healed. All patients tolerated the procedure well.&lt;br&gt;At the end of the 4th, 8th, and 12th weeks ulcer healing was complete in 2 (8%),&lt;br&gt;11 (42%), and 17 (65%), respectively, of the cetraxate group (26 patients); and&lt;br&gt;in 8 (35%), 18 (78%), and 22 (96%), respectively, of the ranitidine group (23&lt;br&gt;patients). All the differences in the healing rates were statistically&lt;br&gt;significant. Pain relief was significantly earlier with ranitidine. Incidences&lt;br&gt;of side effects were similar and not serious in the two groups. The results&lt;br&gt;suggest that at the doses prescribed to the elderly, ranitidine is significantly&lt;br&gt;more effective than cetraxate in gastric ulcer healing and pain relief.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tam HC, Lee YC, Wong HY, Ng NS</AU>
<TI>Healing of gastric ulcer in the elderly: a double-blind study of cetraxate versus ranitidine</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-07-29 08:10:23 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ISRCTN11225767" MODIFIED="2014-07-29 08:10:23 +0100" MODIFIED_BY="[Empty name]" NAME="ISRCTN11225767" YEAR="2013">
<REFERENCE MODIFIED="2014-07-29 08:10:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<TI>Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial</TI>
<SO>ISRCTN</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-07-29 08:09:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-07-29 08:09:31 +0100" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="11225767"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Agnelli-1982" MODIFIED="2009-07-01 09:53:03 +0100" MODIFIED_BY="[Empty name]" NAME="Agnelli 1982" TYPE="JOURNAL_ARTICLE">
<AU>Agnelli G, Gresele P, De Cunto M, Gallai V, Nenci GG</AU>
<TI>Tranexamic acid, intrauterine contraceptive devices and fatal cerebral arterial thrombosis. Case report</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1982</YR>
<VL>89</VL>
<PG>681-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkun-2003" MODIFIED="2009-07-01 09:52:42 +0100" MODIFIED_BY="[Empty name]" NAME="Barkun 2003" TYPE="JOURNAL_ARTICLE">
<AU>Barkun A, Bardou M, Marshall JK; Nonvariceal Upper GI Bleeding Consensus Conference Group</AU>
<TI>Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<PG>843-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barkun-2004" MODIFIED="2011-11-30 02:49:15 +0000" MODIFIED_BY="[Empty name]" NAME="Barkun 2004" TYPE="JOURNAL_ARTICLE">
<AU>Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, et al</AU>
<TI>The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>7</NO>
<PG>1238-46</PG>
<IDENTIFIERS MODIFIED="2011-10-05 14:25:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="15233660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Barkun-2010" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NAME="Barkun 2010" TYPE="JOURNAL_ARTICLE">
<AU>Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P; International Consensus Upper Gastrointestinal Bleeding Conference Group</AU>
<TI>International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2010</YR>
<VL>152</VL>
<PG>101-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blatchford-1997" MODIFIED="2011-11-30 02:49:34 +0000" MODIFIED_BY="[Empty name]" NAME="Blatchford 1997" TYPE="JOURNAL_ARTICLE">
<AU>Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J</AU>
<TI>Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>510-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cid-2005" NAME="Cid 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cid J, Lozano M</AU>
<TI>Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials</TI>
<SO>Transfusion</SO>
<YR>2005</YR>
<VL>45</VL>
<PG>1302-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CRASH_x002d_2" MODIFIED="2011-11-30 02:50:02 +0000" MODIFIED_BY="[Empty name]" NAME="CRASH-2" TYPE="JOURNAL_ARTICLE">
<AU>CRASH-2 Collaborators</AU>
<TI>Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study)</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d3795</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="21724564"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dworzynski-2012" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NAME="Dworzynski 2012" TYPE="JOURNAL_ARTICLE">
<AU>Dworzynski K, Pollit V, Kelsey A, Higgins B, Palmer K</AU>
<TI>Management of acute upper gastrointestinal bleeding: summary of NICE guidance</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2012</YR>
<VL>344</VL>
<PG>e3412</PG>
<IDENTIFIERS MODIFIED="2014-08-06 08:21:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22695897"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Endo-1988" MODIFIED="2009-07-01 09:53:28 +0100" MODIFIED_BY="[Empty name]" NAME="Endo 1988" TYPE="JOURNAL_ARTICLE">
<AU>Endo Y, Nishimura S, Miura A</AU>
<TI>Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura</TI>
<SO>JAMA</SO>
<YR>1988</YR>
<VL>259</VL>
<PG>3561-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gradepro-3.6" MODIFIED="2014-07-26 15:24:03 +0100" MODIFIED_BY="[Empty name]" NAME="Gradepro 3.6" TYPE="COMPUTER_PROGRAM">
<TI>GRADEpro. [Computer program]. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008</TI>
<YR>2008</YR>
<PB>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7650</NO>
<PG>924-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="18436948"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2014-07-26 15:16:21 +0100" MODIFIED_BY="[Empty name]" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="16345038"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henry-1989" MODIFIED="2014-07-27 12:27:12 +0100" MODIFIED_BY="[Empty name]" NAME="Henry 1989" TYPE="JOURNAL_ARTICLE">
<AU>Henry DA, O'Connell DL</AU>
<TI>Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>1989</YR>
<VL>298</VL>
<PG>1142-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hernandez-2002" NAME="Hernandez 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez-Diaz S, Rodriguez LA</AU>
<TI>Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2002</YR>
<VL>55</VL>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]</TI>
<SO>The Cochrane Colloboration, 2008. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kahi-2005" NAME="Kahi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kahi CJ, Jensen DM, Sung JJ, Bleau BL, Jung HK, Eckert G, et al</AU>
<TI>Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>129</VL>
<PG>855-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laine-1994" MODIFIED="2011-10-14 14:57:50 +0100" MODIFIED_BY="[Empty name]" NAME="Laine 1994" TYPE="JOURNAL_ARTICLE">
<AU>Laine L, Peterson WL</AU>
<TI>Bleeding peptic ulcer</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>331</VL>
<NO>11</NO>
<PG>717-27</PG>
<IDENTIFIERS MODIFIED="2011-10-05 14:15:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8058080"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lau-2013" MODIFIED="2014-08-06 08:26:11 +0100" MODIFIED_BY="[Empty name]" NAME="Lau 2013" TYPE="JOURNAL_ARTICLE">
<AU>Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS, Chan FK</AU>
<TI>Challenges in the management of acute peptic ulcer bleeding</TI>
<SO>Lancet</SO>
<YR>2013</YR>
<VL>381</VL>
<NO>9882</NO>
<PG>2033-43</PG>
<IDENTIFIERS MODIFIED="2014-08-06 08:26:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="23746903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Laupacis-1997" MODIFIED="2009-07-01 09:54:48 +0100" MODIFIED_BY="[Empty name]" NAME="Laupacis 1997" TYPE="JOURNAL_ARTICLE">
<AU>Laupacis A, Fergusson D</AU>
<TI>Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1997</YR>
<VL>85</VL>
<PG>1258-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mangano-2006" NAME="Mangano 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mangano DT, Tudor IC, Dietzel C</AU>
<TI>The risk associated with aprotinin in cardiac surgery</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>353-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manno-2014" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NAME="Manno 2014" TYPE="JOURNAL_ARTICLE">
<AU>Manno D, Ker K, Roberts I</AU>
<TI>How effective is tranexamic acid for acute gastrointestinal bleeding?</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>2014</YR>
<VL>348</VL>
<PG>g1421</PG>
<IDENTIFIERS MODIFIED="2014-08-06 08:29:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="24535627"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ng-2006" MODIFIED="2009-07-01 09:55:41 +0100" MODIFIED_BY="[Empty name]" NAME="Ng 2006" TYPE="JOURNAL_ARTICLE">
<AU>Ng W, Wong WM, Chen WH, Tse HF, Lee PY, Lai KC, et al</AU>
<TI>Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>12</VL>
<PG>2923-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2002" MODIFIED="2009-07-01 09:55:19 +0100" MODIFIED_BY="[Empty name]" NAME="Palmer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Palmer KR</AU>
<TI>Non-variceal upper gastrointestinal haemorrhage: guidelines</TI>
<SO>Gut</SO>
<YR>2002</YR>
<VL>Suppl 4</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paspatis-2000" MODIFIED="2009-07-01 09:56:30 +0100" MODIFIED_BY="[Empty name]" NAME="Paspatis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Paspatis GA, Matrella E, Kapsoritakis A, Leontithis C, Papanikolaou N, Chlouverakis GJ, et al</AU>
<TI>An epidemiological study of acute upper gastrointestinal bleeding in Crete, Greece</TI>
<SO>European Journal of Gastroenterology &amp; Hepatology</SO>
<YR>2000</YR>
<VL>12</VL>
<PG>1215-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2014-07-24 13:51:45 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>Version 5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rockall-1995" MODIFIED="2011-11-30 02:52:27 +0000" MODIFIED_BY="[Empty name]" NAME="Rockall 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rockall TA, Logan RF, Devlin HB, Northfield TC</AU>
<TI>Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage</TI>
<SO>BMJ (Clinical Research Edition)</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rydin-1976" MODIFIED="2009-07-01 09:55:23 +0100" MODIFIED_BY="[Empty name]" NAME="Rydin 1976" TYPE="JOURNAL_ARTICLE">
<AU>Rydin E, Lundberg PO</AU>
<TI>Tranexamic acid and intracranial thrombosis</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taparia-2002" MODIFIED="2009-07-01 09:55:27 +0100" MODIFIED_BY="[Empty name]" NAME="Taparia 2002" TYPE="JOURNAL_ARTICLE">
<AU>Taparia M, Cordingley FT, Leahy MF</AU>
<TI>Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia</TI>
<SO>European Journal of Haematology</SO>
<YR>2002</YR>
<VL>68</VL>
<PG>307-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Leerdam-2003" MODIFIED="2011-11-30 02:52:54 +0000" MODIFIED_BY="[Empty name]" NAME="van Leerdam 2003" TYPE="JOURNAL_ARTICLE">
<AU>van Leerdam ME, Vreeburg EM, Rauws EA, Geraedts AA, Tijssen JG, Reitsma JB, et al</AU>
<TI>Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000</TI>
<SO>The American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>7</NO>
<PG>1494-9</PG>
<IDENTIFIERS MODIFIED="2011-10-05 14:24:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="12873568"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vermylen-1968" NAME="Vermylen 1968" TYPE="JOURNAL_ARTICLE">
<AU>Vermylen J, Verhaegen-Declercq ML, Fierens F, Verstraete M</AU>
<TI>A double blind study of the effect of tranexamic acid in essential menorrhagia</TI>
<SO>Bulletin de la Société Royale Belge de Gynécologie et D'Obstétrique</SO>
<YR>1968</YR>
<VL>38</VL>
<PG>385-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2010-06-12 19:42:11 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woo-1989" NAME="Woo 1989" TYPE="JOURNAL_ARTICLE">
<AU>Woo KS, Tse LK, Woo JL, Vallance-Owen J</AU>
<TI>Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1989</YR>
<VL>43</VL>
<PG>465-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yavorski-1995" NAME="Yavorski 1995" TYPE="JOURNAL_ARTICLE">
<AU>Yavorski RT, Wong RK, Maydonovitch C, Battin LS, Furnia A, Amundson DE</AU>
<TI>Analysis of 3,294 cases of upper gastrointestinal bleeding in military medical facilities</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>1995</YR>
<VL>90</VL>
<PG>568-73</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-10-14 14:55:05 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gluud-2008" MODIFIED="2011-10-14 14:55:05 +0100" MODIFIED_BY="[Empty name]" NAME="Gluud 2008" TYPE="JOURNAL_ARTICLE">
<AU>Gluud LL, Klingenberg SL, Langholz E</AU>
<TI>Systematic review: tranexamic acid for upper gastrointestinal bleeding</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2008</YR>
<VL>27</VL>
<PG>752-8</PG>
<IDENTIFIERS MODIFIED="2010-06-26 16:58:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-10-04 15:34:37 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Endoscopy" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Definition of re-bleeding" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Duration of therapy">
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bagnenko-2011">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial on tranexamic acid vs no intervention</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with endoscopically verified severe upper gastrointestinal bleeding</P>
<P>Number of participants randomly assigned: 47<BR/>Mean age tranexamic acid/control: 62/64 years<BR/>Proportion:</P>
<UL>
<LI>of men: 62%</LI>
<LI>with peptic ulcer: 100%</LI>
<LI>with oesophageal varices: 0%</LI>
<LI>with massive bleeding: 100%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 10 mg/kg IV or oral 3 times/d vs no intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality, rebleeding and surgery</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Performed within 24 hours of admission</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Endoscopically verified bleeding</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>3 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>No funding reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barer-1983">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial on tranexamic acid vs cimetidine vs placebo<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with upper gastrointestinal bleeding confirmed by observation of haematemesis or melena<BR/>Number of participants randomly assigned: 516</P>
<P>Mean age: 60-63 years<BR/>Proportion:</P>
<UL>
<LI>of men: 65%</LI>
<LI>with peptic ulcer: 58%</LI>
<LI>with oesophageal varices: 5%</LI>
<LI>with massive bleeding: 13%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 1 g IV 4 times/d then 1 g orally 4 times/d vs cimetidine 400 mg IV 4 times/d then 400 mg orally 4 times/d vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality, rebleeding, surgery and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Performed within 24 hours of admission</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Severe hematemesis or fresh melena or a fall in haemoglobin of at least 2 g/dL within 24 hours after the first day of admission</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-07-29 12:21:42 +0100" MODIFIED_BY="[Empty name]">
<P>7 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Kabi Vitrum Ltd and Smith Kline and French supplied medications; details of funding not supplied</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bergqvist-1980">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial on tranexamic acid vs placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with massive upper gastrointestinal bleeding confirmed by haematemesis or melena and circulatory involvement (criteria not specified)<BR/>Number of participants randomly assigned: 50</P>
<P>Mean age tranexamic acid/placebo: 61/58 years<BR/>Proportion:</P>
<UL>
<LI>of men: 79%</LI>
<LI>with peptic ulcer: 65%</LI>
<LI>with oesophageal varices: 7%</LI>
<LI>with massive bleeding: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 2 g orally 6 times daily vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality and surgery</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Performed after admission (time frame not specified)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>2 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>No funding reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Biggs-1976">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial comparing tranexamic acid vs placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with upper gastrointestinal bleeding observed by medical officer or confirmed by gastric lavage or observation of melena<BR/>Number of participants randomly assigned: 200</P>
<P>Mean age: not reported<BR/>Proportion:</P>
<UL>
<LI>of men: 78%</LI>
<LI>with peptic ulcer: 54%</LI>
<LI>with oesophageal varices: 6%</LI>
<LI>with massive bleeding: 21%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 1 g IV and 1 g orally 4 times/d then 1 g orally 4 times/d vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality, rebleeding, surgery and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Some participants were evaluated with full endoscopy (time frame and number not specified). Early in the trial, endoscopy was unavailable</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Not described</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>5 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Funding from Fauldings Australia Ltd</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cormack-1973">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial comparing tranexamic acid vs placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with upper gastrointestinal bleeding confirmed by haematemesis or melena<BR/>Number of participants randomly assigned: 150</P>
<P>Mean age: not reported<BR/>Proportion of:</P>
<UL>
<LI>men: 67%</LI>
<LI>with peptic ulcer: not reported</LI>
<LI>with oesophageal varices: not reported</LI>
<LI>with massive bleeding: 11%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 1.5 g orally 4 times/d vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality. Continued bleeding, rebleeding and surgery reported only as a composite outcome</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Not performed</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Not defined</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>7 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Funding from AB Kabi, Stockholm, Sweden</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Engquist-1979">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial comparing tranexamic acid vs placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with massive upper gastrointestinal bleeding defined as circulatory embarrassment, loss of 1800 mL blood (4 blood units), or haemoglobin concentration lowered by at least 30 g/L<BR/>Number of participants randomly assigned: 204</P>
<P>Mean age tranexamic acid/placebo: 59/56 years<BR/>Proportion:</P>
<UL>
<LI>of men: 78%</LI>
<LI>with peptic ulcer: 47%</LI>
<LI>with oesophageal varices: 16%</LI>
<LI>with massive bleeding: 100%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 1 g IV 6 times/d then 1.5 g orally 4 times/d vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Mortality, bleeding, surgery and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Performed (time frame not specified)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Not defined</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>7 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Funding not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hawkey-2001">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial comparing tranexamic acid alone vs lansoprazole vs tranexamic acid and lansoprazole vs placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with suspected upper gastrointestinal bleeding</P>
<P>Number of participants randomly assigned: 206</P>
<P>Mean age tranexamic acid/control groups: 58/58 years<BR/>Proportion:</P>
<UL>
<LI>of men: 61%</LI>
<LI>with peptic ulcer: 37%</LI>
<LI>with oesophageal varices: 14%</LI>
<LI>with massive bleeding: 16%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 2 g orally (bolus) then 1 g orally 4 times/d vs lansoprazole 60 mg orally (bolus) then 30 mg orally vs tranexamic acid and lansoprazole vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>All-cause mortality, bleeding-related mortality and surgery. Adverse events are reported without information about intervention arms<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Endoscopy was performed on the day after admission or earlier for 359 of 414 included participants. The number of participants who were not evaluated with endoscopy was 12 for placebo and 21 for tranexamic acid</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>New haematemesis, melena or hypotension plus a drop in haemoglobin or rebleeding seen at endoscopy</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>4 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Funding from Lederle Laboratories</P>
<P>Additional data received</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Holstein-1987">
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial comparing tranexamic acid vs placebo</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: patients admitted with suspected (criteria not specified) upper gastrointestinal bleeding. After randomisation, endoscopy was performed, and all patients without a benign gastric or duodenal bleeding source were excluded<BR/>Number of participants randomly assigned: 128</P>
<P>Mean age tranexamic acid/placebo: 62/65 years<BR/>Proportion:</P>
<UL>
<LI>of men: 70%</LI>
<LI>with peptic ulcer: 90%</LI>
<LI>with oesophageal varices: 0%</LI>
<LI>with massive bleeding: 1%</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid 1 g IV 6 times/d then 1.5 g orally 4 times/d vs placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Mortality, bleeding, surgery and adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Performed within 24 hours of admission</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Drop in haemoglobin of at least 20 g/L</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>6 days</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>KabiVitrum AB supplied tranexamic acid and placebo and gave advice about the trial design</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IV: intravenous.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Adachi-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised trial on lansoprazole alone or with cetraxate for healing of peptic ulcers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hollanders-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial on tranexamic acid for ulcerative colitis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sabovic-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial on tranexamic acid as adjunctive therapy for upper gastrointestinal bleeding in patients with renal failure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tam-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial on cetraxate vs ranitidine for treatment of patients with gastric ulcer</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Target sample size" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Sponsor" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Conditions assessed">
<ONGOING_CHAR MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN11225767">
<CHAR_STUDY_NAME MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double-blind placebo-controlled trial (Haemorrhage ALleviation with Tranexamic acid? IntesTinal system HALT-IT)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Inclusion criteria: all adult patients with acute significant upper or lower gastrointestinal bleeding when the responsible clinician is substantially uncertain as to the appropriateness of antifibrinolytic agents in the patient</LI>
</UL>
<UL>
<LI>Exclusion criteria: fundamental eligibility criterion: the responsible clinician's 'uncertainty' as to whether an antifibrinolytic agent should be used in a particular patient with upper or lower gastrointestinal bleeding</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 3 g over 24 hours) or matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-07-29 08:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>Death in hospital within 28 days of randomisation (cause-specific mortality will also be recorded)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Date of first enrolment: January 2 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-07-29 08:18:00 +0100" MODIFIED_BY="[Empty name]">
<P>Professor Ian Roberts, haltit@lshtm.ac.uk</P>
<P>Ms Haleema Shakur, haltit@lshtm.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>8000 participants</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-07-29 08:12:16 +0100" MODIFIED_BY="[Empty name]">
<P>London School of Hygiene and Tropical Medicine (UK)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-07-29 08:15:37 +0100" MODIFIED_BY="[Empty name]">
<P>Upper and lower gastrointestinal bleeding</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Funded by Health Technology Assessment programme, which is part of the National Institute for Health Research (NIHR), UK</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>Allocation sequence based on random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>Not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>Central packaging of coded drug containers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>Blinded administration of tranexamic acid or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>Blinded administration of tranexamic acid or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>Blinded administration of tranexamic acid or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>Blinded administration of tranexamic acid or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Blinded administration of tranexamic acid or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>Blinded administration of tranexamic acid or placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.06 CMP-001.14 CMP-001.15 CMP-001.11 CMP-001.12 CMP-001.13 CMP-002.02 CMP-002.03 CMP-002.04">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>Double blinding (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>Double-blind placebo-controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>Double blinding (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>Double blinding (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>Double blinding (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Double blinding (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>Double blinding (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>Participants and personnel blinded (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>Participants and personnel blinded (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>Participants and personnel blinded (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>Participants and personnel blinded (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>Participants and personnel blinded (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Participants and personnel blinded (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>Participants and personnel blinded (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>Open</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>Outcomes assessed in a blinded manner (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>Outcomes assessed in a blinded manner (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>Outcomes assessed in a blinded manner (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>Outcomes assessed in a blinded manner (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>Outcomes assessed in a blinded manner (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Outcomes assessed in a blinded manner (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>Outcomes assessed in a blinded manner (using placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>In total, 99 participants were excluded after randomisation. Reporting of follow-up and handling of missing outcome data are clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>Outcomes for participants who were excluded or withdrawn from treatment (14%) are not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>No withdrawals or exclusions are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>No withdrawals or dropouts are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>Outcome measures are not reported for participants who were withdrawn or excluded (27%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Although several participants were withdrawn or lost to follow-up, all randomly assigned participants are accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>Outcome measures are not reported for participants who were excluded or lost to follow-up (47%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>Mortality and bleeding are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>Mortality and bleeding are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>Continued bleeding or rebleeding is not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>Mortality and bleeding are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>Mortality and bleeding are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>Mortality and bleeding are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>Mortality and bleeding are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>Mortality and bleeding are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bagnenko-2011">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barer-1983">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bergqvist-1980">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Biggs-1976">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cormack-1973">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Engquist-1979">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hawkey-2001">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Holstein-1987">
<DESCRIPTION>
<P>No other apparent biases are reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">Tranexamic acid vs placebo for upper gastrointestinal bleeding</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>Tranexamic acid vs placebo for upper gastrointestinal bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with upper gastrointestinal bleeding<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> tranexamic acid vs placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Tranexamic acid vs placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality</B>
<BR/>Clinical<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.6 </B>
<BR/>(0.42-0.87)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1701<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>84 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
<BR/>(34-72)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
<BR/>(34-71)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Rebleeding</B>
<BR/>Clinical and endoscopic assessment<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.72 </B>
<BR/>(0.50-1.03)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1651<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>a,b,c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>177 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>142 per 1000</B>
<BR/>(113-177)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>196 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>157 per 1000</B>
<BR/>(125-196)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Any thromboembolic event</B>
<BR/>Clinical and radiological assessment<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.86 </B>
<BR/>(0.66-5.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1095<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>20 per 1000</B>
<BR/>(7-57)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>10 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
<BR/>(7-52)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Surgery</B>
<BR/>Number of participants who underwent surgery<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.61 </B>
<BR/>(0.35-1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1551<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>142 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>103 per 1000</B>
<BR/>(79-135)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>154 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>112 per 1000</B>
<BR/>(86-146)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Transfusion</B>
<BR/>Number needing blood transfusion<BR/>Follow-up: median 3 weeks</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.02 </B>
<BR/>(0.94-1.1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>931<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>a,d</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>564 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>558 per 1000</B>
<BR/>(507-620)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>583 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>577 per 1000</B>
<BR/>(525-641)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>Most trials had high risk of attrition bias.<BR/>
<SUP>b</SUP>Not possible to evaluate because number of trials was limited.<BR/>
<SUP>c</SUP>Statistical between-trial heterogeneity approached 50%.<BR/>
<SUP>d</SUP>The number of participants who needed transfusion is an indirect measure of bleeding and varies among clinical sites.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">Tranexamic acid vs cimetidine or lansoprazole for upper gastrointestinal bleeding</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Tranexamic acid vs cimetidine or lansoprazole for upper gastrointestinal bleeding</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with upper gastrointestinal bleeding<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> tranexamic acid vs cimetidine or lansoprazole<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Number of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Tranexamic acid vs cimetidine or lansoprazole</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality</B>
<BR/>Number of participants who died<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.91 </B>
<BR/>(0.50-1.64)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>720<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>61 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>56 per 1000</B>
<BR/>(31-101)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>48 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
<BR/>(24-79)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Rebleeding</B>
<BR/>Clinical and endoscopic assessment<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.87 </B>
<BR/>(0.64-1.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>720<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>188 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>166 per 1000</B>
<BR/>(121-226)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>161 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>142 per 1000</B>
<BR/>(103-193)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Surgery</B>
<BR/>Number of participants who underwent surgery<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.83 </B>
<BR/>(0.54-1.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>720<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>a,b</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>139 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>115 per 1000</B>
<BR/>(79-168)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>105 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
<BR/>(60-127)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Transfusion</B>
<BR/>Number of participants who required at least 1 blood transfusion<BR/>Follow-up: median 5 days</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.97</B>
<BR/>(0.78-1.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>720<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>a,b,c</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>573 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>579 per 1000</B>
<BR/>(510-654)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>599 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>605 per 1000</B>
<BR/>(533-683)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>a</SUP>High risk of bias based on assessment of attrition.<BR/>
<SUP>b</SUP>Not possible to evaluate because number of trials was limited.<BR/>
<SUP>c</SUP>This outcome measure is a surrogate estimate for bleeding.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-07-29 10:12:31 +0100" MODIFIED_BY="[Empty name]">Adverse events</TITLE>
<TABLE COLS="6" ROWS="7">
<TR>
<TH ROWSPAN="2" VALIGN="TOP">
<P>Trial</P>
</TH>
<TH COLSPAN="3" VALIGN="TOP">
<P>Serious adverse events</P>
</TH>
<TH VALIGN="TOP">
<P>Non-serious adverse events</P>
</TH>
<TH VALIGN="TOP">
<P>Non-serious adverse events</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Tranexamic acid</P>
</TH>
<TH VALIGN="TOP">
<P>Control group</P>
</TH>
<TH VALIGN="TOP">
<P>Intervention group not specified</P>
</TH>
<TH VALIGN="TOP">
<P>Tranexamic acid</P>
</TH>
<TH VALIGN="TOP">
<P>Control group</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Barer-1983" TYPE="STUDY">Barer 1983</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Fatal stroke (n = 1)</P>
</TD>
<TD VALIGN="TOP">
<P>Confusion <BR/>(n = 1)</P>
</TD>
<TD VALIGN="TOP">
<P>Pulmonary embolism (n = 5). Myocardial infarction (n = 8)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>Confusion (n = 1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Biggs-1976" TYPE="STUDY">Biggs 1976</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>Thrombophlebitis at injection site (n = 3). Nausea or headache (n = 4)</P>
</TD>
<TD VALIGN="TOP">
<P>Thrombophlebitis at injection site (n = 2). Nausea or headache (n = 5). Fever (n = 2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Engquist-1979" TYPE="STUDY">Engquist 1979</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Pulmonary embolism (n = 2). Myocardial infarction (n = 2)</P>
</TD>
<TD VALIGN="TOP">
<P>Cerebral infarction <BR/>(n = 2)</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Hawkey-2001" TYPE="STUDY">Hawkey 2001</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>Several participants experienced thromboembolic complications. The numbers were described as not significantly different in treatment and control groups, but no specific data are provided</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<LINK REF="STD-Holstein-1987" TYPE="STUDY">Holstein 1987</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
<TD VALIGN="TOP">
<P>Cerebral infarction <BR/>(n = 2)</P>
</TD>
<TD VALIGN="TOP">
<P>Five additional participants were excluded as the result of thromboembolic disease, but whether these participants were randomly assigned to tranexamic acid or placebo is not reported<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>Nausea and vomiting, tachycardia (n = 3). Hypotension (n = 3). Thrombophlebitis at injection site (n = 2). Deep venous thrombosis (n = 1)</P>
</TD>
<TD VALIGN="TOP">
<P>None described</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Tranexamic acid vs placebo</NAME>
<DICH_OUTCOME CHI2="2.808196379834625" CI_END="0.8728318204669249" CI_START="0.41658317581110693" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6029983845078704" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.05906942923766944" LOG_CI_START="-0.3802982735143904" LOG_EFFECT_SIZE="-0.21968385137602994" METHOD="MH" MODIFIED="2014-09-16 17:41:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9021606240793216" P_Q="1.0" P_Z="0.007345009558339615" Q="0.0" RANDOM="YES" SCALE="5.36" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="851" TOTAL_2="850" WEIGHT="100.0" Z="2.680783151037048">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.382676819813181" CI_START="0.04241618835007269" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5292605073722718" LOG_CI_START="-1.372468361111934" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2014-07-29 09:21:08 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="1.2478787878787878" WEIGHT="2.8531977444489147"/>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2014-08-06 12:44:23 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="42.73267665651572"/>
<DICH_DATA CI_END="2.2452542631126713" CI_START="0.160338187934635" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35126552966630087" LOG_CI_START="-0.7949630288990137" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2010-06-12 19:09:07 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.6733003292241385" STUDY_ID="STD-Bergqvist-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.45333333333333337" WEIGHT="7.853922668208977"/>
<DICH_DATA CI_END="2.5128262300673816" CI_START="0.08823615420475847" EFFECT_SIZE="0.470873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40016245678509504" LOG_CI_START="-1.0543534289909122" LOG_EFFECT_SIZE="-0.32709548610290856" MODIFIED="2010-06-12 19:09:06 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.8543898312745809" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.7299819837854069" WEIGHT="4.877442213653411"/>
<DICH_DATA CI_END="4.670644787160695" CI_START="0.20298288245648952" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6693768394903016" LOG_CI_START="-0.6925405845899318" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2010-06-12 19:09:05 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.7999970365047054" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.639995258416311" WEIGHT="5.563236439800882"/>
<DICH_DATA CI_END="1.9812284739981296" CI_START="0.4241195747010907" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2969345609878881" LOG_CI_START="-0.3725116827666878" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-06-12 19:09:04 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.39323603739378893" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.15463458110516937" WEIGHT="23.024894674108435"/>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-11-16 19:25:42 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="8.268902573188376"/>
<DICH_DATA CI_END="2.6922439739115647" CI_START="0.09285934054363382" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4301144135468989" LOG_CI_START="-1.0321744048748613" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-06-12 19:09:09 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.8589556903873333" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.7378048780487805" WEIGHT="4.82572703007529"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.734716035046283" CI_END="1.8057634231167474" CI_START="0.43047091208899746" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8816624227934502" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="71" I2="70.50733621727802" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2566608518661884" LOG_CI_START="-0.36605618949729474" LOG_EFFECT_SIZE="-0.05469766881555313" METHOD="MH" MODIFIED="2014-09-16 17:17:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0012683277662567383" P_Q="1.0" P_Z="0.7306092801666704" Q="0.0" RANDOM="YES" SCALE="79.50737202205846" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.6510465602297073" TOTALS="YES" TOTAL_1="851" TOTAL_2="850" WEIGHT="99.99999999999999" Z="0.34431516658689754">
<NAME>Mortality scenario analysis, treatment failure if participant missing</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.382676819813181" CI_START="0.04241618835007269" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5292605073722718" LOG_CI_START="-1.372468361111934" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2014-07-29 09:21:18 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="1.2478787878787878" WEIGHT="7.046100185645164"/>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" ORDER="118" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="18.219832903326747"/>
<DICH_DATA CI_END="3.82415621117103" CI_START="0.5125313642456595" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5825356242588624" LOG_CI_START="-0.29027955290238633" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2014-09-16 15:16:49 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="0.5126959555693247" STUDY_ID="STD-Bergqvist-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.2628571428571429" WEIGHT="14.640512126869066"/>
<DICH_DATA CI_END="2.5128262300673816" CI_START="0.08823615420475847" EFFECT_SIZE="0.470873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40016245678509504" LOG_CI_START="-1.0543534289909122" LOG_EFFECT_SIZE="-0.32709548610290856" ORDER="120" O_E="0.0" SE="0.8543898312745809" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.7299819837854069" WEIGHT="9.68844438865352"/>
<DICH_DATA CI_END="4.670644787160695" CI_START="0.20298288245648952" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6693768394903016" LOG_CI_START="-0.6925405845899318" LOG_EFFECT_SIZE="-0.011581872549815147" ORDER="121" O_E="0.0" SE="0.7999970365047054" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.639995258416311" WEIGHT="10.363737296957495"/>
<DICH_DATA CI_END="5.5647581182322625" CI_START="1.7084200683037927" EFFECT_SIZE="3.0833333333333335" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="12" LOG_CI_END="0.7454462917255317" LOG_CI_START="0.23259466431320872" LOG_EFFECT_SIZE="0.4890204780193702" MODIFIED="2014-09-16 15:16:49 +0100" MODIFIED_BY="[Empty name]" ORDER="122" O_E="0.0" SE="0.3012515845984971" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.09075251722310546" WEIGHT="18.0372538258983"/>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="123" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="12.370246362226382"/>
<DICH_DATA CI_END="2.6922439739115647" CI_START="0.09285934054363382" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4301144135468989" LOG_CI_START="-1.0321744048748613" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="124" O_E="0.0" SE="0.8589556903873333" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.7378048780487805" WEIGHT="9.63387291042331"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.050130139433728" CI_END="0.7241815919318815" CI_START="0.48414720377839476" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5921237140679361" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="242" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.1401525187678506" LOG_CI_START="-0.3150225720976563" LOG_EFFECT_SIZE="-0.22758754543275347" METHOD="MH" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9930660217148818" P_Q="0.9121244103920012" P_Z="3.366950587427965E-7" Q="0.9845848307497621" RANDOM="YES" SCALE="5.36" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2843" TOTAL_2="2838" WEIGHT="499.99999999999994" Z="5.101655588070219">
<NAME>Mortality in trials with low risk of bias</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.8174946978753818" CI_START="0.2636851652371889" DF="0" EFFECT_SIZE="0.46428571428571425" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.08751505541499308" LOG_CI_START="-0.578914302655772" LOG_EFFECT_SIZE="-0.3332146790353825" MODIFIED="2014-08-06 09:03:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.007858769664033797" STUDIES="1" TAU2="0.0" TOTAL_1="256" TOTAL_2="260" WEIGHT="99.99999999999999" Z="2.65807802391451">
<NAME>Allocation sequence generation</NAME>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2014-08-06 09:00:56 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6288995582244885" CI_END="0.8896158389957588" CI_START="0.42003991305151966" DF="6" EFFECT_SIZE="0.6112889330431505" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="68" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.05079749337980042" LOG_CI_START="-0.3767094400915093" LOG_EFFECT_SIZE="-0.21375346673565482" MODIFIED="2014-08-06 09:03:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.853772033088251" P_Z="0.010142457511888154" STUDIES="7" TAU2="0.0" TOTAL_1="829" TOTAL_2="825" WEIGHT="99.99999999999997" Z="2.570934269820141">
<NAME>Allocation concealment</NAME>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2014-08-06 09:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="43.987733681757824"/>
<DICH_DATA CI_END="2.2452542631126713" CI_START="0.160338187934635" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35126552966630087" LOG_CI_START="-0.7949630288990137" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-08-06 09:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.6733003292241385" STUDY_ID="STD-Bergqvist-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.45333333333333337" WEIGHT="8.084592066704072"/>
<DICH_DATA CI_END="2.5128262300673816" CI_START="0.08823615420475847" EFFECT_SIZE="0.470873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40016245678509504" LOG_CI_START="-1.0543534289909122" LOG_EFFECT_SIZE="-0.32709548610290856" MODIFIED="2014-08-06 09:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.8543898312745809" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.7299819837854069" WEIGHT="5.0206924987844435"/>
<DICH_DATA CI_END="4.670644787160695" CI_START="0.20298288245648952" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6693768394903016" LOG_CI_START="-0.6925405845899318" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2014-08-06 09:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.7999970365047054" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.639995258416311" WEIGHT="5.726628474261479"/>
<DICH_DATA CI_END="1.9812284739981296" CI_START="0.4241195747010907" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2969345609878881" LOG_CI_START="-0.3725116827666878" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2014-08-06 09:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.39323603739378893" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.15463458110516937" WEIGHT="23.701134921085643"/>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-08-06 09:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="8.511759915098883"/>
<DICH_DATA CI_END="2.6922439739115647" CI_START="0.09285934054363382" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4301144135468989" LOG_CI_START="-1.0321744048748613" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-08-06 09:01:50 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.8589556903873333" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.7378048780487805" WEIGHT="4.967458442307648"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6288995582244885" CI_END="0.8896158389957588" CI_START="0.42003991305151966" DF="6" EFFECT_SIZE="0.6112889330431505" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="68" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-0.05079749337980042" LOG_CI_START="-0.3767094400915093" LOG_EFFECT_SIZE="-0.21375346673565482" MODIFIED="2014-08-06 09:03:45 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.853772033088251" P_Z="0.010142457511888154" STUDIES="7" TAU2="0.0" TOTAL_1="829" TOTAL_2="825" WEIGHT="99.99999999999999" Z="2.570934269820141">
<NAME>Blinding</NAME>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="43.987733681757824"/>
<DICH_DATA CI_END="2.2452542631126713" CI_START="0.160338187934635" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35126552966630087" LOG_CI_START="-0.7949630288990137" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.6733003292241385" STUDY_ID="STD-Bergqvist-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.45333333333333337" WEIGHT="8.084592066704072"/>
<DICH_DATA CI_END="2.5128262300673816" CI_START="0.08823615420475847" EFFECT_SIZE="0.470873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40016245678509504" LOG_CI_START="-1.0543534289909122" LOG_EFFECT_SIZE="-0.32709548610290856" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.8543898312745809" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.7299819837854069" WEIGHT="5.0206924987844435"/>
<DICH_DATA CI_END="4.670644787160695" CI_START="0.20298288245648952" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6693768394903016" LOG_CI_START="-0.6925405845899318" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.7999970365047054" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.639995258416311" WEIGHT="5.726628474261479"/>
<DICH_DATA CI_END="1.9812284739981296" CI_START="0.4241195747010907" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2969345609878881" LOG_CI_START="-0.3725116827666878" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.39323603739378893" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.15463458110516937" WEIGHT="23.701134921085643"/>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="8.511759915098883"/>
<DICH_DATA CI_END="2.6922439739115647" CI_START="0.09285934054363382" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4301144135468989" LOG_CI_START="-1.0321744048748613" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.8589556903873333" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.7378048780487805" WEIGHT="4.967458442307648"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.8949303333429173" CI_START="0.22107613182558383" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-08-06 09:04:28 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7338109964249372" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="103" WEIGHT="100.0" Z="0.34006046225417774">
<NAME>Incomplete outcome data</NAME>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8084800476780845" CI_END="0.8867883907148937" CI_START="0.41037542123136383" DF="6" EFFECT_SIZE="0.6032546389234879" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="66" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="-0.052180001035067196" LOG_CI_START="-0.3868186584792029" LOG_EFFECT_SIZE="-0.21949932975713507" MODIFIED="2014-08-06 09:06:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.8324721779910007" P_Z="0.01013479639903913" STUDIES="7" TAU2="0.0" TOTAL_1="826" TOTAL_2="825" WEIGHT="99.99999999999999" Z="2.571195953512841">
<NAME>Selective reporting</NAME>
<DICH_DATA CI_END="3.382676819813181" CI_START="0.04241618835007269" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5292605073722718" LOG_CI_START="-1.372468361111934" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="1.2478787878787878" WEIGHT="3.096385464326805"/>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="46.3749276083103"/>
<DICH_DATA CI_END="2.5128262300673816" CI_START="0.08823615420475847" EFFECT_SIZE="0.470873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40016245678509504" LOG_CI_START="-1.0543534289909122" LOG_EFFECT_SIZE="-0.32709548610290856" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.8543898312745809" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.7299819837854069" WEIGHT="5.29316315451082"/>
<DICH_DATA CI_END="4.670644787160695" CI_START="0.20298288245648952" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6693768394903016" LOG_CI_START="-0.6925405845899318" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.7999970365047054" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.639995258416311" WEIGHT="6.0374099483033845"/>
<DICH_DATA CI_END="1.9812284739981296" CI_START="0.4241195747010907" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2969345609878881" LOG_CI_START="-0.3725116827666878" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.39323603739378893" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.15463458110516937" WEIGHT="24.987384532064816"/>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="8.973689182030483"/>
<DICH_DATA CI_END="2.6922439739115647" CI_START="0.09285934054363382" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4301144135468989" LOG_CI_START="-1.0321744048748613" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-08-06 09:01:51 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.8589556903873333" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.7378048780487805" WEIGHT="5.237040110453384"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8081963798346252" CI_END="0.872831820466925" CI_START="0.41658317581110704" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6029983845078705" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.059069429237669384" LOG_CI_START="-0.3802982735143903" LOG_EFFECT_SIZE="-0.21968385137602986" METHOD="MH" MODIFIED="2014-09-10 15:37:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.9021606240793216" P_Q="0.8646788642498577" P_Z="0.007345009558339639" Q="0.029043414857173478" RANDOM="YES" SCALE="5.36" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="851" TOTAL_2="850" WEIGHT="100.0" Z="2.6807831510370472">
<NAME>Mortality in relation to endoscopic therapy</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.4454808675321655" CI_END="0.8825588233136108" CI_START="0.4027244128349988" DF="5" EFFECT_SIZE="0.5961778123272632" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="63" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.05425633887029664" LOG_CI_START="-0.3949920430070015" LOG_EFFECT_SIZE="-0.22462419093864905" MODIFIED="2014-08-06 09:12:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7846824610338723" P_Z="0.009762059192783397" STUDIES="6" TAU2="0.0" TOTAL_1="726" TOTAL_2="722" WEIGHT="88.87789968236271" Z="2.58414553538873">
<NAME>Endoscopic therapy not used</NAME>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2014-08-06 09:09:49 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="42.73267665651572"/>
<DICH_DATA CI_END="2.2452542631126713" CI_START="0.160338187934635" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35126552966630087" LOG_CI_START="-0.7949630288990137" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-08-06 09:09:49 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.6733003292241385" STUDY_ID="STD-Bergqvist-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.45333333333333337" WEIGHT="7.853922668208977"/>
<DICH_DATA CI_END="2.5128262300673816" CI_START="0.08823615420475847" EFFECT_SIZE="0.470873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40016245678509504" LOG_CI_START="-1.0543534289909122" LOG_EFFECT_SIZE="-0.32709548610290856" MODIFIED="2014-08-06 09:09:49 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.8543898312745809" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.7299819837854069" WEIGHT="4.877442213653411"/>
<DICH_DATA CI_END="4.670644787160695" CI_START="0.20298288245648952" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6693768394903016" LOG_CI_START="-0.6925405845899318" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2014-08-06 09:09:49 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.7999970365047054" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.639995258416311" WEIGHT="5.563236439800882"/>
<DICH_DATA CI_END="1.9812284739981296" CI_START="0.4241195747010907" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2969345609878881" LOG_CI_START="-0.3725116827666878" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2014-08-06 09:09:49 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.39323603739378893" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.15463458110516937" WEIGHT="23.024894674108435"/>
<DICH_DATA CI_END="2.6922439739115647" CI_START="0.09285934054363382" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4301144135468989" LOG_CI_START="-1.0321744048748613" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-08-06 09:09:49 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.8589556903873333" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.7378048780487805" WEIGHT="4.82572703007529"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.334047948239648" CI_END="2.0017051105719483" CI_START="0.21786615492814054" DF="1" EFFECT_SIZE="0.6603815531496309" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.30140009797626377" LOG_CI_START="-0.6618102312938916" LOG_EFFECT_SIZE="-0.18020506665881394" MODIFIED="2014-08-06 09:12:48 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5632853356279015" P_Z="0.46333196038117497" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="128" WEIGHT="11.12210031763729" Z="0.7333713722745036">
<NAME>Endoscopic therapy used to control bleeding</NAME>
<DICH_DATA CI_END="3.382676819813181" CI_START="0.04241618835007269" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5292605073722718" LOG_CI_START="-1.372468361111934" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2014-08-06 09:12:48 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="1.2478787878787878" WEIGHT="2.8531977444489147"/>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-08-06 09:12:45 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="8.268902573188376"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8081963798346252" CI_END="0.8728318204669249" CI_START="0.41658317581110693" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6029983845078704" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.05906942923766944" LOG_CI_START="-0.3802982735143904" LOG_EFFECT_SIZE="-0.21968385137602994" METHOD="MH" MODIFIED="2014-09-10 15:37:15 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.9021606240793216" P_Q="0.6728247618653158" P_Z="0.007345009558339615" Q="0.17831565172191158" RANDOM="YES" SCALE="5.36" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="851" TOTAL_2="850" WEIGHT="100.0" Z="2.680783151037048">
<NAME>Mortality in relation to language of publication</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6288995582244885" CI_END="0.8896158389957588" CI_START="0.42003991305151966" DF="6" EFFECT_SIZE="0.6112889330431505" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="68" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="-0.05079749337980042" LOG_CI_START="-0.3767094400915093" LOG_EFFECT_SIZE="-0.21375346673565482" MODIFIED="2014-08-06 09:12:30 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.853772033088251" P_Z="0.010142457511888154" STUDIES="7" TAU2="0.0" TOTAL_1="829" TOTAL_2="825" WEIGHT="97.14680225555108" Z="2.570934269820141">
<NAME>Trials published in English</NAME>
<DICH_DATA CI_END="0.8174946978753819" CI_START="0.26368516523718893" EFFECT_SIZE="0.4642857142857143" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" LOG_CI_END="-0.087515055414993" LOG_CI_START="-0.5789143026557719" LOG_EFFECT_SIZE="-0.33321467903538243" MODIFIED="2014-08-06 09:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.2886503502947376" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.08331902472527472" WEIGHT="42.73267665651572"/>
<DICH_DATA CI_END="2.2452542631126713" CI_START="0.160338187934635" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35126552966630087" LOG_CI_START="-0.7949630288990137" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2014-08-06 09:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.6733003292241385" STUDY_ID="STD-Bergqvist-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.45333333333333337" WEIGHT="7.853922668208977"/>
<DICH_DATA CI_END="2.5128262300673816" CI_START="0.08823615420475847" EFFECT_SIZE="0.470873786407767" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.40016245678509504" LOG_CI_START="-1.0543534289909122" LOG_EFFECT_SIZE="-0.32709548610290856" MODIFIED="2014-08-06 09:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.8543898312745809" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.7299819837854069" WEIGHT="4.877442213653411"/>
<DICH_DATA CI_END="4.670644787160695" CI_START="0.20298288245648952" EFFECT_SIZE="0.9736842105263158" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6693768394903016" LOG_CI_START="-0.6925405845899318" LOG_EFFECT_SIZE="-0.011581872549815147" MODIFIED="2014-08-06 09:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.7999970365047054" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.639995258416311" WEIGHT="5.563236439800882"/>
<DICH_DATA CI_END="1.9812284739981296" CI_START="0.4241195747010907" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2969345609878881" LOG_CI_START="-0.3725116827666878" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2014-08-06 09:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.39323603739378893" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.15463458110516937" WEIGHT="23.024894674108435"/>
<DICH_DATA CI_END="2.8949303333429173" CI_START="0.22107613182558383" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46163811686870715" LOG_CI_START="-0.6554581428848198" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2014-08-06 09:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.6561878726948897" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.4305825242718447" WEIGHT="8.268902573188376"/>
<DICH_DATA CI_END="2.6922439739115647" CI_START="0.09285934054363382" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4301144135468989" LOG_CI_START="-1.0321744048748613" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2014-08-06 09:09:51 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.8589556903873333" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.7378048780487805" WEIGHT="4.82572703007529"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.382676819813181" CI_START="0.04241618835007269" DF="0" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.5292605073722718" LOG_CI_START="-1.372468361111934" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2014-08-06 09:12:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.38483142537316606" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="2.8531977444489147" Z="0.8690287307508375">
<NAME>Trials translated from Russian</NAME>
<DICH_DATA CI_END="3.382676819813181" CI_START="0.04241618835007269" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5292605073722718" LOG_CI_START="-1.372468361111934" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2014-08-06 09:12:30 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="1.2478787878787878" WEIGHT="2.8531977444489147"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.66989337453575" CI_END="1.0280619059964464" CI_START="0.501802648043322" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7182507826528848" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="146" I2="48.58564849365052" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.012019267016423916" LOG_CI_START="-0.29946705121676864" LOG_EFFECT_SIZE="-0.14372389210017236" METHOD="MH" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.06975153789031674" P_Q="1.0" P_Z="0.07049662460510481" Q="0.0" RANDOM="YES" SCALE="1.3" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10214781705138716" TOTALS="YES" TOTAL_1="826" TOTAL_2="825" WEIGHT="100.0" Z="1.8087064230113001">
<NAME>Rebleeding</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1128045129918225" CI_START="0.09779019733130115" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3248593158613781" LOG_CI_START="-1.0097046775057905" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2014-07-29 09:21:45 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.7839294959021854" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="0.6145454545454545" WEIGHT="4.671107127704927"/>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="25.507717193025755"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" ORDER="94" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="12.280548322544199"/>
<DICH_DATA CI_END="1.6611180944311976" CI_START="0.30187722533315603" EFFECT_SIZE="0.7081339712918661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22040050899363434" LOG_CI_START="-0.5201696504258275" LOG_EFFECT_SIZE="-0.1498845707160966" ORDER="95" O_E="0.0" SE="0.43501457752440353" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.18923768265873528" WEIGHT="11.4890790813702"/>
<DICH_DATA CI_END="1.273355022923585" CI_START="0.49398091525399396" EFFECT_SIZE="0.7931034482758621" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.10494950577513741" LOG_CI_START="-0.3062898295378638" LOG_EFFECT_SIZE="-0.10067016188136318" ORDER="96" O_E="0.0" SE="0.24156402123039755" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.05835317635299996" WEIGHT="20.85813288955421"/>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="11.393052347106147"/>
<DICH_DATA CI_END="1.0970664196682727" CI_START="0.2524991242855363" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.04023292185201367" LOG_CI_START="-0.5977401237576716" LOG_EFFECT_SIZE="-0.278753600952829" ORDER="98" O_E="0.0" SE="0.3747485250086368" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.1404364569961489" WEIGHT="13.800363038694567"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="21.238059229584312" CI_END="1.2678236950772812" CI_START="0.5064971771482779" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8013420759440639" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="146" I2="71.74883102481377" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.10305886428810014" LOG_CI_START="-0.29542297074267887" LOG_EFFECT_SIZE="-0.09618205322728939" METHOD="MH" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0016623771745919447" P_Q="1.0" P_Z="0.344068087122145" Q="0.0" RANDOM="YES" SCALE="1.38" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.23957981887718438" TOTALS="YES" TOTAL_1="826" TOTAL_2="825" WEIGHT="100.0" Z="0.9461578607217604">
<NAME>Rebleeding scenario analysis, treatment failure if participant missing</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1128045129918225" CI_START="0.09779019733130115" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3248593158613781" LOG_CI_START="-1.0097046775057905" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2014-08-06 09:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.7839294959021854" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="0.6145454545454545" WEIGHT="6.414616375718542"/>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="20.392119006803156"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" MODIFIED="2014-08-06 09:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="13.361898305744438"/>
<DICH_DATA CI_END="1.6611180944311976" CI_START="0.30187722533315603" EFFECT_SIZE="0.7081339712918661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22040050899363434" LOG_CI_START="-0.5201696504258275" LOG_EFFECT_SIZE="-0.1498845707160966" MODIFIED="2014-08-06 09:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.43501457752440353" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.18923768265873528" WEIGHT="12.776731234587917"/>
<DICH_DATA CI_END="2.4416645464035276" CI_START="1.1692575074941756" EFFECT_SIZE="1.6896551724137931" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="29" LOG_CI_END="0.3876859971792568" LOG_CI_START="0.06791016707985843" LOG_EFFECT_SIZE="0.2277980821295576" MODIFIED="2014-09-17 08:09:16 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.18783790551627452" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.03528307874874087" WEIGHT="19.933159451984054"/>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="12.703972182130004"/>
<DICH_DATA CI_END="1.0970664196682727" CI_START="0.2524991242855363" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.04023292185201367" LOG_CI_START="-0.5977401237576716" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-08-06 09:22:41 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.3747485250086368" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.1404364569961489" WEIGHT="14.417503443031885"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.82073705189341" CI_END="0.9303138185838113" CI_START="0.6500046526289908" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7776299315770454" ESTIMABLE="YES" EVENTS_1="414" EVENTS_2="489" I2="45.682782037163065" I2_Q="24.258156262115897" ID="CMP-001.08" LOG_CI_END="-0.03137052812381756" LOG_CI_START="-0.18708353473581302" LOG_EFFECT_SIZE="-0.10922703142981526" METHOD="MH" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.012294719830221124" P_Q="0.25965187221314245" P_Z="0.005965213837246181" Q="5.281096686585283" RANDOM="YES" SCALE="7.65" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-04" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.06909603043405538" TOTALS="YES" TOTAL_1="2793" TOTAL_2="2788" WEIGHT="99.99999999999999" Z="2.749687420449187">
<NAME>Rebleeding in trials with low risk of bias</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6135683566547687" CI_START="0.8267896508664757" DF="0" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:29:32 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3981657007403788" STUDIES="1" TAU2="0.0" TOTAL_1="256" TOTAL_2="260" WEIGHT="8.520108468792824" Z="0.8449017589234208">
<NAME>Allocation sequence generation</NAME>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:25:35 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="8.520108468792824"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.052803395922737" CI_END="1.0663011454303468" CI_START="0.500827295221036" DF="5" EFFECT_SIZE="0.7307754227921004" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="141" I2="54.762607992788084" ID="CMP-001.08.02" LOG_CI_END="0.027879875730523432" LOG_CI_START="-0.300312009987633" LOG_EFFECT_SIZE="-0.13621606712855483" MODIFIED="2014-08-06 09:29:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.050343089867446844" P_Z="0.10374423374726915" STUDIES="6" TAU2="0.1132281335703001" TOTAL_1="804" TOTAL_2="800" WEIGHT="29.016042931648425" Z="1.626966401703988">
<NAME>Allocation concealment</NAME>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:26:01 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="3.208001827914831"/>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:26:01 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="8.520108468792824"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" MODIFIED="2014-08-06 09:26:01 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="3.4923775422984757"/>
<DICH_DATA CI_END="1.6611180944311976" CI_START="0.30187722533315603" EFFECT_SIZE="0.7081339712918661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22040050899363434" LOG_CI_START="-0.5201696504258275" LOG_EFFECT_SIZE="-0.1498845707160966" MODIFIED="2014-08-06 09:26:01 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.43501457752440353" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.18923768265873528" WEIGHT="3.2384999798371927"/>
<DICH_DATA CI_END="1.0970664196682727" CI_START="0.2524991242855363" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.04023292185201367" LOG_CI_START="-0.5977401237576716" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-08-06 09:26:01 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.3747485250086368" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.1404364569961489" WEIGHT="3.992763770920953"/>
<DICH_DATA CI_END="1.273355022923585" CI_START="0.49398091525399396" EFFECT_SIZE="0.7931034482758621" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.10494950577513741" LOG_CI_START="-0.3062898295378638" LOG_EFFECT_SIZE="-0.10067016188136318" MODIFIED="2014-08-06 09:26:01 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.24156402123039755" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.05835317635299996" WEIGHT="6.564291341884146"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.052803395922737" CI_END="1.0663011454303468" CI_START="0.5008272952210359" DF="5" EFFECT_SIZE="0.7307754227921004" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="141" I2="54.762607992788084" ID="CMP-001.08.03" LOG_CI_END="0.027879875730523432" LOG_CI_START="-0.30031200998763313" LOG_EFFECT_SIZE="-0.13621606712855483" MODIFIED="2014-08-06 09:31:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.050343089867446844" P_Z="0.10374423374726915" STUDIES="6" TAU2="0.1132281335703001" TOTAL_1="804" TOTAL_2="800" WEIGHT="29.01604293164842" Z="1.626966401703988">
<NAME>Blinding</NAME>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="3.208001827914831"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" MODIFIED="2014-08-06 09:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="3.4923775422984757"/>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="8.520108468792824"/>
<DICH_DATA CI_END="1.6611180944311976" CI_START="0.30187722533315603" EFFECT_SIZE="0.7081339712918661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22040050899363434" LOG_CI_START="-0.5201696504258275" LOG_EFFECT_SIZE="-0.1498845707160966" MODIFIED="2014-08-06 09:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.43501457752440353" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.18923768265873528" WEIGHT="3.2384999798371927"/>
<DICH_DATA CI_END="1.0970664196682727" CI_START="0.2524991242855363" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.04023292185201367" LOG_CI_START="-0.5977401237576716" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-08-06 09:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.3747485250086368" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.1404364569961489" WEIGHT="3.992763770920953"/>
<DICH_DATA CI_END="1.273355022923585" CI_START="0.49398091525399396" EFFECT_SIZE="0.7931034482758621" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.10494950577513741" LOG_CI_START="-0.3062898295378638" LOG_EFFECT_SIZE="-0.10067016188136318" MODIFIED="2014-08-06 09:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.24156402123039755" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.05835317635299996" WEIGHT="6.564291341884146"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1228663291653715" CI_START="0.38155958708830273" DF="0" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:31:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8098314735090693" STUDIES="1" TAU2="0.0" TOTAL_1="103" TOTAL_2="103" WEIGHT="3.208001827914831" Z="0.24064344746000715">
<NAME>Incomplete outcome data</NAME>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="3.208001827914831"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.669893374535748" CI_END="1.0280619059964464" CI_START="0.5018026480433221" DF="6" EFFECT_SIZE="0.7182507826528849" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="146" I2="48.58564849365051" ID="CMP-001.08.05" LOG_CI_END="0.012019267016423916" LOG_CI_START="-0.29946705121676853" LOG_EFFECT_SIZE="-0.1437238921001723" MODIFIED="2014-08-06 09:31:16 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.06975153789031663" P_Z="0.07049662460510481" STUDIES="7" TAU2="0.10214781705138715" TOTAL_1="826" TOTAL_2="825" WEIGHT="30.2398038399955" Z="1.8087064230113001">
<NAME>Selective reporting</NAME>
<DICH_DATA CI_END="2.1128045129918225" CI_START="0.09779019733130115" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3248593158613781" LOG_CI_START="-1.0097046775057905" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2014-08-06 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.7839294959021854" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="0.6145454545454545" WEIGHT="1.223760908347077"/>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="3.208001827914831"/>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="8.520108468792824"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" MODIFIED="2014-08-06 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="3.4923775422984757"/>
<DICH_DATA CI_END="1.6611180944311976" CI_START="0.30187722533315603" EFFECT_SIZE="0.7081339712918661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22040050899363434" LOG_CI_START="-0.5201696504258275" LOG_EFFECT_SIZE="-0.1498845707160966" MODIFIED="2014-08-06 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.43501457752440353" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.18923768265873528" WEIGHT="3.2384999798371927"/>
<DICH_DATA CI_END="1.0970664196682727" CI_START="0.2524991242855363" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.04023292185201367" LOG_CI_START="-0.5977401237576716" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-08-06 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.3747485250086368" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.1404364569961489" WEIGHT="3.992763770920953"/>
<DICH_DATA CI_END="1.273355022923585" CI_START="0.49398091525399396" EFFECT_SIZE="0.7931034482758621" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.10494950577513741" LOG_CI_START="-0.3062898295378638" LOG_EFFECT_SIZE="-0.10067016188136318" MODIFIED="2014-08-06 09:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.24156402123039755" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.05835317635299996" WEIGHT="6.564291341884146"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.66989337453575" CI_END="1.0280619059964464" CI_START="0.501802648043322" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7182507826528849" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="146" I2="48.58564849365052" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.012019267016423916" LOG_CI_START="-0.29946705121676864" LOG_EFFECT_SIZE="-0.1437238921001723" METHOD="MH" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.06975153789031674" P_Q="0.8363198793989675" P_Z="0.07049662460510484" Q="0.04268488311655695" RANDOM="YES" SCALE="1.54" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10214781705138719" TOTALS="YES" TOTAL_1="826" TOTAL_2="825" WEIGHT="100.0" Z="1.8087064230113">
<NAME>Rebleeding in relation to endoscopic therapy</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.039209725911718" CI_END="1.08310394407124" CI_START="0.45001929260554735" DF="4" EFFECT_SIZE="0.698153042483679" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="131" I2="63.7655221767277" ID="CMP-001.09.01" LOG_CI_END="0.034670137299716706" LOG_CI_START="-0.3467688673523702" LOG_EFFECT_SIZE="-0.15604936502632674" MODIFIED="2014-08-06 09:32:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0261268906198181" P_Z="0.10878682243255412" STUDIES="5" TAU2="0.14970690798517441" TOTAL_1="701" TOTAL_2="697" WEIGHT="83.93584052518892" Z="1.6036699526358804">
<NAME>Endoscopic therapy not used</NAME>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:26:21 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="25.507717193025748"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" MODIFIED="2014-08-06 09:26:21 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="12.280548322544197"/>
<DICH_DATA CI_END="1.6611180944311976" CI_START="0.30187722533315603" EFFECT_SIZE="0.7081339712918661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22040050899363434" LOG_CI_START="-0.5201696504258275" LOG_EFFECT_SIZE="-0.1498845707160966" MODIFIED="2014-08-06 09:26:21 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.43501457752440353" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.18923768265873528" WEIGHT="11.489079081370198"/>
<DICH_DATA CI_END="1.273355022923585" CI_START="0.49398091525399396" EFFECT_SIZE="0.7931034482758621" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.10494950577513741" LOG_CI_START="-0.3062898295378638" LOG_EFFECT_SIZE="-0.10067016188136318" MODIFIED="2014-08-06 09:26:21 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.24156402123039755" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.05835317635299996" WEIGHT="20.858132889554206"/>
<DICH_DATA CI_END="1.0970664196682727" CI_START="0.2524991242855363" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.04023292185201367" LOG_CI_START="-0.5977401237576716" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-08-06 09:26:21 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.3747485250086368" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.1404364569961489" WEIGHT="13.800363038694565"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5793592740469385" CI_END="1.6183760276632937" CI_START="0.36168767528514256" DF="1" EFFECT_SIZE="0.7650795142877244" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.2090794367853281" LOG_CI_START="-0.44166628981965833" LOG_EFFECT_SIZE="-0.11629342651716515" MODIFIED="2014-08-06 09:32:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.4465637069787126" P_Z="0.48360122491607327" STUDIES="2" TAU2="0.0" TOTAL_1="125" TOTAL_2="128" WEIGHT="16.06415947481107" Z="0.7005222417718829">
<NAME>Endoscopic therapy used to control bleeding</NAME>
<DICH_DATA CI_END="2.1128045129918225" CI_START="0.09779019733130115" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3248593158613781" LOG_CI_START="-1.0097046775057905" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2014-08-06 09:32:05 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.7839294959021854" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="0.6145454545454545" WEIGHT="4.671107127704926"/>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:32:06 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="11.393052347106146"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.66989337453575" CI_END="1.0280619059964464" CI_START="0.501802648043322" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7182507826528848" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="146" I2="48.58564849365052" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.012019267016423916" LOG_CI_START="-0.29946705121676864" LOG_EFFECT_SIZE="-0.14372389210017236" METHOD="MH" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.06975153789031674" P_Q="0.5564291479653662" P_Z="0.07049662460510478" Q="0.3459250846132225" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10214781705138719" TOTALS="YES" TOTAL_1="826" TOTAL_2="825" WEIGHT="100.0" Z="1.8087064230113004">
<NAME>Rebleeding in relation to language of publication</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.052803395922737" CI_END="1.066301145430347" CI_START="0.500827295221036" DF="5" EFFECT_SIZE="0.7307754227921004" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="141" I2="54.762607992788084" ID="CMP-001.10.01" LOG_CI_END="0.027879875730523525" LOG_CI_START="-0.300312009987633" LOG_EFFECT_SIZE="-0.13621606712855483" MODIFIED="2014-08-06 09:33:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.050343089867446844" P_Z="0.10374423374726925" STUDIES="6" TAU2="0.11322813357030011" TOTAL_1="804" TOTAL_2="800" WEIGHT="95.32889287229507" Z="1.6269664017039875">
<NAME>Trials published in English</NAME>
<DICH_DATA CI_END="1.6135683566547687" CI_START="0.8267896508664757" EFFECT_SIZE="1.1550245098039216" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="51" LOG_CI_END="0.20778736843167175" LOG_CI_START="-0.08260496818373315" LOG_EFFECT_SIZE="0.06259120012396932" MODIFIED="2014-08-06 09:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.17057789599313822" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.029096818601445883" WEIGHT="25.50771719302575"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" MODIFIED="2014-08-06 09:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="12.280548322544199"/>
<DICH_DATA CI_END="1.6611180944311976" CI_START="0.30187722533315603" EFFECT_SIZE="0.7081339712918661" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.22040050899363434" LOG_CI_START="-0.5201696504258275" LOG_EFFECT_SIZE="-0.1498845707160966" MODIFIED="2014-08-06 09:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.43501457752440353" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.18923768265873528" WEIGHT="11.4890790813702"/>
<DICH_DATA CI_END="1.273355022923585" CI_START="0.49398091525399396" EFFECT_SIZE="0.7931034482758621" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="29" LOG_CI_END="0.10494950577513741" LOG_CI_START="-0.3062898295378638" LOG_EFFECT_SIZE="-0.10067016188136318" MODIFIED="2014-08-06 09:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.24156402123039755" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.05835317635299996" WEIGHT="20.858132889554206"/>
<DICH_DATA CI_END="2.1228663291653715" CI_START="0.38155958708830273" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.32692264874276167" LOG_CI_START="-0.4184376298641118" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2014-08-06 09:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.43782831724656157" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.19169363538295578" WEIGHT="11.393052347106147"/>
<DICH_DATA CI_END="1.0970664196682727" CI_START="0.2524991242855363" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.04023292185201367" LOG_CI_START="-0.5977401237576716" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-08-06 09:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.3747485250086368" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.1404364569961489" WEIGHT="13.800363038694567"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1128045129918225" CI_START="0.09779019733130115" DF="0" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.3248593158613781" LOG_CI_START="-1.0097046775057905" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2014-08-06 09:33:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3145234172177147" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="4.671107127704927" Z="1.0057758567393535">
<NAME>Trials translated from Russian</NAME>
<DICH_DATA CI_END="2.1128045129918225" CI_START="0.09779019733130115" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3248593158613781" LOG_CI_START="-1.0097046775057905" LOG_EFFECT_SIZE="-0.3424226808222062" MODIFIED="2014-08-06 09:33:12 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.7839294959021854" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="0.6145454545454545" WEIGHT="4.671107127704927"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.026614118033443" CI_END="5.277908837498477" CI_START="0.3562819922915049" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3712854829527288" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="1.3132306637273585" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.7224618846120934" LOG_CI_START="-0.44820612782038194" LOG_EFFECT_SIZE="0.13712787839585575" METHOD="MH" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.36301660103943434" P_Q="1.0" P_Z="0.6461146852595328" Q="0.0" RANDOM="YES" SCALE="124.56" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.023115222217076764" TOTALS="YES" TOTAL_1="522" TOTAL_2="526" WEIGHT="100.0" Z="0.45916639060430114">
<NAME>Myocardial infarction, pulmonary embolism and cerebral infarction</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.44247461479745" CI_START="0.1246913927781633" EFFECT_SIZE="3.046692607003891" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8718208015045166" LOG_CI_START="-0.9041635240512192" LOG_EFFECT_SIZE="0.48382863872664883" ORDER="109" O_E="0.0" SE="1.6306269341754684" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="2.658944198458488" WEIGHT="17.630893099446588"/>
<DICH_DATA CI_END="10.678056908317199" CI_START="0.3745999889628213" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0284922310847553" LOG_CI_START="-0.42643223975679284" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="110" O_E="0.0" SE="0.8546298361646083" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.7303921568627452" WEIGHT="62.75599183917909"/>
<DICH_DATA CI_END="4.1340102742273395" CI_START="0.00967583468511726" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6163715516417035" LOG_CI_START="-2.014311560313741" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="111" O_E="0.0" SE="1.54527628205405" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="2.387878787878788" WEIGHT="19.613115061374337"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08320192982458197" CI_END="8.892685454159786" CI_START="0.6030443573811151" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="2.315746917324123" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.9490329310271628" LOG_CI_START="-0.2196507418277799" LOG_EFFECT_SIZE="0.3646910945996915" METHOD="MH" MODIFIED="2014-08-06 11:22:57 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.9592524806125393" P_Q="1.0" P_Z="0.2212448337761047" Q="0.0" RANDOM="YES" SCALE="120.58" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="522" TOTAL_2="526" WEIGHT="100.0" Z="1.2232247741628268">
<NAME>Deep venous thrombosis</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.44247461479745" CI_START="0.1246913927781633" EFFECT_SIZE="3.046692607003891" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8718208015045166" LOG_CI_START="-0.9041635240512192" LOG_EFFECT_SIZE="0.48382863872664883" ORDER="112" O_E="0.0" SE="1.6306269341754684" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="2.658944198458488" WEIGHT="17.72392625492795"/>
<DICH_DATA CI_END="10.678056908317199" CI_START="0.3745999889628213" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0284922310847553" LOG_CI_START="-0.42643223975679284" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="113" O_E="0.0" SE="0.8546298361646083" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.7303921568627452" WEIGHT="64.5227778620613"/>
<DICH_DATA CI_END="73.1079911933941" CI_START="0.12310555731441337" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.863964850849951" LOG_CI_START="-0.9097223414106257" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="114" O_E="0.0" SE="1.6292775867068985" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="2.6545454545454548" WEIGHT="17.753295883010757"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4287210681547928" CI_END="5.237556407258594" CI_START="0.6609812010677514" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8606252510190981" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.7191287132496225" LOG_CI_START="-0.1798108920856759" LOG_EFFECT_SIZE="0.2696589105819733" METHOD="MH" MODIFIED="2014-08-06 11:23:02 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.4895051038636782" P_Q="1.0" P_Z="0.2396435629039616" Q="0.0" RANDOM="YES" SCALE="57.42" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="544" TOTAL_2="551" WEIGHT="100.0" Z="1.1758782229955025">
<NAME>Any thromboembolic event</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-08-04 17:26:39 +0100" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.0" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.968362615158899" CI_START="0.4971204592452134" EFFECT_SIZE="2.5390625" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.112885145545026" LOG_CI_START="-0.3035383628830139" LOG_EFFECT_SIZE="0.404673391331006" ORDER="115" O_E="0.0" SE="0.8320141802600759" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.6922475961538461" WEIGHT="40.27863807951968"/>
<DICH_DATA CI_END="12.591026920843696" CI_START="0.4963852463577454" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.100061152496109" LOG_CI_START="-0.30418113515203354" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="116" O_E="0.0" SE="0.8248588708759488" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.6803921568627451" WEIGHT="40.98047002108968"/>
<DICH_DATA CI_END="5.460447754910022" CI_START="0.04578379122393407" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7372282561687894" LOG_CI_START="-1.3392882474967518" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="117" O_E="0.0" SE="1.2197560731756085" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="1.4878048780487805" WEIGHT="18.74089189939064"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.213401041908508" CI_END="1.0404008210328894" CI_START="0.3518504507598457" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6050334683728957" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="110" I2="62.99357559532908" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.017200686247703493" LOG_CI_START="-0.45364188825634344" LOG_EFFECT_SIZE="-0.21822060100431992" METHOD="MH" MODIFIED="2014-09-16 17:44:17 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.012653265110206813" P_Q="1.0" P_Z="0.06925351815963812" Q="0.0" RANDOM="YES" SCALE="31.69" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2971953524712726" TOTALS="YES" TOTAL_1="775" TOTAL_2="776" WEIGHT="99.99999999999999" Z="1.816762297265351">
<NAME>Surgery</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.382676819813181" CI_START="0.04241618835007269" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.5292605073722718" LOG_CI_START="-1.372468361111934" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2014-08-04 17:11:49 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="1.1170849510573437" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="1.2478787878787878" WEIGHT="4.950822221262703"/>
<DICH_DATA CI_END="1.7532405953862757" CI_START="0.8122710605994324" EFFECT_SIZE="1.193359375" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="40" LOG_CI_END="0.2438415179642042" LOG_CI_START="-0.09029901943075724" LOG_EFFECT_SIZE="0.07677124926672348" ORDER="99" O_E="0.0" SE="0.1962758056881362" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="260" VAR="0.038524191898527" WEIGHT="22.78505233260279"/>
<DICH_DATA CI_END="2.4325889590333376" CI_START="0.4110846578853914" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.38606873124701274" LOG_CI_START="-0.38606873124701274" LOG_EFFECT_SIZE="0.0" ORDER="100" O_E="0.0" SE="0.4535573676110726" STUDY_ID="STD-Bergqvist-1980" TOTAL_1="25" TOTAL_2="25" VAR="0.20571428571428568" WEIGHT="15.210262056503002"/>
<DICH_DATA CI_END="0.7050911547536038" CI_START="0.13975946938439557" EFFECT_SIZE="0.313915857605178" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="21" LOG_CI_END="-0.15175473343782908" LOG_CI_START="-0.8546187568793504" LOG_EFFECT_SIZE="-0.5031867451585899" ORDER="101" O_E="0.0" SE="0.412865806602578" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.17045817426159734" WEIGHT="16.35695434819822"/>
<DICH_DATA CI_END="1.144391871109998" CI_START="0.26969955231268467" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="18" LOG_CI_END="0.05857476424628847" LOG_CI_START="-0.5691197744529005" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="102" O_E="0.0" SE="0.36871087916998146" STUDY_ID="STD-Engquist-1979" TOTAL_1="102" TOTAL_2="102" VAR="0.13594771241830067" WEIGHT="17.660186685647627"/>
<DICH_DATA CI_END="2.644926157672412" CI_START="0.262557214472698" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4224135516970792" LOG_CI_START="-0.5807760437923288" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="103" O_E="0.0" SE="0.5892785342590644" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.34724919093851137" WEIGHT="11.869737226837563"/>
<DICH_DATA CI_END="0.6778086202281711" CI_START="0.059013708008810485" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.16889291219719255" LOG_CI_START="-1.229047096474845" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="104" O_E="0.0" SE="0.6227398156925414" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.38780487804878044" WEIGHT="11.166985128948093"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.2664831428175685" CI_END="1.1143989429446302" CI_START="0.9382131243122348" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.022518319635562" ESTIMABLE="YES" EVENTS_1="264" EVENTS_2="261" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.04704069146909092" LOG_CI_START="-0.027698496163411853" LOG_EFFECT_SIZE="0.009671097652839553" METHOD="MH" MODIFIED="2014-09-16 17:43:51 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.686877830673623" P_Q="1.0" P_Z="0.6119929987314078" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="468" TOTAL_2="463" WEIGHT="99.99999999999999" Z="0.5072306427449612">
<NAME>Transfusion required</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours tranexamic acid</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0006787336848104" CI_START="0.748560086467102" EFFECT_SIZE="1.2237762237762237" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="13" LOG_CI_END="0.3011773558078194" LOG_CI_START="-0.1257733333653542" LOG_EFFECT_SIZE="0.08770201122123263" MODIFIED="2014-08-04 17:26:12 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.2507929482603187" STUDY_ID="STD-Bagnenko-2011" TOTAL_1="22" TOTAL_2="25" VAR="0.0628971028971029" WEIGHT="3.0643707497388704"/>
<DICH_DATA CI_END="1.2040795132176023" CI_START="0.8663205269391359" EFFECT_SIZE="1.0213318747436073" ESTIMABLE="YES" EVENTS_1="77" EVENTS_2="71" LOG_CI_END="0.08065516716385429" LOG_CI_START="-0.06232139513489585" LOG_EFFECT_SIZE="0.009166886014479248" ORDER="105" O_E="0.0" SE="0.08398514043968358" STUDY_ID="STD-Biggs-1976" TOTAL_1="103" TOTAL_2="97" VAR="0.007053503814673375" WEIGHT="27.325432497851885"/>
<DICH_DATA CI_END="1.1879414338909255" CI_START="0.929775185342288" EFFECT_SIZE="1.0509607351712615" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="63" LOG_CI_END="0.07479503023695515" LOG_CI_START="-0.03162204883127615" LOG_EFFECT_SIZE="0.021586490702839474" ORDER="106" O_E="0.0" SE="0.06250991901771613" STUDY_ID="STD-Cormack-1973" TOTAL_1="76" TOTAL_2="74" VAR="0.00390748997560143" WEIGHT="49.32579317277253"/>
<DICH_DATA CI_END="1.2238879191037897" CI_START="0.763504917287447" EFFECT_SIZE="0.9666666666666667" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="60" LOG_CI_END="0.08774164792105603" LOG_CI_START="-0.1171881615624687" LOG_EFFECT_SIZE="-0.014723256820706347" ORDER="107" O_E="0.0" SE="0.1203767845095397" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="103" VAR="0.014490570248856159" WEIGHT="13.301066766258726"/>
<DICH_DATA CI_END="1.2053586793765008" CI_START="0.6284806295255723" EFFECT_SIZE="0.8703703703703703" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="54" LOG_CI_END="0.08111629943788194" LOG_CI_START="-0.20170810321238405" LOG_EFFECT_SIZE="-0.060295901887251056" ORDER="108" O_E="0.0" SE="0.16613245412013833" STUDY_ID="STD-Holstein-1987" TOTAL_1="164" TOTAL_2="164" VAR="0.027599992311979862" WEIGHT="6.983336813377977"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Tranexamic acid vs cimetidine or lansoprazole</NAME>
<DICH_OUTCOME CHI2="0.9605184697965812" CI_END="1.6387164655862547" CI_START="0.5003384425253017" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9054903887573814" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.2145038174610038" LOG_CI_START="-0.30073612766783164" LOG_EFFECT_SIZE="-0.043116155103413954" METHOD="MH" MODIFIED="2014-09-16 17:45:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3270564749859455" P_Q="1.0" P_Z="0.7428918226151259" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="359" TOTAL_2="361" WEIGHT="100.0" Z="0.32802624079700765">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Cimetidine or lansoprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5262278228322108" CI_START="0.42922025193418223" EFFECT_SIZE="0.809375" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.18361936639335139" LOG_CI_START="-0.3673197948706597" LOG_EFFECT_SIZE="-0.09185021423865418" MODIFIED="2014-07-24 15:35:45 +0100" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.32362439051931197" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="259" VAR="0.10473274613899614" WEIGHT="87.46046128368248"/>
<DICH_DATA CI_END="10.575540616508771" CI_START="0.3709226107389305" EFFECT_SIZE="1.9805825242718447" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0243025775378969" LOG_CI_START="-0.43071669209644387" LOG_EFFECT_SIZE="0.29679294272072654" MODIFIED="2014-07-24 15:35:45 +0100" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.8546855214447563" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="102" VAR="0.7304873405672949" WEIGHT="12.539538716317521"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.002125720364589892" CI_END="1.1964654770773322" CI_START="0.639456339995325" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8746927660056595" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.07790017195813308" LOG_CI_START="-0.1941891023915876" LOG_EFFECT_SIZE="-0.05814446521672724" METHOD="MH" MODIFIED="2014-09-16 17:45:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9632261454231046" P_Q="1.0" P_Z="0.40221381825471714" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="359" TOTAL_2="361" WEIGHT="100.0" Z="0.8376740170849318">
<NAME>Bleeding</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Cimetidine or lansoprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2210581479242484" CI_START="0.6229702008819603" EFFECT_SIZE="0.8721713362068966" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="58" LOG_CI_END="0.08673634594433563" LOG_CI_START="-0.20553272685936802" LOG_EFFECT_SIZE="-0.0593981904575162" MODIFIED="2014-07-24 15:36:03 +0100" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.1716803001201389" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="259" VAR="0.029474125449340964" WEIGHT="86.66767003294609"/>
<DICH_DATA CI_END="2.1018080877592284" CI_START="0.37793564481698294" EFFECT_SIZE="0.8912621359223301" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.3225930588700704" LOG_CI_START="-0.42258214587793" LOG_EFFECT_SIZE="-0.04999454350392979" MODIFIED="2014-07-24 15:36:03 +0100" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.4377196039457292" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="102" VAR="0.191598451678406" WEIGHT="13.332329967053903"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0323412252103674" CI_END="1.2599062913215362" CI_START="0.5442391442720811" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8280642015277825" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="50" I2="3.1328038075566558" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.10033824458152932" LOG_CI_START="-0.2642102249046942" LOG_EFFECT_SIZE="-0.08193599016158251" METHOD="MH" MODIFIED="2014-09-16 17:45:13 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3096097322654493" P_Q="1.0" P_Z="0.3782941072635462" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.008976433083810732" TOTALS="YES" TOTAL_1="359" TOTAL_2="361" WEIGHT="100.0" Z="0.8810438292645129">
<NAME>Surgery</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Cimetidine or lansoprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1540431819346422" CI_START="0.5203634970603784" EFFECT_SIZE="0.7749335106382979" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="47" LOG_CI_END="0.06222205953467496" LOG_CI_START="-0.28369317633273083" LOG_EFFECT_SIZE="-0.11073555839902795" MODIFIED="2014-07-24 15:36:12 +0100" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.20319232185654745" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="259" VAR="0.04128711966145477" WEIGHT="91.22892980143266"/>
<DICH_DATA CI_END="6.72610910689725" CI_START="0.4050041612621382" EFFECT_SIZE="1.6504854368932038" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8277639078996828" LOG_CI_START="-0.3925405145534793" LOG_EFFECT_SIZE="0.2176116966731017" MODIFIED="2014-07-24 15:36:12 +0100" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.7168128583533001" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="102" VAR="0.5138206739006282" WEIGHT="8.77107019856734"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.7795914471480683" CI_END="1.2168043882985489" CI_START="0.7807178743059406" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9746696545386972" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="207" I2="64.0234898180441" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.08522076729281193" LOG_CI_START="-0.1075058774771534" LOG_EFFECT_SIZE="-0.011142555092170736" METHOD="MH" MODIFIED="2014-09-16 17:45:18 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0954726102060548" P_Q="1.0" P_Z="0.8207099542424405" Q="0.0" RANDOM="YES" SCALE="1.5049876507101594" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.016675755697828153" TOTALS="YES" TOTAL_1="359" TOTAL_2="361" WEIGHT="100.0" Z="0.22663193978678597">
<NAME>Transfusion</NAME>
<GROUP_LABEL_1>Tranexamic acid</GROUP_LABEL_1>
<GROUP_LABEL_2>Cimetidine or lansoprazole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.25466617045652" CI_START="0.9240763910594048" EFFECT_SIZE="1.0767578125" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="140" LOG_CI_END="0.09852818827569676" LOG_CI_START="-0.03429212526882025" LOG_EFFECT_SIZE="0.03211803150343824" MODIFIED="2014-07-24 15:36:20 +0100" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="0.07801930964720488" STUDY_ID="STD-Barer-1983" TOTAL_1="256" TOTAL_2="259" VAR="0.006087012677826436" WEIGHT="56.30327357461157"/>
<DICH_DATA CI_END="1.0687303704321693" CI_START="0.6876447392146763" EFFECT_SIZE="0.8572670627445298" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="67" LOG_CI_END="0.028868151042633017" LOG_CI_START="-0.16263587520492068" LOG_EFFECT_SIZE="-0.06688386208114379" MODIFIED="2014-07-24 15:36:20 +0100" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.11249041297803146" STUDY_ID="STD-Hawkey-2001" TOTAL_1="103" TOTAL_2="102" VAR="0.012654093011968067" WEIGHT="43.69672642538842"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-11-13 11:31:52 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-08-07 13:29:05 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAMrCAYAAABj2BRuAABUo0lEQVR42u2dD6RV2f/3v2SMjJFI
kmREMpIkklwZuSQZGbkkI/n5iSQZSXyNZFxjyEiSRJKRkUiSMRJJcmVEklwjkWuMJDGSjDH287zX
86xjnXX3Xn/2Pufec/Z5vbjqnL332mvt/Vmf99577bPe/ykc/vOf//A3Qn+DBueE+IPh5D9uJ4YR
O/kDdM6JP+IPhlxIOKF0ZhIKcO6hwXnkRBIE/xnJfQPxBwgJICRA/AFCAggJ8Uf8EQMICdCRSSJA
DCAkQEcmiQAxAAgJICRA/AFCksrTp0+pJ0LSCoYlRogBaCQkHz58KFavXj3r+/fv3xcHDx4sPvnk
k+Ljjz8uJiYmirdv3yZvnxtM7nLtr19B28ug9uvplv3LL78UH330UbFhw4ae7LfJ9oMqJO/evSuO
Hz9eLFu2zByrFStWmM9//fXX0CVDd3kolufyXAxKAkdIWi4k//zzT7F79+7SE33kyJHi3Llzxb//
/mv+1MElJqnbNwmmfgZeL8sOlaXE+Ouvvw5EvQdRSP7+++9ibGys+P7774s3b96Y7xRnDx8+LMbH
xwdOTOpeoHA3iJC0Xki++OKLYmZmpvREL1682HRsVzT8q6vQ9mXBdObMmWLlypXFggULZiVaW0bZ
fD326l7brVu3rrh3715S0Kr+hw4dKj799NNi+fLlxc8//zyrrt99912xaNEic+f1zTffzCrr0qVL
pXUuq2eoDTn7Tan3sAuJBOTHH38sXXb58uXixIkTSech5Xj6vHjxovjyyy+LhQsXmrLWrFlT3Lhx
I/n4x5bnxIEu0FRn1UX96Y8//khud6wdCAnMiZDcuXMn+UTrCnLp0qW1t9c6O3fu7HQUdQgFf+zR
gH91f/v27WLVqlVJQXv69GmTsNTxX79+ba6A3eXnz583HVXLJZRKCD/88ENXWeqoKXWOtSFnv7F6
t0FI1q9fX3nXoTavXbs2+TzEjmfZvq9cudK52z579mxXbMeOf2x5ahxISLVvWw+1Y9++fcntjrUD
IYE5EZKcE/3TTz91XSXmbq913KutUIfzy1PnuHbtWnbQbty40Qig5dGjR13LNX7h3nUJV6Ry6pyz
LLbfWL3bICSxcTB3eew8xI5nCrriTz3+seWpcSCxdMvR/5csWZLc7lg7EBIYKCHRM+w9e/aYq70m
QhL6LtT5dBei75QwTp48mbwf9+rNPpLwl/uPH2IdsRdCEttvrN6jKCSx8xw6nmVoLEYXRnv37jUJ
PTduQstT46CsjqE73rLvQu1ASGBghETi8fXXX5tb+CaB0kRIbIe5detWsX379uLYsWO1hCSlI9et
c9MEUpVMetEZB1FIdFGgt7bK0BuDGgtLPQ+x4+mjMZjPP/+8uHjxonk8++eff2bFTWx5zgVFTnz5
38XagZDAQAiJ7kT0CvDLly8bB0pTIbE8efIkuNxdtnnz5q5HB8+ePetarmQVejuoX0IS22+s3m0Q
Eo0P6OWLMjRg/O233yafh9jx9NEgubu+4jsnbmLLc+LAf7SVcycWawdCAvMuJA8ePCi2bt1avHr1
qieBkpOU9RaKng3bTqarLr25JfwBx1CZGoicnJzsDIpu27Zt1mCnHTTVnz7rzZnUOvv1zBlkDe03
Vu82CInudNUuiYlNhmrv3bt3ix07dnT9Zil2HmLH00dvQdm3myQCmzZtyoqb2PLUGLFiauut1+3d
32TF2h1rB0IC8y4k+nFYqn1mr4VEb9zoysxenemxlp7/2lcgraik7OfUqVNmAFOvhuqtGH+5rnx1
Zad96Q0ZPR5IrbNfz1Qhie03pd7DLiRCP2bVcVBCtD9I1GNL/4evKWMFsePpcv/+fTMYr33qIkUv
cuTGTWh5aowI+/qv/vTG1vPnz5PbHWsHQgJzKiTQ+iAgiQAxAAgJICRA/AFCAggJEH+AkAAdmSQC
xABCAnRkkggQA4CQAEICxB8gJICQAPEHCAnQkUkiQAyMsJBgATo6xwQhIRYREuiLkMynBehcBmBO
GbkWv8PSQRCS3tQXG2eEBCGJnFyEJH9/CMloCclctnVYbJwRkhEWkioL0JgVrua8ksmUjH0sMavQ
WFDJIlVzJMnaVw5v/lxBoTr5xCxQQ9akZcckxcpU7dUcSVpHkw3K5Chlf+6VZZWFcI597LAJSVU8
hdqsiQ/tsdaxnJqa6loei0V/f7mWxtg4IyQIScIdScwK9/DhwyYQ7YR4KVahof2qI2mSPjuL6pYt
W2YJSahOPjEL1Fxr0pT1NaW4ZkjW8uvXrxf79+9P3j5kIZxrHzuMQuLHU6zNMnCyTpnyptFEhZaU
WPT3l2tpjI0zQoKQJAhJzFbWX55iFRrar03CljLL0hyr0ToWtbnWpP767h2IOqd9bp2yfchCuBf2
sYMuJP65jbVZwuEvz4lFf3+58YKNM0KCkCQISWidsuVNrUL9AcWQZWnqs+NQeSLXmjR3fb8Ooe1D
FsJ17GOHTUjKjl2OBXHTWMy1NMbGGSFBSPogJE2tQnO8r+sIib9+rjVpHStTVxxj21uhKbMQrisa
wywkdSyIm8RirqUxNs4ICULSByHJtQr1rUDl6OZ6wT9+/LiRkMQsUHOtSVPWn56e7mq/zJlSt3fx
LYRz7WPbICSxNss9sOrRVh3b2lxLY2ycERKExCNkAZoqJDGrUHcweWZmxgwuhgbb9aZNEyGJWaDG
rEn9Y5JiZTo+Pm687bVPDWK6g+2x7UMWwrn2sW0Qklib9YhQjwOFLHn9wfZc29pcS2NsnBEShMQj
ZgGaIiQiZBVqk6Nut9WplTT9chTUelVRryLqjZPYVWQsKEMWqDFrUv+YpFiZah/al7aRqLgDqLHt
YxbCOfaxbRCSWJtlzTsxMWGOlY6b+6JDLBar9pdjaYyNM0KCkAwBShTuoyEY/o5MEgFiACHpK7oq
0kCzfeddV5TugDMgJED8AUISRG8y6b123YLrl+1Hjx41ggIICRB/gJAAHZkkAsQAQgJ0ZJIIEAOA
kABCAggJICSAkADxBwgJICRA/AFCAnNDPyxWB1FIRtHqeVTtrclBCMlABFq/26BpN+R7YtHU9l99
9ZV5LVlTVejX1O6cYC7+r9Wbti/X7ndYhWRUrJ6Hrc0ICbRWSPqNpnF3J1/U/ENXr17tzFek/2v6
Ex/NH+bPD9a0ff04FsMwRcooCMkwtBkhgSwhaWLzmmJB69uahmxSU2x+3f9XWZS6da+y7/V58ODB
LJEom2q77DtN/f77778nCUlK+8psVGPnaRiFpK1Wz6H61GlzrB9WHROEBOZMSJrYvKZY0Pq2piGb
1BSbX/f/IYvSmH2vz5EjR4xviIu9I3EfX23durVrHU02qXanPrrKaV/qeWrbHcmwWz3n1idWfopd
r39MEBKYUyHptc2r7/7m24iGbFJzbEdj68bse300tbumeHfRYy5dodqrR/3fffT122+/dd3FpAhJ
TvtSz1PbhGTYrZ5z6xMrv45dL0ICcyokTW1em1rQpjz+SEm0/ncx+14fPYLwO6vueHR1aa8sNe32
7t27zbJ3796ZxwhuAqozRpLavtB5apuQpB6jsouXsjiba6vn3PqkOIjm2vUiJDCnQmLFoI7Nax0L
2rkSklxP6rK2KsG44qL/S3CEjKuuX7+e1VGatq/qPI26kAyb1XNum+vY9SIkMOdCYsm1ec21rBUh
m9ReCknMvjfljsSKhptgNNhp91X11y8hqTpPoy4kg2b1nFufWPl17HoREphTIWli85piQesTsknt
pZDE7Ht9VHffaU8DmLrb0gCnyjl9+nRx6NCh2h0lp32+xWroPA2zkLTR6jlWn9w217HrRUhgToWk
ic1rigWtT8gmtZdCIkL2vT56a0vr+HWVmFirU4mIvpsLIfEtVmPnaViFpK1Wz6H65LY51g8REhio
R1ttJmbfq9+zuFd5LQ0CkkgPYgUQEoRkRKhj36s3oto8DxJC0rtYAYQEIRkB6tj36hHIrl276Mgj
lkSweiYGACEBhASIP0BIACEB4g8QEqAjk0SAGEBIgI5MEgFiABASQEiA+IPhEZJRtQylI5NEgBhA
SHp0cgfRMnS+XAjnuu1tmWsLEBIY8TuSUbUMRUhIIkAMICQVJzfFvtZdt9eWoWXELFR9i9FcC9XU
tqfYCleRsm1o3/rFteb5Ujs0F5Qc8toiJDEL4SYWurlWz7H47IXdMUICIyEkIfvalDuSJpahPimW
pb7FaK6FamrbU2yFq0jZNrRvzTpsZ39VO8bGxlojJCEL4aYWurlWz7H47IXdMUICIyEkOZaivbYM
9UmxLG1it9uk7aKJS13MktgtT1fT7nGI2QYPk5CELISbWujmWj3H4rMXdscICYyEkOSc/F5bhoaS
rVtG6v5yLFRT2p5rK9xk2yZuj8MkJCEL4abnP9ehMxafvbA7RkgAIWkoJDHL0JRO3y8L1VhZdWyF
m2wbakfdTjmog+1VFsJNz3+ukKTEZ1O7Y4QEEJKGQhKzDPXJtSz1v8uxUI2VVcdWuMm2/iM69zjI
jbKNb22VWT03sdDNtXrOic+6dscICSAkHr22DPWJWZY2tdvNaXsdW+Em27rfaaBeDn62Hdu2bWuN
kMSsnptY6OZaPcfisxd2xwgJICQevbYMLSNkWdrUbjen7XVshZts63936tQpM9CstqgdbRGSmIVw
EwvdXKvnWHz2wu4YIYFWCskoMeoWqvwgERASQEgywUIVIQHiDxCSRmChipAA8QcICSAkQPwBQgJ0
ZJIIEAMICdCRSSJADHAOOYmAkABCAggJICRA/AFC4jJfVr2jahGMkABCAn0TEv2+Qr/m1ZQn+tWv
O/W6PxtqbMbeWLCEZuedq6AcRItghASIPxhaIdHUG655kKYUCc1/dfPmTTONRC+CZb4Ca1QtghES
QEigL0KiOaDev3/f9V3VZHQSGrn9vXv3LhgsIbtd15bXt+rNsTIddItgOjJJBIiBkRESF02hrYQp
86UyNFlg6G7EBkvIbjc0qV6OlekgWwTTkUkiQAyMpJDs2bOnM8uqfDvK0N2IPB9iwRKyjQ0JSY6V
6SBbBNORSSJADIzsHYnQwLseK/lMT08bH406wZIqJDlWpoNsEUxHJokAMTDSQqJHN2WPhTSGIJHp
p5CIVCvTQbYIpiOTRIAYGCkh0eMk145Wboeaft1n9+7dJsH3W0gsMSvTQbYIpiOTSIBzP1JCorsM
PUayr//+97//NX8+GhOIuRnmColv1ZtjZTrIFsF0ZhIKcM5HSkj0KOvw4cPmR3oaaK96fKWk7g84
NxUS36o3x8p00C2C6dDhevA3On8wAkICXBkCxx8AIQESGccfACEBEhnHHwAhARIZcPwBIQESGXD8
ARASIJFx/AEQEiCRcfwBEBIgkQHHHxCSuWBUbW9JZBx/AISkRx2mid3usHXQWD31i/m7d++SyBAS
AIRkru122yIkmqp/48aNJDKEBGC4hCRlbqzLly+bGYE1F5fm5frw4UNnuebfOnTokJmHavny5cY9
0N3+xYsX5kpbEyVq/qw1a9YUN27c6JRdNidPyNY2tj+fmH1vaF+hutv6a34wzaBsBUATQe7bt89s
o/Wnpqa61o9Z+o6PjxcPHjwgkSEkAO0SEhlNabZcJXEl3iNHjnSWnz59ujMzrqajHxsb69peropX
rlzpzJx79uxZk3ir9h+ztY3tzydk3xvbV0rdJaxaZidxPHHiRMflUdPua0Zjd/2Qpa+4ePFi1/El
kSEkAK0QEveq+v3798WKFSs6n3UlbqdjF48ePYp2GNcoyl83Zmubu7+QfW8dC12/7r5Fr4Sjapbk
FEvgZ8+eJTlRksgQEoChEhI/MbpX0f4Vtdb1y9TjH12p792710wTH5oCPmZrm7I/l5B9b4qFbk7d
y+qXc6xte/SYjUSGkAC0SkhCybIscbrbaHxFV+l6ZHPnzh3zCChUfszWNra/Mqrse2P7yq17L4Qk
VgaJDCEBGHghefny5axkKdtby9u3b81At2Xz5s1dj5r0aMbdXuu6NrVl5bvEbG1j+wvh2/fG9pVb
d7F69ergo63Ydxqr4Y4EIQEYKiFxB6NnZmbMW0p+spStrAa2rRWv/NstGoyenJzsDH5v27ata3u9
oWTfdLLP/0N2uzFb29j+fEL2vbF9xepetl89BtPjNKHfhPiD7bHk8vjxY8ZIEBKA4RISm1z1mEdX
00q6frJUMl22bJkZuD569Ki5K3E5deqUeT1Yr9HqTSh3+/v375sBbO1DSVUD3yG7XRGztQ3tzydm
3xvaV6zuZfvVq9ETExNmG+1XLwPkCMmFCxd4awshARguISH4Bwu9zizxI5EhJAAICWSjx2d6u4xE
hpAAtEpIejEXFqSxa9cu5tpCSADaJyRAIgOOPwBCAiQyjj8AQgIkMo4/AEICJDKOPwBCAiQy4PgD
QgIkMuD4AyAkQCLj+AMgJEAi4/gDICRAIgOOPyAkQCIDjj8AQgIkMo4/AEICJDKOPwBCAiQy4PhD
q2OYQCaJAecAoLGQEMwkMOA8ADQWEhvQ/I3OHyAkAD0XEjoyAPEHgJDQkYH4A0BI6MhA/AEgJHRk
AOIPEBI6MgDxB4CQ0JGB+ANASOjIQPwBICR0ZADiDxASOjIA8QeAkNCRgfgDQEjoyED8ASAkdGQA
4g8QEjoyAPEHgJDQkYH4A0BI6MhA/AEgJHRkIP44CICQ0JEBiD9ASOjIAMQfAEJCRwbiDwAhoSMD
8QeAkAxnR+aPv/n8A0BIgCtqAEBIABASAEBIACEBAIQEEBIAQEgAIQEAhAQAIQEAhAQQEgBASAAh
AQCEBBASAEBIABASAEBIACEBAIQEBk9AmDMKAOj5gJAAAEICgyEmAICQACAkAICQAEICAAgJICQA
gJDAqIkJACAkAAgJACAkg5BQ+cNnnbjnb9Tint7AVTlwzjkG0OicEwV0JuDc03ZodO6JBDoTEAO0
GRrFANFAhwJigDYDQkKHAmKANgNCQocCYoA2A0LCwQRigDYDQgJ0KCAGaDMgJHQoIAZoMyAkLepQ
Hz58KFavXj3r+/fv3xcHDx4sPvnkk+Ljjz8uJiYmirdv3yYvJ+HQxmGMe8Xwl19+WSxcuNDE9p49
e4rXr193lev/LViwgJhASEa3Q/3zzz/F7t27S9c5cuRIce7cueLff/81f8ePHzdikbqcDkUbhzHu
v/vuu+LkyZOduP7pp5+Kb7/9trKsmzdvBpcTEwhJ6zvUF198UczMzJSus3jxYtOR3M6nO4/U5WX1
ePjwYbF06dJi48aNXR130aJF5urvm2++6drm77//Lvbt22euDtesWVNMTU11LZd4aTstV1v++OOP
4P5U30OHDhWffvppsXz58uLnn3/uavsvv/xSfPTRR+YKc926dcW9e/cQkhGL+/Hx8eLZs2ddcb1j
x47SchRP69evL969e0fcIySj26Hu3LmTnGgU3ArOusu1j8OHD5ug/vPPP81358+fLy5dumS+U4dV
gP/www+dbU6cOFFcu3bN/P/WrVvF559/3ln2448/FmfPnu1cOaosdb7Q/k6fPl18//335js9rhgb
G+tquzrTr7/+av5/+/btYtWqVQjJiMW9kq17gWS/K0MxF7sbIe4RkpFJIinr6BZfAV53ufbhXjmJ
DRs2zOq0bhCrA/nLLWvXrjXi5QrZkiVLgvvTFZq7zaNHj7raLiG0HZhHW6MZ90qqKd8J3Y28fPky
ug/iHiFBSP4vb968MYOOunqqszzUaUMDl1UdWJQNcLrrpyQJdVZ3PV2N6bM6up6TIySjF/exuLJM
T08XmzZtqi1WxD1CMlJCInH4+uuvu95cyVme22lTrgSrlnUFTuLVpr+eni/rccL27duLY8eOISQj
Fvdlj7HKvjtz5owZq+iVWBH3CElrhUR3GnrFt+r2PbY8tg8N7P3111+V2+j1zKpbfG3r3+K7g/1l
+9u8eXPXNhpUrWr7kydPWpOAEZL0dZRI9Wq7Ra8Ja0DbR299KfES9wgJHSqwzoMHD4qtW7cWr169
Kt0mtjxlHxo4tIOA+tNnt9NqzEW33eLu3buzBh11VWi31avI7u8CyvZ35cqVYnJysjPouG3btq71
VL7eYBEafAxdGSIk7Yx7vU3lxuTFixdLH/doTMMOZhP3CAkdqmKdFStWBG0sY8tT66G3XvToQFdV
+iGY2zl1NajfpiiwNcioQUIX+xqk/vTmyvPnz6P7O3XqlBmc1KuXeuPFXU+399qPHj1on7ZzISSj
E/eKPyVaxaP+du7cWfpDW8VH1V0DcY+QjGSHAmKANkObY4BooEMBMUCbASGhQwExQJsBIaFDATFA
mwEh4WACMUCbASEBOhQQA7QZEBI6FBADtBkQEjoUEAPz3qY6v1sChARIIkAMdAlJ1Q9iiXtASEgi
tLsPx6Iq+bb1b1hibb63R0iAIKPd3JHM8x0JQoKQjGwSCdlrhqw+61iHxparTDnGrVy5sjPfj3Vs
S9k+ZiVKDDBGkhJL8tTRJIluH7E2u7E+Edqv+11KrBLrCMnQJJGQvWbI6rOOdWhsucrUxHXW2c2f
gTS2fcxKlBjgra2UWFI8y6xKyzRxovqEDKxS+kSqkMRilVhHSIaqQ4XsNUNWn3WsQ2PLy8p06x3b
PmYlSgwgJKmxpESuZK3kfeTIkeQ+kSoksVgl1hGSoepQIXvNkB9BXevQ0PJY58u1JvWtRIkBhCQ1
lmwy15TrMm7L7RMpsRyKVWIdIRm6JFJlr5krJDHr0NjyWOerY01K50JI6sSikAeJ7kDmQkiIdYSk
NUnEt9cMWX3WsQ6NLY91vtj2OVaixMBotzkWS3Ic1BiFnBHdR1upfcLfr2yo3e9isUqsIyRD1aFC
9pohq8861qGx5TEhiW0fsxIlBhCSlFjSYPuWLVu6kvrvv/+e1Sfcl1hmZmbMSyTu8lisEusIyVB1
qJC9Zsjqs451aGx5TEhSyg9ZiRIDCElKLCnm3dd/9X8tz+kT9qJM/Up3MepXfl1isUqsIyQkESAG
aDMgJHQoIAZoMyAkQIcChASIe4SEDgXEAG0GhIQOBcQAbQaEhA4FxABtBoSEgwnEAG0GhAToUEAM
0GZASOhQQAzQZkBI6FBADNBmQEjoUEAM0GZASIAOBcQAbQaEhA4FxABtBoSEDgXEAG0GhIQOBcQA
bQaEBOhQQAzQZkBI6FTAuaft0KdzTyTQqYBzzjGARuecKOjxAeZvdP6AuCfuERLgqhQAepEDOASA
kAAAQgIICQAgJICQAABCAggJACAkAAgJACAkgJAAAEICCAkAICSAkAAAQgKAkAAAQgIICQAgJICQ
AABCAggJACAkAAgJACAkgJAAAEICCAkAICSAkAAAQgKAkAAAQgIICQAgJICQAABCAggJACAkgJAA
AEICgJAAAEICCAkAICSAkAAAQgIICQAgJAAICQAgJICQAABCAggJACAkgJAAAEICgJAAAEICCAkA
ICSAkAAAQgIICQAgJAAICQAgJICQAABCAggJACAkgJAAAEICBBFCAoCQACAkAICQAEIC83b++Rud
P4QEEBLg3EPPzzlRACQT4LxDo3NPJAAJBTjn0CgGiAYgqQDnHBASIKkA5xwQEiCpAOccEBIgoIBz
DggJAEkFOOeAkABJBTjn7eLp06cICZBUYHTO+bt374rjx48Xy5YtKz766KNixYoV5vNff/1FP6jJ
xx9/3NP996KuCAkgJNCXc/73338XY2Njxffff1+8efPGfPfvv/8WDx8+LMbHx1svJsPSxxASQEhg
YM+5BOTHH38sXXb58uXixIkTXWVcunSpWLlyZbFgwQJz9/Lrr792bfPdd98VixYtKj755JPim2++
idZLdz5ad+HChcUXX3xR/PHHH9n7+/TTT4vFixcXZ8+endXOWPm93Jdblj/Xlf6VOC9durTYuHHj
rP2/ePGi+PLLL009te81a9YUN27cQEgAIYHBP+fr16+vvOt4/fp1sXbt2q4ylOxsMlaiVdKznD9/
3iRj3dH8888/xc8//1z88MMPlXWSgCkha339aft9+/Yl70/7OnbsmNlWdd2yZUtXO1PK79W+Ysdb
nw8fPmy2//PPP2eto/Nw5cqVTl1Vb4kOQgIICQz8OY89y3eXqwz3it4vd8OGDSYJuqxataqybImU
Hq1Z9P8lS5Yk72/z5s3Fq1evOp8fPXrUtTyl/F7tK0VIQuWXoTsjhAQQEmidkITK1RW8/1jHTYah
ROmWkbo/v+4SMXd5TvlN95UiJLF19OhLjxL37t1rRDBWP4QEEBIYiHOuuwi9tVXG+/fvi3Xr1iUn
w5BolOEm9TrJ3d/eT+455TfdV1Mh0XjU559/Xly8eLG4c+eOefyFkABCAkNxzjWOcObMmdJlGuz9
9ttvk5OhRCfnLS+t7z96yrkD2rRpkxmvsDx+/HhWfVLLb7qvpkKiQXz32L18+RIhAYQEhuOca1B8
27ZtRkxsItPV9t27d4sdO3YUb9++TU6GEiW9BWYHjPVZb0pVYUXMrn/u3Lli9erVyfvzB8C1L78+
qeU33ZeP3r7SmIgVslj5elvMvqX17NkzI1wICSAkMDTn/MOHD+bOQ8nM/iBRSdMVkZRkKFSOrq51
5a+3oOwbSlXY13P1pzeqnj9/nrW/yclJ87rx8uXLzVtZ/lhGavm92JeL3lbTcrtOrPz79++bFxN0
/PWI69q1awgJICTAOZ9rJIgSwbbtqx8xQAYAkgpwzv8vepX31q1bnd+t6O5Dd1LDvi+EBEgqwDmf
I/R2k34lrsdH+rX50aNHTZIf9n0hJEBSAc45ICRAUgHOOSAkACQV4JwDQgIkFeCcA0ICJBXgnANC
AiQV4Jy3k17Z4Q6irS5CAiQVGOpznrov/9fbZfzyyy/m196aXDI7WUbKTrHDTaFX5SAkQFIBznnG
vmZmZqLzVYkyp8JeCUmvjsmw9CeEBBAS6Ms5T7F4DVnQ6pfehw4dMvNraQ4quSKmxNf27duL33//
PTqDbpllbap45JYtqqyC9+zZYyaydO+UNKllVTkICSAkMDLnPMXiNWRBe/r06c6Mv5oVd2xsLBpf
mvxQ+6lz19ArISlbHrIK1uSTmpFXyzTPliZYnJ6e5o4ESCrAOS/Dt3gNWcRq2hDX8yNmQfvbb78V
4+PjtZN9P4UkZhUsoZFwSlyOHDkydP0JIQGEBPp2znMtXus6B8qJUcLjep8PkpCkWAVLbDSB45s3
bxASIKkA51zUsXjNsbN12b9/f3H9+vWsWOyFkFSNY/hlpVgF79y50xwvhARIKggJ5/z/U8fi1f1u
8+bNXY+25O5XtS8/oacMUseEJFTfXJGKWQXLYVFjKBJdHm0BSQUh4Zz/f+pYvLrfaaBeg+d2sF22
vTnxVefxk31rTK8Q60WAukLi2+GGrIJ1p7Zly5Yu0dFbZ2XlICSAkMBInfM6Fq/+d6dOnTLjBnpt
VgPS/RQS+9aYHkPJf12v4dYVEt8OV1RZBU9MTHS9/qv/a3lVOQgJICTAOYdWxwDRACQV4JwDQgIk
FeCcA0ICJBXgnANCAgQUcM4BIQEgqQDnHBASIKkA5xwQEiCpAOccEBIgqQDnPIVhsJYdFvtbhARI
KjCS59z/BXdq2f2Mu9u3b5sJFZvWESEBQEhgDs553bL6GXea3t0aTZXti5hHSAAhgT6d8xSrXfmV
yDVRXiIx+1tNXLhv3z5TnsqampqqrEOVra3QHFp2Ti1NkHjv3r3Ktj148GCWWVZZHc+cOVNpGey3
M6WOKcsREkBIoPXnPMVq9/Dhw2aZncAwdLUvgyxN/Chu3bplJoIsWy9kayvcRK/HVq5ToY+mdJev
Sqi9+qxHX1WWwWXtjNUxthwhAYQERvac51jt+p8lHL5dbdl6MVtbiZkVpBia+l5T4MfqGGpH2fJY
HWPLERIgqcDInPMmVrv+5zLHxKr1Qra2ugvRd0rWJ0+eDLZNj9H8hN7EWTG1jinWvAgJICTQ+nPe
1Gq3rpCkJFwJnB6Pbd++vTh27FjSHVQvhSRWx0EWDYQEEBKYs3Pe1GrX/yyzqZRHWzFbW5cnT54E
Y7ZfdySxOua0ASEBhARae87rWO361rL+YLseSwm5CFYNtodsbYW205tbwh8Y91GdHz16lFzHVCGJ
1TG2HCEBhARG4pzXsdr1rWXddT58+GBsaVWexlvcBO+XVWVrK/RYS9vbV3WtqJSht7b0BlVqHVOF
JFbHlOUICSAkwDkfAvRblUG+E0BIgKQCnPMhQG93Mb8WQgIkFeCc10bjKLt27eJEIyRAUgHOOSAk
QFIBzjkgJEBSAc45ICQAJBXgnANCAiQV4JwDQgIkFRjwc84rs4N1TPq5b4QEEBLoyzn3LWmbxksb
YivlmAzjvhESQEigL+e817HQhtiazzb0c98ICdDZoefnvMqS1recdbdNsea15NjliuPHjxvLWpWt
KU9coymVKzfCKqtcn5Dlr6iyyE09JqEy9uzZYyasdI/Djh07osevbN+h/SAkgJDAQN6RxKx1U6x5
LTl2uZo5V2XZcjUJo4TALVcJuMoq1ydk+RuzyE05JqEytI5mJNYyTWKpdk9PT2cfv5S6IiSAkMBA
CknMWtfHt+a15NjlaqZfO+W7vaNYsmRJ7XqFLH9jFrkpxyRWhgTg9OnTJulrduI6xy9lPwgJICQw
kEISWyfVmjfHLrfMbdC940ipV9W2ZctCFrkpxyTFZlftlhi+efOm1vFL3Q9CAggJDJWQ5Frzptrl
liX+XKfGVCGJJeKUY5KSzHfu3GmOlSskucevl3a+CAkgJDAQQlLHmlfE7HI1GO8/2nJfhc0VkpDl
b8wiN+WYxMo4d+6cGduQYLiPtnKPXy/tfBESQEigL+c815I2x5o3xy5Xg+1nzpzpDEIrEUsM6gpJ
yPI3ZpGbckxCZeguY8uWLV1i8PvvvycdP3/fvbTzRUgAIYG+nPNcS9oca94cu1xhX//Vn97Yev78
eW0hCVn+ipBFbsoxCZWh/bqv/+r/Wp5y/Px9x+qKkABCApxzmJcYIBqApAKcc0BIgKQCnHNASICk
ApxzQEiAgALOOSAkACQV4JwDQgIkFeCcA0ICJBXgnANCAiQV4JzPB/20l51L29y5tujN3R9CAggJ
tPac+/ayvaxrv21z3br2sx29aBtCAj0L+ioXNkBI2li3uWx3ymSP89k2hAQQEuhb0olZ3JbZzPpl
a3p0eW+oHLkJaq4rS669rF/XkNVsyIK3rOxU+9/PPvusM/27naH3t99+M59fvXpllrt1rWqHJqIM
2QPHjn3VeazTjxES6IuYAEKSYnHr28yWlS0TJyVBrafE706dnmsv635OscUNWfCWGUWl2P9+/fXX
xfXr183/r169ah4jqS72sz1GoSng9VmeJFV1Szn2QTHgjgQQEhgEIaljcVtW9tTUVOfz+/fvixUr
VgS3SXUkTLHFDVnw+mWn2v/qDuvgwYPm///7v/9r3Az1J/bv328ELUVIQnVLOfYICSAkMPBCUsfi
tqxsP9n73iM59rLu51xb3FiyTbX/nZ6eNndSQo/AZMxlxVGP5vS4K0VIQnVrai+MkABCAgMhJHUs
blPKdsvNtZeNJducZF22PNX+d/HixcXr1687AqKxDplRuXdbTYSkqb0wQgIDmVRg9M55HYvbsrJ1
xW55+/atMWKy5NrLup9zbXFzkm3M/nf37t3F//zP/3QeadnHW/ZzUyHJPfaptsYICSAkMKfnvI7F
bVnZeuNIV+8q47///a9JwpZce1l3WcxqNpas/bJz7H91XDRmoWMiLly4YMrT4H/KvmJ1ix1798WA
mZkZ81JBaH8IyQA85uGv/X8ISTm5FrdlZUsoli1bZgazjx49au5KLLn2sv4+Q1azsWTtl51j//vg
wYOu135l16vP1n89tq8Ue+DQsbdCp7pKYFTXmC0vQsJVOXDOh7Lt9KXhiwHOGIEPnHuEBBASEgkQ
A+1pc7/nswKEhCQCxABtBoSEDgXEAG0GhAToUICQAHGPkNChgBigzYCQ0KGAGKDNgJDQoYAYoM2A
kHAwA8iQx52mwKL5ftrwa2kSCkICxD3R0McOJeMczRFUto5mC52YmCChkFRpMyAkHMzqQ6jJ4DQ5
Wtk6k5OTZoK1nP2UWZSGbEM1+Zrm29FkbPI8cM2CRK4lqiaCO3TokJmnaPny5caMx21bqu0oSbW9
bU6ZPTdkoxtbHov5FCtfQEiGKonIK6FqHd2pjI+Pmw6hxKykHtuPb1Easw2V8Y91b9MdkCa4s9Sx
RD19+nRn5lTNzDo2NjbLDyHFdhQhGW0hCdnoxpanWOXGrHwBIRnKJFK2jmY2/emnnzpX+ppSWok/
VIZvsxmzDZVw+MstdSxRdYXnbmNnL7Wk2o4iJKMtJCEb3djyOla5gJC0Vkh81DkkLjllxGxDQ94I
dWw5/fJUZ3e9VNtRhGS0hSRkoxtbXscqFxCSkRGSquQeKiNmGxoSkjq2nLFtRKrtKEIyukLS5AKm
jlUuICStFRI9Rnr37l3nsx4ZaUA8p4yYbaheO656tFXHEnXz5s1d28idrqr9MdtRhGQ0hKTMzjVk
oxtbXscqFxCS1gqJXN80kGgHuzVgaC04U8uI2YZqzEWPm8Tdu3dnDbbnWqJeuXLFvG1mB9u3bdvW
tV6O7ShC0s42x+xcYza6seV1rHIBIWmtkOiVxgMHDpi7gMWLF5vOUWc/IdtQ7UO/VVHn1uC6Bsdd
6liinjp1ytxN6W0zvUHjrpdjO4qQtLPNMTvXmI1ubHks5hEShIQkAsRAy9sc247+hJCQRIAYoM0I
CUICJBEgBvrX5piNLja7CAlJBIgB2gwICdChgBigzYCQ0KGAGKDNgJDQoYAYoM2AkNChgBigzYCQ
wNx2qKdPn3JASaq0eUD6Ry/318a+jZAMaIdKefVxPpNWaN/W1Eoz/xIDtLkf9OLV4Jx69/JVZL+s
Xh6/+Yo/hGRAO9SgJ6RQ/dw5logB2tyGfQ5L30ZIWtyhcq1xfY+FqjL8/ZWVp1mFZQbkW5Rq5l7N
nhqri4jZ6vpt9esucq18SartaLPiSnGjOeTkwumu++LFCzM/lmJCFx+a8Vpza/l3tr5dc2r/SIk7
9/9yW1y5cmVnfjh7MVQV06E+k1v3lHqkHDOEpOVCkmuN65dVVoa7Tqi8gwcPmplRXWSVq46QUpeY
rW7sONSx8kVIhr/Niin50Ni42bJlS9e669evN7NI27hQjEgIyu5sfbvmlP6REnfu/5WgrdD4M1b7
+4v1mdy6p9YjdswQkpYLSa41blmw+WW464TKm56eNncldrn+/eyzzzrlxeoSs9WNHYc6Vr4IyfC3
WZ41r169So4b4ZpVheyaU/pHStyl9i9/f7E+k1v31HrEjhlC0nIh8cm1CY25zcXK27p1q7mCErqi
0VVP6rYxW91Ye+tY+SIkw99mf1C5LG70OEpeOXv37jWJP9WuOaV/5MRdrptjrM/UrXusHrFjhpCM
mJDk2oTGAixWnixvreuintneuXMnedsUW93QsjpWvgjJ8Lc5dgFy+fJlY4B28eJFE496JJVq15zS
P3LiLldIYn2mbt1j9YgdM4RkxIQk1yY0FmCx8oQG8DTeocdaOXXJsdUtq2sdK1+EZPjbvGnTJjM2
Ynn8+HHXuhqEd+POt+J18e2aU/pHTtzlCklKf6tT91g9YscMIRkxIYnZhOqtDD0rtR0hFmCx8oQG
A/XWlTsomLJtzFY31t46Vr4IyfC32R9sV0y56+rCxr5xpIsTCU+qXXNK/8iJu1j/8vcX6zN16x6r
R+yYISQjJiQiZBOqZK/v7RVUyrPTUHnizZs3Zpl7lZi6bchWN6W9dax8EZLhb7MuQBQzuoBR3Lh3
BPfv3zcD1EqySrwanE61a07pHzlxF+tf/v5ifaZu3WP1iB0zhIQkAsRAq9us3zLp7UFodwyQBUki
QAz0rM26g9Vgs/2the4O3EFnQEiAJALEQLDNeqtIv0HSIxz9sv3o0aNGUAAhAZIIEAPEPSAkdCgg
BmgzICR0KCAGaDMgJHQoIAZoMyAkQIcChIS4J+4RkuHoUFjvEgO0GRCSEe5QvbCe7ac9J5BU+9Hm
2LHo97Ea5olBh7m+ZKY+nfxeWM+mTFIHJACEpB3nAiEhicz6LmStWXX15NqGVpWhCemqLDlFyAq0
Tfa2JIDBFRJNTqg5rjRR4Y4dO4y5VdV2oXiNLY/ZQefY2dp9VVkE+6TY34b2l2NlbYlZCKe0L3Ss
EZIhuDJLEZKQra79vHPnzkpLzhQr37bY2yIkgxv31iVRcXb9+vVi//79pdvF4rWpHXSOnW3MItgn
xf42tL9cK+sUC+HQ/mLHEiFpkZDE7DabWO9WbQ8ISa/j3r0DUTy644Q58drUDjqnf9WxCPbx3U5D
+8u1sq5jXZ1zrBGSFglJ0zJyrXwBIel33Nu4rBOvTe2gc/pXikWwT679rd/2nP3Vsa7OOdYICUIS
DLZRT3gIyfwLSZVDYSxem9pB9zOx17G/De0vFkd1rKtzjjVCMqRCkmKX2WvrXYQEIclpU66Rmf1+
enq66xGM60eSE69N7aBz+lfMItinjv2t/ygtx8q6jnV1ri03QjIEQuK+RTEzM2MGxmKB12vrXYQE
IckVkrK3B2NxPz4+bpw5FYOKx6rB9li8NrWDzknsMYtgnzr2t+53uVbWdayrc225EZIhEBL7FoVu
MRUA+sFiLPB6bb2LkPQ3BqqSb1v/qo6F3hDSa6aKQYmK/5pqarymLA/ZQefe8Ycsgn3q2N/63+VY
WYtc6+rcY42QcDUKxMBA3JG0BSyCERKSCBADPRKSUWkzFsEICUkEiAHa3AgsghESOhQQA7QZEBI6
FBADtBkQEg4mEAO0GRASoEMBMUCbASGhQwExQJsBIaFDtZu2WQgjJMQpQgJ0qDkm9IvhFHphY0wM
zE+bh+lYzafV9TAcJ4SEJDLUx6wXNsbEAEIyyHVFSOhQhpgVp72q1txbmpnz3r17SctEyDKzbrlq
h6bE1i989YOsq1evmondNDdPHUvfKtvPlPmaRJWtaOr2dPr5a3PMEjZkxdsk9l0rad2taooTTXXi
oglQVW6sj6bYZTexvk2x6kVI6FBRK043sG7fvt3lVhZaFrPMrFuu2qFZWlXmzZs3jYAcOHDAfK5j
6Ruy/Yx1khRbUa5cB7PNKecuZMXbJPZ9K+mDBw+a+rjI4lZilNJHQzYOTa1vc/eNkHCL38E1l1HQ
aMbQMkLLYpaZdcv1rTr12fUvaGrpmzPhX4qtKEIymG1OOXchK94mse/HnXxRdFdit9G/n332WdBu
OuQo6n5uan2bu2+EZISFJGTFqastfVbnOHnyZNd2oWUxy8y65cZMtJpa+uYISR1bUYRkMNpc59y5
y5vEflnZW7duNXcxQncAuktI7aOhPtDU+jZ33wjJiHaomBWnDSTNOLp9+/ZZM41WLUuxzKxTbo6Q
1LH0zekkdWxFEZLBaHOdc+e/HVU39svKVjkafxAaG1FfTO2jsYup3Ha639Wx6kVIRrBDxaw4XZ48
eZK8LMcyM6fcHCGpY+mb00nq2IoiJIPR5pRzF7LibRL7VXXSgLfGRvRYK6ePxvpAE+vbOla9CMkI
dqiYFaeuRvSGivAH4kLLYpaZdcvNEZI6lr7ud76FsE8dW1GEZDDanHLuQla8TWK/qk4akJfroTsw
n9JHQ1bXTa1v61j1IiQj2KFiVpy6fddzUftqoO08sWUiZJlZt9wcIYnVIdaJfAvhMnJtRRGSwWlz
7NyFrHibxH5VnSRaWl/e6Dl9NGZ13cT6to5VL0Iyoh0KiAHaDKMQA0QDHQqIAdoMCAkdCogB2gwI
CR0KiAHaDAgJBxOIAdoMCAnQoYAYoM2AkNChgBigzYCQ0KGAGKDNgJDQoYYD7ESJgblqM7GGkECP
k0jdX7HmbFe1rvv/pra3gJCk0otYS92vfvV+9+7doYuF+d4eIRliIZmLfVetyyMKhGSu2jyXMa+J
ITdu3IiQICTD36FitqBVZWg7zScky1s5p4XuLEK2pbE7Et/bQa5tPnKi0+ys796942QjJNE2V1nl
pljX+t9pMsRDhw6ZvqBJF+WIqOWa0yolVjWP14MHD4LtqOqje/bs6bqjUbvUv4QmcbR9TlPUT01N
JT8xSGlfag5J2R4hGfIOlWILWvZ/bSMPBm2nSea2bNkSFISQbWnKoy33/9u2bZvlka36yHIXEJKU
NsfsnGNluN9p6nc726/6wtjYWGd5SqzK6+PIkSOVbQj1UU0GqRl5tUy+72qHnf5eZlTWxVF+J5p0
sY6QhNqXkkNi2yMkLehQKbagZf+3wmDRHUZIBEK2pblCYs2EXPR44PHjx5xohCSpzTE75xwhUey5
VgNuX0iJVTs9exWxPqpErmSt5O0KkoTD366OkITal1K/2PYISUuuzFJtQUOD3wqkFBFw91tXSIR8
EuyVlwJzPp4zIyTD2+Ymds7+d74Lod8XYrGq9fVIqIpYH7XJXF7smoq+ql51hSTWvlj9YtsjJC3o
UDm2oDnBlWNbWkdIJicni4MHD5r/6znwhQsXOMkISVab69o5x/qCvzwlVkNJP8W2eufOneYOZC6E
xF8eq19se4SkBR0qxxbU/b9uxV0DHt2qh0QgZFtaR0i0bw0i6vGaBvn0fBgQkjptzrVz9u1m9ZjX
fXSjR1Xu8lisalwhdEcS66NyPdQYhT/WIifEOo+2ctsXq19se4SkBR0qxxY0NNiubUIiELItTRGP
MttbXd3t2rWrOHz4MCcYIclqc8gq1481d2B+ZmbG/PbDLffKlSvmrsP2BQ2w+/sNxaouwkJjJKE+
qsF2vejiJvXff//d/F+D7XqEJ/RmV9Vge9P2xXJIyvFBSFqQRFJtQcseL+kKS6/0acAv9LgqZFua
IiRltrd6nVHr8EtkhCS3zSGrXD/WrNBoXV3la12/3FOnTpkxCsW4Yt1fHopVPeoKvbUV6qMTExNd
r//q/1oudOej5aq72lr1yn0v2hfKISnb9zM2EZIhSiIKWvdx1VygYNVAJiAkg97mUKzqdVgJGyAk
I9ehdHWhgUr77vjx48e7Biz7jfarqyD/jRtASAatzaFY1XiB+yo8ICQj1aHu3LljXmPUrax+2X70
6FEjKHOFnmPrERmD7AjJoLc5FKsaN5mPubYQEiCJADFAmwEhoUMBMUCbASGhQwExQJsBIaFDATFA
mwEhAToUEAO0GRASOhQQA7QZEBI6FBADtBkQEjoUEAO0GRASoEMBMUDcA0JChwJigDYDQkKHAmKA
NgNCQocCYoA2A0ICdChASDjxxD1CQqcCzj1th96ceyKBTgWcc44BNDrnREGPDzB/o/MHxD1xj5AA
V6UA0IscwCEAhAQAEBJASAAAIQGEBAAQEkBIAAAhAUBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQA
EBJASAAAIQGEBAAQEkBIAAAhAUBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQAEBJASAAAIQGEBAAQ
EkBIAAAhAYQEABASAIQEABASQEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBIAAAhAYQEABAS
AIQEABASQEgAACGBgRMQ/w8AEBIAhAQAEBKYHzEBAIQEACEBAIQEEBIAQEgAIQEAhARGTUwAACEB
QEgAACEZhITK3+j8AQBCwlU5cM4BEBISCnDuARASEgkQAwAICUkEiAEAhARIIkAMACAkJBEgBgAQ
EpIIEAMACAlJBIgBAIQESCJADAAgJPObRF69elV89dVXxccff1wsXLiwmJiYKF6/ft3apNfPZDro
iRohAYQE+pJEtm3bVly9erX4999/zZ/+Pz4+TtJDSAAQEkhLIh999FHSd245Dx8+LJYuXVps3LjR
fPfixYviyy+/NHc02nbNmjXFjRs3ura5dOlSsXLlymLBggVmnV9//bWzXAJ26NCh4tNPPy2WL19e
/Pzzz7Pqe/z48eKTTz4x+/jiiy+KP/74o6v8ixcvFkuWLCkWL15sxPDHH3805fn7csv95ZdfzHLV
ad26dcW9e/e69vndd98VixYtMvv95ptvupal1BkhAUBIRuqOxHLt2rVi69atwXIOHz5sEumff/5p
vlu/fn1x5cqVzl3N2bNnjdC420hobPJXYnfF6vTp08X3339vttVjtbGxsa76ShRUpi3//Pnzxb59
+7rK379/f/HPP/8UN2/eNMn9wIED5rO/L7dcV2Ru375drFq1qrNM+5D4aX8qR0Lxww8/JNcZIQFA
SEZGSKanp81VvJ0pVv/Xd6Fy3LuBKnSVH9rGrY/ubP7+++/O50ePHnUtX7t2bddy/V93H1Xl6/Nf
f/1Vui/3/xI7CWcZGzZsMCLh4gpNrM4ICQBCMjJCojsFXfHbq/1Tp04Vu3fvzi5Hj7tOnDhR7N27
1yT+quRddWfgonq4y11RKtvGLz/02f2/7kL0WaJx8uTJWeX707G79YjVGSEBQEhGRkj0tpZ75a3/
axwip5zLly8Xn3/+uRmnuHPnjnnk1URIcpfXFRIrgLdu3Sq2b99eHDt2LCheVUI2LIkaIQGEBPqS
RHzRkJBocDmnHI1JuI+SXr58mSUkmzdv7npM9OzZs67lGgj3H21JAHshJJYnT57M2qfbJp9YnRES
AIRkZIREA+e6k9CAskREg8h6GymnHL2NZd/SUkLdtGlTlpBooH5ycrIzcK0XAPzB9jNnznQev507
d65YvXp1YyHRXZTe3BL+oLz2aQfT9afPelsstc4ICQBCMjJC8uHDByMmusLXn0RE3+WUc//+fTMQ
rUSs5KwB7BwhERqb0QC6XrfVG1NVr//qT29sPX/+vLGQ6LGWxnPsK8lWVCzffvutudvScdFYkn1L
LbXOCAkAQjISQgLEAABCAiQRIAYAEBKSCBADAAgJSQSIAQCEhCQCxAAAQgIkESAGABASkggQAwAI
CUkEiAEAhGQ0ksjTp085OAgJAEIC9ZOIO2dVLxJQk2Sl2Xh37tw5kMkwZb6ufiX5Xu0PIQGEBPqS
RHqdXJqUp+ncQ14og5IM51pIuCMBQEgGVkh8vw37nW+l626bYqtriVnZujx48GCWV3yKnW3IDje0
f83cqzm71A61YWpqqqsNoWNgjbTs9jt27DDGVqn1yrXp9fcdsi1GSAAQknm/Iymz0nXXSbHVtYSs
bH2OHDlifE1cYna2MTvc0P5lwmXdEeVHoskmU4+B/q9p5F+9emXWuX79urH6Ta1Xrk2vv++QbTFC
AoCQDISQhGxxy/BtdS0hK1sfTT2vKehdYna2MTvc0P4lHP62qcdA/3fvQFSO6pJar1yb3rK7oToC
gZAAQgJzJiSxdVJtdUNWtj56ROQn35idbcwON2alm3OsYoPtbnm9tunNnZIfIQFASAZaSHJtdaus
bEN3NaFkH/Ny96naf6+FxH37rdc2vQgJAELSKiGpY6srfCvblDuSFAvekB1uaP9yWAw92oolc/ft
MtVxxYoVyfXKtelFSAAQkoEWEiVwPXO3iS2WqHJsdUNWtj4qx3/zKcWCN2SHG9q/Hs3p0Ze4e/fu
rMH2WDLXG2Zv3rwx+1Ud3MH2Xtv0IiQACMlAC4neJrI2uymJKsdWN2Zl66K3tvS2k0/MzjZkhxva
v+yEJyYmzPdaxxWxFCFRXVQn7Vei4g+A99KmFyEBQEgGWkgGBf2Ow71qh9GLAQCEhCTSGL1dxdxf
CAkAQkISqY3GMXbt2sXJQkgAEBKSCBADAAgJSQSIAQCEBEgiQAwAICQkESAGABASkggQAwAICUkE
iAEAhIQkEj6E+qW35p/yefv2bcfISiZNe/bsMdN69BJrQOVOxd4WdOw0BQtCAoCQtFpIZL60e/fu
0nXk9Kcp2O28UT/99JOZ/qOX5Lj8DRua3NG6LCIkAAhJa4VEU5PMzMyUrqN5pFzDKYmOrGVD+/Ft
aq0glVnPltn9htavsw+7TciiNmS9Gys7ZimsYygrYYQEACFprZDIV6RqHU086E+3ru9C+/FtamPW
s/5+U9avs4+QRW3IereJpa+Qd4smpURIABCS1gpJaJ2yqd9jplD+TLgx61l/vynr19lHyKI2ZL3b
xNJX2On2ERIAhGQkhSTVuTAmRiHrWX+b3PXrbuPb9lbRxNJXSIT0SAwhAUBIRlJIyh5jxR5tpYhR
aJvc9etukyokTSx9U8pHSAAQklYLiRLj+/fvO5/1mnDIN6SsjJj1rL9N7vp1t0m13m1i6Ss0rsId
CQBCMrJCoreVXNtYDRyXPb4JlRGznvW3yV2/7jbudyHr3SaWvuLx48eMkQAgJKMrJHorSp7i1o53
586d5keKufsJWc+WbZO7fp1t3O9C1ruxsmOWwhcuXOCtLQCEZDSEBPrD2NiYERtiAAAhQUggG736
OyhTvxADgJAASWQIkXUwc20BICQICRADAAgJkESAGACEBEgiQAwAICQkESAGABASkggQAwAICUkE
iAEAhAR6lER6lVyaltPP7UmgHAcAhGQIksggCwlwjAAQkjm6I2liR+uXE9qPJj48dOiQmbtq+fLl
xnHQ3yZkbZuyfd02IiQACAk0FJK6drQ5QnL69OnObLqvX782c1G5y2PWtrHtm7QRIQFASKChkNS1
o80Rko0bN5q7G4tm2nWXx6xtY9s3aSNCAoCQQEMhCS1PtdjNLUei4S8PWdvGtm9SN4QEACGBIRQS
f3nM2ja2PUKCkAAgJAMqJCE72lA5L1++7Ppu8+bNXY+mNNW6uzxmbRvbHiFBSAAQkgEVkpAdrX/H
Yd+EmpmZMYPb7vIrV64Uk5OTncFyOTC6y2PWtrHtERKEBAAhGVAhCdnRuuvZN6H0iEp3MbKe9cs+
depUsWTJEvOKr97S8peHrG1TtkdIEBIAhIQkAsQAAEJCEgFiAAAhIYkAMQCAkABJBIgBAISEJALE
AABCQhIBYgAAISGJADEAgJCQRIAYAEBIoAVJ5OnTp31dHxASAISkJUmk6lfl+sV6Dv76JEWEBAAh
GUEhaVIfkiBCAoCQDHASOX78uJnXaunSpcXly5ez5qZ68eKFmQtL9ruaX0sWvDdu3AjekfheI7Fy
ytbXv+/evStWrFhh5gBz0czAmkHYErLtJQYAEBJomERkW2tn0tXEiHIfzBGS9evXm9l47Uy9Z8+e
NYIUEpKycnPKcT8fPHjQzA7st0niIWK2vcQAAEICDZOIbG3dK/qpqanGs+W6xlSpQpJTjvt5enra
3JVYnxT9+9lnn3XsdGO2vcQAAEICDZNIzLY2RUgePnxovEr27t1rppdPEY+yclPL8T9v3brV3HUI
3dXoEZnbvpBtLzEAgJBAj4UkJeG732lMRQZXFy9eLO7cuWMej9URkpxy/M+3bt0yYypCYyPavuyu
hhigGwFCAn1IIlu2bCnevn3b+ezb1sZsczVI79ri+stThSSnnLLPK1euNGMjeqzlErPtJQYAEBJo
mESuX79u3tqqsq2N2eYqgdu3qyRCmzZtShIPvZ2lcQzrvR4rx1/fb48G0JcvXz5rID1m20sMACAk
0IMkojeb9IbUsmXLTDLPsc29f/++GbzWOno0de3atSQhUcLXjwztDw1j5fjr++158+aNWSYx9InZ
9hIDAAgJ9DiJkHCIAQCEBBAS4LwCICTzl0Ry58EChAQAISGJADEAgJAASQSIAQCEhCQCxAAAQkIS
AWIAACEhiQAxAICQwHwnEaxxiQEAhIQk0oi5tMYlQXKcABCSFiaR2CSLgJAAICQtSSKaO8vOpaWZ
cu/du1c8f/7cOBb6yGFQJlKyuFV58gDRZIva1p3cscoa98yZM6XrW0KWuGX1LGtbaD1igG4ECAn0
IYm4Cf327dsd90DNAuwnYQnHgQMHOuVpAkTrRGgndwzdkezcubNy/ZglblU9/X2F1iMG6EaAkEAf
kohm/dVMuz4yi9q+fXvXd/Jzf/z4cac8Kwpl+ygTktD6MUvcqnr65YTWIwboRoCQQB+SiK7atUyJ
/OTJk13L9BhKnuji0aNHRkhC5eUYUZXdSYQscUP1dMsJrUcM0I0AIYE+JRF5pds7kGPHjnW+n5yc
LA4ePGj+v2/fvuLChQt9E5IUS9yqepZ5yJetRwzQjQAhgT4nkSdPnnStJ5MoORO+evXKDIJ/+PCh
b0KSY4nr17Oqbf56xADHAhAS6EMSkRuh3nQS/gC4vRPZtWtXcfjw4SxhiFnj+t/FLHFD9XTLibWH
GABASKDHSUSPgdauXdt5JdcmYcvU1JTZ1v+lekwYYta4Zd+FLHFD9XTLibWHGABASGCOk4iSuQbd
ASEBQEhIItnb6BGT7hJ4+wkhAUBIoFYS0TjH+Ph41yA7ICQACAlJBIgBAIQESCJADAAgJCQRIAYA
EBKSCBADAAgJSQSIAQCEBEgiQAwAICQkESAGABASkggQAwAICUkEiAEAhARIIkAMACAkJBEgBgAQ
EpIIEAMACAlJBIgBAIQESCTAuQdASEgowDkHQEgGL7HwNzp/AICQAFfmAICQAEICAAgJICQAgJAA
QgIACAkAQgIACAkgJACAkABCAgAICSAkAICQACAkAICQAEICAAgJICQAgJAAQgIACAkAQgIACAkg
JACAkABCAgAICSAkAICQACAkAICQAEICAAgJICQAgJAAQgIACAkAQgKAkAAgJACAkABCAgAICSAk
AICQAEICAAgJAEICAAgJICQAgJAAQgIACAkgJACAkAAgJACAkABCAgAICSAkAICQQCsFxP8DAIQE
ACEBAIQE5kdMAAAhAUBIAAAhAYQEABASQEgAACGBURMTAEBIABASAEBIBiGh8jc6fwCAkHBVDpxz
AISEhAKcewCEhEQCxAAAQkISAWIAACEBkggQAwAICUkEiAEAhIQkAsQAAEJCEgFiAAAhAZIIEAMA
CMn8JpFXr14VX331VfHxxx8XCxcuLCYmJorXr1+3Nun1M5kOeqJGSAAhgb4kkW3bthVXr14t/v33
X/On/4+Pj5P0EBIAhATSkshHH32U9J1bzsOHD4ulS5cWGzduNN+9ePGi+PLLL80djbZds2ZNcePG
ja5tLl26VKxcubJYsGCBWefXX3/tLJeAHTp0qPj000+L5cuXFz///POs+h4/frz45JNPzD6++OKL
4o8//ugq/+LFi8WSJUuKxYsXGzH88ccfTXn+vtxyf/nlF7NcdVq3bl1x7969rn1+9913xaJFi8x+
v/nmm65lKXVGSAAQkpG6I7Fcu3at2Lp1a7Ccw4cPm0T6559/mu/Wr19fXLlypXNXc/bsWSM07jYS
Gpv8ldhdsTp9+nTx/fffm231WG1sbKyrvhIFlWnLP3/+fLFv376u8vfv31/8888/xc2bN01yP3Dg
gPns78st1xWZ27dvF6tWreos0z4kftqfypFQ/PDDD8l1RkgAEJKREZLp6WlzFW9nitX/9V2oHPdu
oApd5Ye2ceujO5u///678/nRo0ddy9euXdu1XP/X3UdV+fr8119/le7L/b/ETsJZxoYNG4xIuLhC
E6szQgKAkIyMkOhOQVf89mr/1KlTxe7du7PL0eOuEydOFHv37jWJvyp5V90ZuKge7nJXlMq28csP
fXb/r7sQfZZonDx5clb5/nTsbj1idUZIABCSkRESva3lXnnr/xqHyCnn8uXLxeeff27GKe7cuWMe
eTURktzldYXECuCtW7eK7du3F8eOHQuKV5WQDUuiRkgAIYG+JBFfNCQkGlzOKUdjEu6jpJcvX2YJ
yebNm7seEz179qxruQbC/UdbEsBeCInlyZMns/bptsknVmeEBAAhGRkh0cC57iQ0oCwR0SCy3kbK
KUdvY9m3tJRQN23alCUkGqifnJzsDFzrBQB/sP3MmTOdx2/nzp0rVq9e3VhIdBelN7eEPyivfdrB
dP3ps94WS60zQgKAkIyMkHz48MGIia7w9ScR0Xc55dy/f98MRCsRKzlrADtHSITGZjSArtdt9cZU
1eu/+tMbW8+fP28sJHqspfEc+0qyFRXLt99+a+62dFw0lmTfUkutM0ICgJCMhJAAMQCAkABJBIgB
AISEJALEAABCQhIBYgAAISGJADEAgJAASQSIAQCEhCQCxAAAQkISAWIAACEZjSTy9OlTDg5CAoCQ
QP0k4s5Z1YsEVDdZ9SrJNS2nn9vPdyJHSAAhgb4kkV4nl2FPlvO9PUICgJAMVRLx/Tbsd76Vrrtt
iq2uJWZlW1W/mDWvZt3VfFuqg/Y/NTVVWU5oPyl2ub20281pI0ICgJAM7R1JmZWuu06Kra4lZGUb
S7Iha14ZaFlnQ3mJaKLIOkISs8vttd1uThsREgCEZKiFJGSLW4Zvq2sJWdnGkmyoDhIO3wa3jpDE
7HJ7bbeb00aEBAAhGWohia2TaqsbsrJtIgChK/deWvz22m43d2p9hAQAIWmlkOTa6lZZ2Q6ikPjL
e223i5AAICQISVHPVlf4VrZNkqzcEes82vLrmmLx20u7XYQEACFppZDozSc9q7cJMZbgcmx1Q1a2
TZKsHqvpsZm4e/du5WC7O9g/MzNjBrdzLX57abeLkAAgJK0UEr2FZG12UxJcjq1uzMq2bpKVFfDE
xIQpU+VrkLtsPSte2r/uYrT/XIvfXtrtIiQACEkrhQSIAQCEBEgiQAwAICQkESAGABASkggQAwAI
CUkEiAEAhARIIkAMACAkJBEgBgAQEpIIEAMACAlJZC4IWf3m2gBjG4yQACAkI5hEfKtft54pNsCp
ZQHHA4Ae0NIk0kuPcxIlxwcAIZmnJHL8+HEzn5SMqDRNfM6cUCnWu1WWslVWv1XLQvuqKuvdu3fF
ihUrzPxcLpqkUrP7WkKWuggJAEICgSQiu1g7g60mJJTrX46QpFjvhixlQ9PY+8tybH7dzwcPHjQz
9/rtlniImKUuQgKAkEAgici90L1an5qaajxLrW+9G7KUzRGSlH2VlTU9PW3uSqyHif797LPPOvWK
WeoiJAAICQSSSMwutpfWu70Qkpx9uZ+3bt1q7jqE7mp0l+Qeg5ClLkICgJBAhpCkJPMm1rtNhCR3
X+5n2f1qTEVobETbl93VjGIMACAk0CiJbNmypXj79m3ns28XG7OrrWO9W1dIcvflf9aAv8ZG9FjL
JWapi5AAICQQSCLXr183b21V2cXG7GpzrHfLvgtZ/frLYvuK2QZrAH358uWzBtJjlroICQBCApEk
oreW9PbTsmXLTKLOsavNsd4t+y5k9esvi+0rZhv85s0bs0yC6ROz1EVIABASDmBGEiHhEAMACAkg
JMB5BUBI5i+J5M5xBQgJAEJCEgFiAAAhAZIIEAMACAlJBIgBAISEJALEAABCQhIBYgAAIYH5TiLY
3hIDAAgJSaQRc2l7S4LkOAEgJC1MIrEJFAEhAUBIWpJENHeWnUtLs+Deu3eveP78uXEj9JF7oAyi
ZF9bx0L3zJkzpetbQna3ZfUsa1toPWKAbgQICfQhibgJ/fbt2x1nQM0C7CdhCceBAwc65eVa6O7c
ubNy/ZjdbVU9/X2F1iMG6EaAkEAfkohm/dUsuj4ygtq+fXvXd/Jzf/z4cae8XAvd0Poxu9uqevrl
hNYjBuhGgJBAH5KIrtq1TIn85MmTXcv0GEp+5+LRo0dGSELl5ZhMld1JhOxuQ/V0ywmtRwzQjQAh
gT4lEfmg2zuQY8eOdb6fnJwsDh48aP6/b9++4sKFC30TkhS726p6lnnIl61HDNCNACGBPieRJ0+e
dK0nAyi5Dr569coMgn/48KFvQpJjd+vXs6pt/nrEAMcCEBLoQxKR06DedBL+ALi9E9m1a1dx+PDh
LGGI2d7638XsbkP1dMuJtYcYAEBIoMdJRI+B1q5d23kl1yZhy9TUlNnW/6V6EwvdqjJCdreherrl
xNpDDAAgJDDHSUTJXIPugJAAICQkkext9IhJdwm8/YSQACAkUCuJaJxjfHy8a5AdEBIAhIQkAsQA
AEICJBEgBgAQEpIIEAMACAlJBIgBAISEJALEAABCAoOcRLDcJQYAEJIRSCKaMVdeIf3At9xta4JN
LUO/2L979y5CAoCQtEtINOW6nS5+FJPXXNZRx9mdjh8hAUBIhl5IHjx4YH506K978eLFYsmSJcXi
xYuLq1evmkkUNQ9WjkVumeXuixcvzFW5fuyostasWVPcuHEjWPfYNiHb39TtU+yFe2X3q+Ot446Q
ACAkrRCSI0eOFJcvX5617v79+00SvXnzphEQWezqc65Frr9fJesrV650Zvk9e/ascTUMEdsmZvub
sr2I2Qv3yu5XIq3jjpAAICStEJJNmzYVz549m7Wua4urz65XSI5FbkrySjG1Cm0Ts/FN2V7E7IV7
Zfer463jjpAAICStEBI97vGFIGZKlWORW7ZfTfV+4sSJYu/evWbK95QEF9omZYr61O1D9sK9svvV
8dZjQIQEACFphZCU3Q3kCEnsbsLfVo/RZD6lxzt37twx09TbdcrGVGLbpAhJzvYhe2ErSL2w+50P
wy2EBBASGMg7kphFrr+txlvc9V++fBlNcLFtYkKSs33IXtilid2vxpK4IwFASFojJHpWr0c4dYUk
ZpHrW+7q0ZF9Y8qOFcQSXGybmJDkbl9lL9wru1+NuTBGAoCQtEZI9PaQ3ryqKyQiZJHrW+7ev3/f
DMYruSrhalA6luBi28SEJHf7KnvhXtn96nEZb20BICStERIlTfcOAvpvLzw2NmbEBiEBQEhaISRC
bxcxJ9b/o9/2wnq0puM9aDEAgJBAoySi5/gaE4D+2wvrODPXFgBC0johAWIAACEBkggQAwAICUkE
iAEAhIQkAsQAAEJCEgFiAAAhAZIIEAMACAlJBIgBAISEJALEAABCQhIBYgAAIQGSCBADAAgJSQSI
AQCEhCQCxAAAQkISAWIAACEhkQDnHgAhARIKcM4BEJJ5Tyz8jc4fAPw//g8kakE7iUob/gAAAABJ
RU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-11-05 14:51:42 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWAAAAJFCAIAAABsiroDAAAdnUlEQVR42u3dsY4cx7nF8QUMGA42
YLBP4GfYyFg4siO/kxluIMAK+RaGH0EwpZCXkTPDMilIDBSs7Eyihb6jS99719zunpqZruo+Xb+D
hUDNLg97u6v+9X1V1fVdXRERzWggInoigCAigCAigCAigCAigCAigCAigCAigCAigCAigCBatKnZ
vAsQRE8bWcmHBBDUXQs7+7sEEEQEEKSp/W8z0+QAgmiSDpILgCACCIAgAgiAIFqqqaEDQBARQBAR
QBAt2dTstgYIoqft7PEfNDmAIJoEBEYABBFAAATR6YzQ5ACCiACCiACC6JLMQkVYgCAigCAigCCq
0tTkFwBB9LSdHf2EAIIAAiAAgmiWEZocQBA9amGWOQGCiACCiACCiAACIIgIIIgIIGjjTc2RcwBB
9LSdTf2BAIK0M4AACCKAAAii85uabZQAQUQAQUQAQbRQUxv9MwEEaWfOgwAIIoAACKLzm5pVDIAg
IoAgIoAgqpBiaHUAQfT/7cxNAAiiFQAhMAEIwojJ5lvyIQEEbb6dLTrUzzto1QBBRABBVBZKaMwA
QfvJMhang+QCICh+kF+2DwMEQNDeALFgNwYIgCCAON6I0QEgaCeM0OQAgogAgmgjjdhua4Ag3Xgm
cxnMQQAEtezGC9rWu+CpPxBA9NjZql5tyYcAARC03c5WtZvV695tGKExA0TAPV2ln/Q5B0EAQSvQ
LWUOggBCZ1vhgpft2JVOixnqnDRBABHc2UKvWTMDCAKI0gkIrQ4gACIMEEPmi0+4AxDBN1eAPTRZ
45TLAARhBEAABG0mXI+Yg3hspTEDRO+drcEgH/Hi09W0tD2AGHS22tdsQCaA0NkaXbNBHiAofjRu
ttVaqwMIN9dbhgABEEQAARC0+w5cezGy0hyEVQyA0Nn2Eztk+WvMAEEtcAkQAEF7aRD1t1F6kRwg
3Nyw/KLeVGLVCEIqBxB7yL2DNkoFAYIAAiDWuezF1xq0CoCgFp2tTaAe9Dan/AIgUqcetF2RGkAQ
AQRAEF0cWA2VD8vWngGCUsd5L5IDBFFTQBBAUOtEYPFVDIAACGrR2RqM8w3uxlJXa7UIILKDatdM
AEE76Wxxl20VAyAwYrWcaMtrDTakAcSuJiB6vs9eAwMIIokAQFBPgU8lRqQ4E0BEdrbERKDSfIHY
BCAE1a55nWs2hQQQOlvda553qLGcsWDHKPkQIKijkU1nawM1gCCdTbgOEGRk2wx6hmrrI+YgCHoi
N3fVe0/UG6gAkdrZjGwAARC0WpcISlsAAiB2Ml+w5YYb/eJT7TWdbukAEC3aa9DpTDVagncuAYIa
dTYj2z7SIoCgPfS3zquBDYGHBgKEzpY6Gjeri7G4c40dFgCBDu22Wm9/FSNxRcAqBkBEAqLqyNZg
40ZcbAIQANEiSe654YbuVrAhDSCCY5OskQ0uAYJWYESlFGNIm1gFCIBITTF0tqzYRM0ugNDZVsjn
7aQECKrY2WqPbFmbuAkgACI+XK/3u7ffSQkQFNDZ0olZ1bkq1MxBUNfoaVwXY/vXDBAAsYehuOfz
IGpvae+ZDgDRYniPHjP7jKecYQEQ+wkiUh6fzgYQlB2bDFEvZSsCABA76c9D9zspK/36CuQBRHwW
YCdl7V8/MXNJuWaAAIhGEYQ5iMSoByAAIn40bnY3ImqdA0Rq83JDQhGvDbsRvY9scNkYEClnVQGE
kW1yjsCG6HqLLynpJ0A0moaIWA4Yol58agC1uNfqASKSDnEjW9A4n9h6AYIilwxb1vLQPCKWtzwt
o0R8N3ZgDEAYJah1iuE8CIAIf2xp4/xTbnYLiJSFaoBoPabV2I3nLY8sQASVBQaI6snF/IcAsfhQ
vP05CKsY1KJ5AUR6jAkQlIGeZkfRoMNTNEgxKHICJW6Zc6lrVnoPIKhp8tJgrUF4AhCeVqPSezU6
dtyLT5XeH8mKTQCC6s5uzMxxbBYQjr0HiBU6m4pPcVDThgGiXT5faRz2BEENIACi0cgWV3Gj3h0O
nesBCIwIhlqlrdbqiQJE/ATE9ovKJgIiN1KLGEgAYg+BicXIFEbEzSIBBEC0i3oq9Yeqdf0scwJE
oywjwnkf2Zy2BxBdJwK0yhyECIJ6b165Zyv0PFMAEAAx3oKHOjOU9Zwr3Y2s2AQgqMWYWW9FIOLF
p5nRPvGaVfemfgExRJ000eb4nJnbDhC09W7c4G3O7b+G0Dj9BIiOOnDonoJ0YobWDQcIosh4qiXi
AaLHhpuSeAPEvLPSe7T1fNv6/IqAGGyUoqoRBFVtxDXyi8TkBSCo0YCcUnEj6G7EDR4A0TTXWNw5
a8wUXgEEjXc2OynrdZIaUU/t7h1WlEh/rg2IrG6ctdW6xjXXLr9sDgIgUjdEV5q0T6yUbakIIBox
woExcSAmgKD9NOIIOii9R0NESy1Pj7fvTACBES2Sl5YHxmgYEfcHINoNxVYxat/qwUkTAEE7ODAm
4m4MDcsvSzEopktUSl7S4ylbrSkm9A2atxdPRTMCICLHeZoJTyLQYw5Cq12+edV7R6D9MXk9v82Z
B1/9OSWCqPqOQLO7ockBBKnN2Tqfr31qQ4dveQAExefzNVK5qrsVbJSi7LSo0phZdZwP2twFEDQ+
EPUMiMTkxX0GiHaNIO6ys9bqa1yz0kcAkQeIGuOPA/WPxiaWOWnrjNCNJS8AsdsJiA5f9Wnfkx1m
BxCkG7frxlWvefvQB4idhCfdhutWMQAivhsP3Z/OBBAzD1GK0XtEXalLJEIt4qj+BjspUyabASIP
EEPy6UxZQZBygQARGUHEnc4U/QR7ZgRAtJiD8M5lyzcjs67ZHAR1DbVmb0bWO9ovq1wgQFDSQe+1
O0D0MidA6MNXNcZkMwUAARD7abtDnZMpa6+PBL0Z+fif6DOVA4hgOiybJCdOJWpj2YGwGxEEiKH+
5BlANG4bAGEaIqY+fb2DdnOfYI2ECyCIJicgOn/BTOEcatrf3JMgQJiDoNQMNrT+VcoLZvVqowEE
VW9GieiJO/cpqzYaQGBEU/RkvUjeDJdSjK5nCobATUcp+byZAoDIHuSzKj5JBNqAGCAAIvJEqTY3
pPMXzACCIk+UIjcZIFaYg6hata22edx9BmKAoBZRT9bhK0HoCSqPBhDUIi1KfA2sNnpmbjtAdJfE
Jh7fNuScSZkFiKpv+gJEHh2CEtp6aw3RR9EABAFE/XZWIfZJ3BUy5BwFABDtekXEmLkDEBNAiE1q
xaWhy5xaBUDQOCCGba8I/B/FWi4ZigEBIjLx7hAQe0peOrzPABEZ97ZZa/AEAQIgJMaNQt9my5zb
B8Tg0FpKZET7rUHb78Zxb9MAROpQvP3a0ABBALGfwCTrRfLERIAAAiAiQ98G6BnqvE0jxaBGiYBT
GNuAuOfYBCBSE4GUd5PixswGgAhCD0BEAqJlr8i65o0voNZ+YR8gAKJdMl9j92fPo3EihQGiXX+L
GDPbQKdz9AAERebGoWNmYiJgJyVFAsLx0A2u2RwERb6GvI+TI7VngNjDsN9VbFLpsLnasxtO7gII
jDC7scI/pLo3VWxhiWcoeYKJINYO2s1BbHnMbNAGdpAIAAR1mqrUrstQ9aDdxDANICiPEYk1u1ac
lTAHQcv3t0qz9xvvWgCR3YzdiNot1ZtalQ7arToBYcoWINp1NozwBKUYFNy8bA1q8wRNUlLdbhwa
m2QlAgABEEY2o/FqUIt4fAABEONdYqj8plbnB8aknCsFEC3awZBWS6r2gfoSrrA27EbUG+ezjpyr
dM1Vx0yzqgABEK5ZdAkQALFquG40BmKAWGGUsMxpnAcIaj3+RAAi952LqjMyAEF5sclQ54ToYRev
qA+2WlO9FtbzmZTN1i9yX1EHiK7pkNK8EkvFZFXcaHPNCw5LAAEQk21Xw2jJ4m22OoAAiOMR+8a3
MyW+rJWSFgFE9f5mNB7S3sWIq8ENEHSkBVeNeGv4K7EbMSwBhPR1pGHNf9gJIAggACJ+pqCNc7fc
AQiMoEb5fGL6CRB7mIDwBOMA0eYtD3MQHbGcdgOIIGcNVxZArWc3AIJSpxJpB8nL40YixeiOEY13
+PX8vhbEA0TeHETtU61nBrpOnHN3UgKEFGOFTUf1dlJu2bl2r6vRKhaHGkCYgwCIlQNMEQRGpKZF
yyYC+3COCCgAIm8Cwn1O53u9fdybjS413LwmCz3pgKj3yBa/Zs2LjgQ+nTtnJYwAEZ/Pb3xka9Zw
I5wXX+xsEAMuCzWASApQa6/PA8SeQj/LnP1msC0vGyOC2kYt7ujPPTeC+VGoW+ehztF+WXs0ASJv
DmLwIvlKiO8w5NG8ghtuz0ehRQMib5BzI3IBMSy3YblG6Jvo3DiI2PIFA0SjTF7NyH08ykrdeLOM
AIhGMerij+3x83Or0+cgNjtlCxBDXCPIinoSnRs8LwfGAERkQZcGUU+oc9dJlv6cNUo0m+JKLJAX
scOiQasbbLUWm+jGuZFag7oYg5e1AGKoU9BF6b0GT9Cx91KMFluA3eqsJBEgyPyWSG0FQAxOlAKI
fUQ923cOTeWqtAf9OYsR0TuLc53VxaCKQ3HiikDPgBgy53rspISemJ38O2BEg2Fjy7s/AQIgGkU9
iQfGyGoBIibYSw990/tbUIoBEEnPybEuIrUZxA91ioCZgwgDxLD5tzkHB8Y0TOVS2gZAJAFCWfp1
k8TtDx4K56Qywk2mxMEDIKhubJJ7YEx0bCLF0I2lGCvc8E7vgKZQqWFVpTu1SQR6njQBiLoN6/FM
e9U2sSzUKu1lCnKuB4jHF7n9ZReAqA6Iqu2sRttavDx0nHPVlL7B3VjwVwCIFhFEJS40qBnfMyDq
7d0ACICoAoh6kxoAsW7bAAiAEEEARN1rNgcRA4gGi5EN3onsdh9E1Sf4kdXG3+IDiJ3wyH2giqOd
G0FEAEFEAEFEAEFEAEFEABF314j2IoBYGBCcOffgDBAaAWfOAKERcOYMEADBmTNAAARnzgABEJw5
A8T+APHjjw/ffXf/7t3d27fP/v73qzdvrr/55vbh4fmPP367Wef3Dw9v7u9f3919/uzZZ1dXL6+v
X93efvn8+Q/f9uj88P7h/s393eu7Z58/u/rs6vrl9e2r2+dfPv/2h76cAWJ5QPzzny/evr059N6n
X4de/Y9/fLpB569fvPji5ubQx55+HfreV5/25fzi6xc3X9xcjVkf+t6nX3XkDBALA+IwmI924Mdf
h5/ZlPNhyB3tZo+/Dj/TifNhyL06Zn34mU6cAWJJQBxG+KN9+MPX1Gjf3vkwDh/taR++psbkPTkf
xuGrMuupMXlPzqWAWL12yBn/6FRlitFfYdR//q6Nzg48jv///OerX//66he/+Onrd7+7+q//+jgj
+Ne/3q3ufMjhp6L00bj9+3d7dj7k8FNR+mjc/u77PTufBog2s6lLAWL0tL+Z4wBHkXEqIL777v5x
R/3lL39y+NOfrv74x5/+8KtfFaUDjZ3f3N8X9rSZoH03zvdv7q9OsR4N2nfjvAwgZgbqp52zZEgf
/cmpDn/Sxc9QY/QXPBUQ797djcb8f/3rTxf5859//Pk339yu7vz67u6kzvbqds/Od6/vRv7+B41Z
377as/MCgJgfqKdO5jz612d+8mg4cCogFkwxPqw7fvT1l79c/eY3P/1Gf/jDx9968+Z6decPq4Pl
Xy+v9+z8YXWwvLNdv9yz88JzEIXUuOTDM44ML/wriwBidJD/7W9/umO///34hOLqzk+b0M1/Puun
P7Bj5/FuNmu9Y+eFU4zzun35Xy9JOtYFxOg4/7Of/XTZf/vbSB++MIJYxFkEIYJYLcU46cPC+cWT
Uox5ri0OiKmZgqmvy+cgLnc2B2EOogUgpiYOFkdJOSDm1zJrAOKjtYYPXx9UvqmpsbNVDKsYdecg
RsvATa1ilCyCnJGhlF9wy30Q8934kn0QCzrbB2EfxLDiTsq97tG0k3KvznZSVgfEunsu1wXE4F2M
fGfvYrSLIDoExPDvdy6fTb9z+ckGnQ9j8tTqwOHzt5/05XwYk8dXB/4nSv/kbUfOAFEldZo6tWF0
dmAjzlNnK4zm8Lt3njpbYTSH37EzQGxrboUz5005A4RGwJkzQGgEnDkDBEBw5gwQAMGZM0AABGfO
AJEICCLVvcn4w1kEARCaF2fOAKERcOYMEADBmTNAAARnzgABEJw5A8SuAKE2dLpzvSrqqnv3Dgi1
odOd61VRV927d0A4jyjdud7JXU6U6h0QTjRMd6539qczKU/oXW3OrZwqyVtS8ruwjNhHGaAzkaOd
61VRd6r1+f220r8+2uef/vmkOuDzH6qqkO5cr4r6zutiNAPETLHvwh84+uEiLFCXaZfO9aqo77yy
VhtAlBf7nvqBk0i0OCBUdkx3rldFfee1OdvPQZSU5Cr53aY8C8ttnTQHoTZ0unO9Kuo7r+7dPsWY
AsT8DxROUoogODeuoi6CqJhinNFXy79lDoLz0TmIy6uom4NYEhBH5x0uTDGsYnBuXEXdKsYycxDz
KcBwrBq4fRCcF9wHsWAVdfsg+pJdiXt1tpMSICoCYvBeQ76zdzEAoiIgBrWh853rVVFX3Rsg/p0Z
qg0d7Vyvirrq3gDBmfNOnAFCI+DMGSA0As6cAQIgOHMGCIDgzBkgAIIzZ4BIBASR6t5k/OEsggAI
zYszZ4DQCDhzBgiA4MwZIACCM2eAAAjOnAFiV4BQGzrd+f3Dw5v7+9d3d58/e/bZ1dXL6+tXt7df
Pn/+w7fbdVbdOwMQakOnO3/94sUXNzejB68cevVXn27RWXXvDEA4jyjd+TCYHz297fAzm3J2olQG
IJxomO58GOELD4ieGu3bO2/uTMpm5bkLg6vys6ernmqtNnS68/uHh6n4fzQj+P7d+s5bPNW6TXnu
C/HRvrq32tDpzm/u708xHk8HGjtvsS7G5eW5R//WMFaVe+qHZ+p9DxdX9z4PEGpDpzu/vrs7qRu/
ul3feYuVtS4vzz3/4Txf5v/dcpAtDgi1odOdP6w7ln+9vF7feYu1OafmIE7qbCVddBQiZ89BlFf3
Pg8QakOnOz/tUDdHjNd33mJ17/mON1+e+0JADKdU3zu7uveCEUS3taFFEF1HEEdTjKOj8dmAODvF
OCktWnAOos/a0OYgzEGc39mOTkycPWWw4hyE2tBWMaxiHNkHcTT+L1nFOBp6jE4ibG0fROe1oe2D
6HcfRNXNC0OC7KTcq7OdlGsC4uj+y3RADN7FyHf2LsYmIohoqQ29b+fDaD+17nD4/O0nW3RW3TsG
EIPa0PnOU6c2jM4ObMRZde8YQHDmvA9ngNAIOHMGCI2AM2eAAAjOnAECIDhzBgiA4MwZIBIBQaS6
Nxl/OIsgAELz4swZIDQCzpwBAiA4cwYIgODMGSAAgjNngNgVIFT3Tnf2BAGiFiBU90539gQBohYg
nCiV7uwJAkQtQDiTMt3ZE1wTECUluap246kTsWc+L7+hqnunO3uC6wOizazsUFzde/QHVPfu09kT
3CggSmpkHC3z/dT5JECcFNGo7r1LZ09w64A4oyb4cFllrZn/PTXFUN073dkT3PocxOXl9gp5dBQQ
Z9QTV9073dkTjIkgSmYESl5ln5qYKIkgTgWE6t67jCC6fYLxgDg1xVhwPkJ1767mIPp8guYgFgaE
6t47W8Xo/AludB/EIqsY5fsgZhCgunfn+yA6f4IrAOKScKPB1okLr22wDy/f2RPcNCDmNzVu6jqn
vmUnf7qzJ5gRQWxZqnvv29kTBIiKgBhU98539gQBoiIgOHPehzNAaAScOQOERsCZM0AABGfOAAEQ
nDkDBEBw5gwQiYAgUt2bjD+cRRAAoXlx5gwQGgFnzgABEJw5AwRAcOYMEADBmTNA7AoQakOnO3uC
AFELEGpDpzt7ggBRCxDOI0p39gQBohYgnGiY7uwJLgmIdY+KPKOCpurenD3BRoA4qdpte0Co7s1Z
de/V6mIcLTYzWvnio//OF8uc+rCkw19Y3fvo52pD79LZE6wIiPl+OIWDqQpaM6P6/M/PXGR5de/z
AKE2dLqzJ7gmII521PKwfyZMKAHEScW1yn99taHTnT3BGEA8nTgsrKNXMknZMoJQ3Vt1bxHECQlC
yZ+PfnheinHeDKvq3uYgVPdechVjQUDMz1AsNQehujdnT7DpPoij9bsLU4ypD8/uxqp7c/YE2wGi
W9mHt1dnTxAgKgJisJM/39kTBIiKgBjUhs539gQBoiIgBrWh8509QYCoCAjOnPfhDBAaAWfOAKER
cOYMEADBmTNAAARnzgABEJw5A0QiIIhU9ybjD2cRBEBoXpw5A4RGwJkzQAAEZ84AARCcOQMEQHDm
DBC7AoTa0OnO7x8e3tzfv767+/zZs8+url5eX7+6vf3y+fMfvlXdmy4DhNrQ6c5fv3jxxc3N6MEr
B1589anq3nQuIJxHlO58CBOOnt52+JlO7gZALAkIJxqmOx9ih8IDoqfiCGdS/uffLNitWTukLz97
WnVvzjPO7x8epjKL0Vzj+3dOtV5jTnWRK1Hdm/Opzm/u708xHk801MUoGrdnanPP178oqbvztPzv
stW9zwOE2tDpzq/v7k4CxKtblbXOAsR8FazCD4djRbTqVfc+DxBqQ6c7f1jRLP96ea025+lzEOeV
2zwDEKfOQZRX9575yZl/UW3odOenHermiLHq3pdNDVaixkwNvpJJyqGguvfUT54aQajuLYLoN4JY
BRBnpxgnJRELzkGo7m0OwhxEKSDK5yDm5zIG1b2tYljF2PgqRvkcRPkqRsnSxuiehfP2QQyqe3O2
D2JTOylPmmjcpuyk3KuznZTrAOLohst9AGLwLka+s3cxVo4gdiC1offtfIgjplY0Dp+//UR1b7oA
EIPa0PnOU+dBjM477PhuAEQVQHDmvA9ngNAIOHMGCI2AM2eAAAjOnAECIDhzBgiA4MwZIBIBQaS6
Nxl/OIsgAELz4swZIDQCzpwBAiA4cwYIgODMGSAAgjNngNgVIBKre6tIzhkgWgAisbq3iuScAaIF
IBJPlHIKFmeAaAGIxDMpnaPJuREg5s+PbzwfM3WAdeGHQ3FZjcc5fFx1bxXJOfcIiAvr9AzTR+nP
XF5idW8VyTlvBRDl5TNmOnOJw9Q1nEqNUwGRWN1bRXLOmwBEIQKefvcMh8sBcV6KkVjdW0Vyzk0B
UfIa6ehAPcqFo8XyThrqawMisbq3iuScN5diFAJitL7ejMPqgEis7q0iOeeNphglEcRQVuD7kuK9
CwIisbq3iuSctwWIp3FBYQcur81dGM4sDojE6t4qknPeVopR2NVLVjHmI4vReZCW+yAiqnurSM55
2PdOylUu3k7Kda+ZcxvneECsdeXexVj9mjm3cfYuxvJgSqzurSI5Z4BoF7kkVvdWkZwzQGw9teHM
eVPOAKERcOYMEBoBZ84AARCcOQMEQHDmDBAAwZkzQCQCgkh1bzL+cBZBAITmxZkzQGgEnDkDBEBw
5gwQAMGZM0AABGfOALErQKiUne78/uHhzf3967u7z589++zq6uX19avb2y+fP//hW9W96TJAqJSd
7vz1ixdf3NyMHrxy4MVXn6ruTecCwulM6c6HMOHo6W2Hn+nkbgDEkoBwvmO68yF2KDwgeiqOcCbl
cfd5w3rfLbmwklOty4uDfTTvoFJ2tPP7h4epzGI01/j+nVOtNwaIk67qwsI5p36oUna685v7+1OM
xxMNdTFOA8To+Dz13fn/HcaqcpVX3DoDEOVVeQaVsvOdX9/dnQSIV7cqa10GiDOKZZV/d74q39C8
9J5K2enOH1Y0y79eXqvNWRzMzxTXLUHAInApBERJua2hj+renB/raYe6OWKsunfNCOJoEjFDnLPL
c05VCR66rO7NWQSxaUAsG1+cEQKcWhP4jDkIlbLNQZiDWGEO4uwUoxIgVMq2imEVo+4qxtPZx/lV
jPNSjJLq3mcAQqVs+yDsg6C5G2onZbqznZQAUREQg3cx8p29iwEQFQExqJSd73yII6ZWNA6fv/1E
dW+6ABCDStn5zlPnQYzOO+z4bgBEFUBw5rwPZ4DQCDhzBgiNgDNngAAIzpwBAiA4cwYIgODMGSAS
AUGkujcRGQsBgogAgogAgogAgogAgogAgogAgojiAEFENKr/Bu/BPHFDtINOAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Billede1.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-11-13 11:31:52 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of eight trials on tranexamic acid versus placebo or no intervention. Outcome measure is mortality. Analysis was performed with alpha 5% and power 80%. Model-based heterogeneity correction was 0%, relative risk reduction 30% and control group incidence 10%. Graph shows the Z-curve, which is the cumulative result of analysis with trials added according to year of publication. Horizontal line represents 'traditional' 5% level of significance, and inward sloping red line shows trial sequential monitoring boundary. Vertical line represents required information size. Analysis shows that the Z-curve crosses the trial sequential monitoring boundary, suggesting that the result of the meta-analysis is confirmed when analysis is adjusted for cumulative testing. Total number of included participants (N = 1701) is only 62% of required information size (N=2714). The meta-analysis therefore remains inconclusive.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA10AAAJ2CAYAAACkZ+geAACAAElEQVR42uzdB5iV1bn+f5Lo+Z+c
c5JfTExiNGoEKaIoVUEBQUA6CoqgooKK2ECNFJWmdARpKlVFUAKKgDRBiqgooDSRFum9ydClw/3f
93qzh5mhOAgDM/D9XNd7zZ49e+/Ze01773nWelYmAQAAAADSTCaGAAAAAAAIXQAAAABA6AIAAAAA
ELoAAAAAgNAFAAAAAIQuAAAAAAChCwAAAAAIXQAAAABA6AIAAAAAELoAAAAAgNAFAAAAAIQuAAAA
AAChCwAAAAAIXQAAAABA6AIApA+rV6/WW2+9pXfffVeHDx8+6uPTp09Xly5dNHv27GN+/OcMHTpU
derU0YEDB37xc/zggw/05JNP6uDBg6f0Wg8dOqTnn38+vNbTYerUqerfv79GjBih7t2761//+peG
Dx+uPn36aPPmzWn+tZs0aZLuv/9+7dmzJ9n1//73v/Xcc89pwYIFP/sY+/btU+/evcPX+EzwuLzy
yisaNmwYP3wAQOgCgPPD7t279fjjjytTpkyaMmXKUSfk+fPn11VXXaVNmzb9osf//PPP1b59+8TA
tHTp0vC4J2PChAnq2LFjCE2nwqGxW7duGj169GkZu379+umbb74Jr+myyy5Thw4dtHbtWvXt2zeE
1bQ2c+ZMNW/e/KjxXLFihf7+97/ryy+/TNXjPPvss7rjjjvOyPfbrl27VKxYMbVo0YIfPgAgdAHA
+ePtt99W9uzZQ9Ukqc8++0w33nijbrvttmRVrh07dhy3kuMAcLyK2Pfff6+aNWvqxx9/TLzNzp07
w/vHC0kn8tNPPx113YYNG7R3795Uv3aHya1btx734wkJCcf8uJ9b/Hp/vuuuuy5UveKSviYHzngw
8v187N+/Pxxx69at+9nnum3btmRjd7zn69sULlxYkydPTrx+48aNR4Uzh1i//jfffPOor31SqXlu
fo3Hu13KCuXDDz8cAmp8HAAAhC4AOOd5up2nx1188cX64YcfEoOEq0tNmjQJJ/Dx6YEOYu+//75e
f/31UMHyibOnsz366KPhcZo1a6aqVatqzZo14T49evRQ06ZNQ1CrW7duqJqNHDkynGw7FLz33nvh
pL9169bh5Hzx4sV64oknQkWqfPny+vrrr9WrV6/wuH48B5unn346TDm85557wsm7+WOeJjlw4ED9
85//1KuvvhoqQUm5CvXMM8+EKY/x1+Kpga+99loInikDiZ+bX1PLli3DlMHjhR1Xbxy6kk5bdCBs
1KiR2rZtG8KOX+tDDz2k5cuXh8cZNGhQeH5+Tp7e5+ftqY/Lli075ufw9E4/b1fRPFYeP09nrFev
XmLI9Lj6cTx2V155paZNmxau//TTTzVq1Cg1aNAgMYg5IPXs2TM8Zrly5VSjRo2jPqennvqxPA7+
mvj1+Wvt6/x94SmfrljNmzcvjKFv52mNDn2u/j311FPh6++gXaJEiRC646HLz9vfc/7cKSusAABC
FwCcc3zSv3DhQhUpUiScNNvEiRNDIPEJ9s033xyCgtcIlS1bNlRcPC2xYMGCYS2QKz6ZM2cOJ96u
NJUqVSqxktGmTZtQKXOI+eSTT0KAcyBZtGiRSpcuHSpmDiX+3A5x27dvD1W3l156KYQ7hzCHnttv
vz08ngNYlixZNH/+fH311VchXPg+H374oe6+++7EEJk1a9bwXJLy5/Xn6dy5cwhpFSpUCJUer4lK
ucbIFaM8efKE1+lQcPXVV4eqXGpDl3Xt2lUFChRIvI3HaMyYMeH9wYMHh9fusOOwZJ4q6LFyiHIA
9XOMV4kefPDBxMDk+/p6B7AbbrghjK3DqYORL69cuTKEW4c6j7lD2vr169WqVSvlyJEjvA6HHk/9
NAfRatWqHfW6vBYvvtarSpUqITw5PL/44ovh8/p5e6qmQ278doUKFdKAAQPC58iZM2f4mEOZA7Kn
Ffr5OXT58Nh7auMDDzzADyEAELoA4NzmiofXATm4XHLJJaEK4gqNQ4qrXQ5d5pP2pGt/fDLvk2zf
zmHBlSPzyb9Dk7kaU7FixXB5/PjxuvXWW8NlP64DXJwDW758+ULIccByZSbO4cIn/eaTfIc6cwBw
APPUOVdU4s/NAaRo0aLHbN7hkOMw5ADnsJE7d+4QllKuF/P7ruq4WcUbb7wRQpzD3cmELofRa665
Jqzvcojza6hVq1a47LFYsmSJLr300hCIzO9fdNFFIVw5kObKlSuMr6uGDsZ+rf4axMOfg7FDpF+L
Q1SnTp3C9R5Df82+/fbbEGrcuMLhy00+HIjmzp0bAnO8AYdf33333XfU67rzzjtDRdNctfMRv331
6tUTb+fxd1MRP74/b7xq6K9jPFA6ZPu1btmyJXF6ofm2d911Fz+EAEDoAoBzm6tHPil2hcXVCYcX
T1Mznxzfcsst4XLjxo3DSX6cpwUWL148hA6/9TQ2c4XEUwrN1apKlSqFy2PHjk0MXa5e3XTTTYmP
5ZNvfx4/VtKT9ZQn5q6+lSxZMoQihxdXoBxKXH3zuqQhQ4aEQOfPdSy+TdJOfX5+8YpM0uDlYOPX
69f03XffhVDl53a80OWA5MYaKTnY1a5dW+PGjQtTBK+//vowbg5aDj9/+MMfwtibKz8OvQ5pnnrn
4OuqXHz9nEOWK4WekufA5PcdLl31cgjymJo/5vAzY8aMEHDiwSnOAckhMr4mziHqWNMLHf58vZ+7
p3c6mJtDa9Lbu0roAO6pkq42OiSbw7G/XuavlatsDq6PPPJIeG3mMOkqGACA0AUA5zSfRHu6Xjxk
/eUvfwknyfFw5KBgXiP0t7/9LUxFNK8R8n3NXQ7jQcdrl+JVEZ+AOyTFQ5en7Dlc+LFc+ZgzZ074
mCtj8eqHA0N83ZW5ElemTJnEE3xXf+In8n4+rszFqzquhDlsHK+ZRuXKlUNVzWui4l0M/drdMCRp
6/X4a3W1ysHL3QA9be9Y67pcWbriiivCuq+UHLS8Vi5euXPA8Jq3eDhy8HRgMU+XdFUwZYXO78fv
7+edN2/e8Jrd1dHVQXOwcqjxOiyHI08v9Hg7CP7xj3/URx99FMbI694cUrNlyxYCnQNjw4YNw9fI
ryMpByJX1lyV8zTPOI+fq2DmoOqvh0OiK4++7O8Jj7/XcXmdl3kMHbbs3nvvTexe6Pt5micAgNAF
AOcsVydc0XFjClc+fDLvaYbmy16/40rVrFmzEk/EXb1xRcmXHRx8Qu6TcE9d81QzT3VziHK4chjw
SbY/jx/PFTGfyPt+no7nphh+LAcrf343knC1xNUgBwyfvHvanNf9rFq1KlS9HFzckMLt2j1F0a3R
ve7K66c8zdGhzW/9OpKGJK/x8vS+du3ahWYPDgEOhQ4Grqwlva3DlgOQ1zG5eYcf0wEmZSc+ByJP
Z3R1ztWblK31/XFP74tXq1w1ShooXUVzSPU0TAeQeCOTpBxsXnjhhRB2HJ78fPw8/HwcIj3+DkyP
PfZYmJboJiIeF1crvV7ODTouv/zyEILiTSv8PBz46tevHxqc+DnEpznG+XE8DdHVSYcpf10caB2O
XTH019S87s9VSn9t4uu1HOxc6fIYf/zxx2G9nsOgx92VP4d5j5Wrjl6vlpoOiQAAQhcAZEg+WXe1
w1WKlIHCwchByOHHH49zhSnpSbIfwyf3vq1Dku/nw5f9sfh1SR8zzmt8jvdYDhs+4o/rtz788fjz
dqjxVEAHwHijCX8Or8fytLmkbdL9GPHn5Pv5sRwcjtf+3p873vrdj3msNWIOap4y54/5+ZxMu/o4
j68rVCe6rz/mUJS0OYg/X3ys4hx6/VxTrlHz9MuUj+9x8Gs/1v5n/nq7sYfDp78vfFtXzhzOfTn+
9U36PREfHz8vP6YDoLs0eozjt41/L8S/L1J+fwAACF0AgHTKUwvdqMLVIlfcHA7cmAK/jEOUq5Ie
13feeSeMqRtlnGhPs6Qcpt2kxPcFABC6AADnAFdZvEbL0xkduOJNH/DLuQrmKYwOsm51f7zujcfi
qaC+rztasgEyABC6AAAAAIDQBQAAAAAgdAEAAAAAoQsAAAAACF0AAAAAAEIXAAAAABC6AAAAAIDQ
BQAAAAAgdAEAAAAAoQsAAAAACF0AAAAAAEIXAAAAABC6AAAAAIDQBQAAAAAgdAEAAAAAoQsAAAAA
QOg6JYcOHdLUqVP1ySef6KuvvtKKFSv0448/ptnn27t3b/hcX3/9darvM2/ePL3++uvav38/XzAA
AACA0JVxbNy4UU8++aT69eun5cuXa86cOapbt65at26dZp9z8+bNKlKkiBo1anTC2/30008hoNmY
MWNUrlw57dmzhy8aAAAAQOjKGA4ePKiqVaseFX5c6erVq1eafu7HH39cTZo0OeFt2rZtq/Xr1/OF
AgAAAAhdGdM333yjP/zhD1qwYMFRH3M1au3aterdu3f4+O7duzVw4EBNmDBBBw4c0EcffaThw4dr
1KhReu655/T999+HqYm+PG7cuPAYU6ZM0VtvvRVuv2TJEvXo0UOrV68OH3vsscfUtGnTcHnlypXh
sf25/JiHDx9Wnz59wnN7++23w/OYPn263n333VDp8m26deuW+FjTpk3Tl19+mXh58ODB6tmzp3bt
2sUXGQAAACB0nT1eI3XxxRdr+/btx/y4A07RokX1xhtvhKrYs88+q/vuuy9M+6tQoYLKli0bQk6t
WrV00003hUD25ptv6pprrtHOnTv17bff6q9//at27NihhISEcL3XcsVDV7NmzcLlO+64I4SuRYsW
KXv27GGaoy9fccUVIWw58HXs2FHXX399CHATJ07U73//ey1cuDDcf9CgQSH0OYw5pPn+FStWVJ06
dUKAAwAAAEDoOis6deoUQpdD0fF4+qErVNauXTvVrFkzXG7YsKHq1asXLo8dO1aFCxcOlx2Qrrrq
qlCdcgUra9as4fEdlm699VZ9+umnR4UuV8YcoPw4WbJk0XfffReqVL6vH8cc6BwA9+3bF953qPLz
dxOQoUOHhrfVqlULocu37dq1q1q2bBmuBwAAAEDoOismTZqk3/72t6FKdCyuEt11111h2p+1b99e
Dz/8cLj8/PPPh6mENmLECJUsWTIEHE9LvPrqq7Vu3TotXbpU2bJlCwHKoatYsWKJUw+TTi/0tERX
3VzVyp07d2jmsW3btvA4q1atSgx2Dl3xxhrDhg0L1TVPYfT9XIlzqHN1LSlCFwAAAEDoOmtcNbr9
9ttVvXr1ZNe7XbynDTqwVKlSJUwZtPr16+v+++9PDF2ebmgjR45U8eLFw2WHpX/84x/atGlTaMjh
y56m6GqXA1V8emHt2rX18ssvhzDm6pYDmm+XI0eO0B7e0xGvvPLKEN78PMaPHx+qab69+bb58uUL
Uxvj1S+/DlfAfF+HP3+u+McAAAAAELrOCk/fu/POO0MI+te//qUhQ4ZowIABiU0qvJ6rYMGCYdqe
q1ylS5cOH3vooYf0wAMPhDDlUHbjjTeGgDRjxowwvfDzzz8PwcjrvvzYboKRJ0+eMO3Pa8hcQXMH
Q6/9uu2221SjRg298847Yd2XpwU6+N1yyy0h2Lna5YYcN9xwQ1ivFefphV7rFTd37twwJdGPUb58
eX3xxRd8gQEAAABCV/rgjYrdiXDmzJlhXVacpxh6GqKrT27fvmbNmhC0HH58ODQ5hLlStWXLFm3Y
sCFcdgAzV7xGjx4d9gPz9Q5cbsSxbNmycH9XohywXJVydcpru+LdFP1xTx/0hsj+HO6A6CpWnJ9n
0udqfgzv6fXDDz/wRQUAAAAIXQAAAABA6AIAAAAAELoAAAAAgNB13mBTYgAAAIDQhVRw58Du3btr
+PDhoTW898vyfl3ekPhYvI/WwIED9dFHH4X7uImGm2sAAAAAIHThGByyBg0aFFrLu8tg//79lSlT
phCoUnJ1q0mTJqHN/NatW0P3wZo1ax61YTEAAAAAQhf+I9763dzqPXv27GrQoMExb+sq13XXXade
vXolXuf270nbt7tFfNLHjHM7+l27dh3zcQ8ePJjs+bDhMQAAAEDoOid5M+Nrr702hK/jqV+/vn71
q1/plVdeCft52YEDB8LbRYsWhQ2QfTzzzDNhXy/vweWNlz0dsVGjRvr444/DbT/88EM98sgjatGi
he65556wv5enN44YMUL16tWjegYAAAAQus4t3rz4f/7nf8ImynGeTuiqkytc8eqTLzdu3FgXXnih
rr766hCUzJsYOzzNnTs3vF+qVCl99dVXevPNNxMrZ9OnT9eVV14ZNkj2Rs1/+ctfwv0dwHr06BHW
lnmT5eeee06FChUKgQ0AAAAAoSvDS0hICGHIYSopV67y5s2ra665RsWLF082PXD27NkqX758qHqN
GTNG8+fPV758+RKrXn7roObw1Ldv38T73XjjjerQoYPmzZun/Pnz69ChQ+H6++67T127dg3hz9Uw
rymLPxYAAAAAQleGVqtWLeXJkydUseK2bdumNWvWhEpVly5dwpTBnTt3hjVcSbm69cADD4QQdckl
l2j16tWJH1uxYkV43M6dOydeV7p06RCu5syZEwLYnj17QkWtQoUKoaFHUoQuAAAAgNCV4b333nth
WuHMmTMTr/NUwbfeeitxzVacq1KeKugqV9xLL70UWsw7sHk9mKtfU6dOVe/evUOw8pqtIkWKhGDl
0Fa2bFktWbJE06ZNC0074uvHXn311TDd0FWuCRMmhJBHQw0AAACA0JWhOdTUrl1bjz76qMaNGxfW
WXnfLa+tcpCKT/2Lc5dBh6mePXuG2w0YMCBUrRymzM0vXL1ydcvVMfOUxOeffz6879v785jXcVWu
XFmzZs1KDHpPPfWUMmfOrDvvvDNMVwQAAABA6MrQXH3yFD4fXtcVPzy10B871u3jvCGy28Cn5KAW
D2FJ+bZ+3DhXuHxbh62k3MUwZdgDAAAAQOgCTsnx9jADAAAACF3AKXJrfXeJ9F5mAAAAAKELOI2m
TJmiSy+9VJkyZdLvfvc7DRs2jEEBAAAAoQs4Hdx45KKLLgqBK35ccMEFiRtOAwAAAIQu4BT88MMP
oc1+0tD197//PbTcBwAAAAhdSGbLli3q1q1bsg2W8fNWrlypfPnyhcB11dVX67vvvmNQAABIT7xv
6fLl0ubNx/64z31if8+1aZNbPZ/84//735JnufyS+8Z5q53Ro0/tMU7Wnj3ShAnSN98cPV4rVkSH
x2XtWre3PvJxd7/euvXYj/nDD9E4gtCFo7lFfKlSpUJwqFGjRtjPC6m3bNEiVbv8cs1gWiEAAOnP
unXSffdJl14qrVlz9McffVTKnl3yP05/Seh5+22pdGlp//4jIe5kz6V69pTKlz/5+/1S27dLL70k
3X+/dNll0tNPR5/b4equu6SLLpL+9Cfp4oul226TDhyIXte//iVdfbU0fvzRj7l0qZQlSxRAQehC
yn9m7Ij9niit6667TldeeaVy5MgR+/m7n+B1MvxL9pZbvMiLsQAAID164w3pwgulli2TX79okZQ5
s1S48On5PD5/ev31IwEsvZox40iFa8QI6YILJC+PcDWwTRvp88+j9325adPodg5k8+ZJf/iD9Omn
yR/PoaxHD+n3v5dGjeL7jdCFlIGrZMmSqlSpkmbPnq0CBQpo4cKFuvnmm3XvvfcSvFLLm0nfdJP0
9deMBQAA6VG/flE1x5UYV3niHBQee0wqWvRIUNqyJQoO/ftLs2ZF13k6nSs4338vvfee9NZbUcBy
ZWzu3Kjy42l5rh65ajZ2rLRvX3Sdpw36saZPjx7Ln9/XOdQ4oK1aFT2Gp/r58RYsiD5/7NxM7dod
uZ859HiLGj+eP756dfLA99ln0uDB0W3ih9+fODH5FEE/t7iffpIuvzwKWinDYuvW0uTJR97ftk36
+9+lceOS3+6LL6IgljUrlS5CF44VuMqWLas9e/Zo+fLloSmEN/n98ccfYxniJoIXoQsAgHODQ9KU
KdJVV0WXzeuPeveWOneWbr45CiUOSbVrR1WgadOiv+8OHYsXS1dcEYUqB5nrrpMGDYqCTv36UvHi
UWDxVMN8+aLbO1w9/nh0fuDKUsGC0qRJ0rJlUfirU0eqWjUKO88/H01RdMXIQcfVt6FDpebNpbx5
o/VXDoCeDrhkidSoUfR4Dmhxfv6eIvnll95E9Mjh9x3QkoaupDxTp1QpxU4Ck1/voPnww1Eoi3Ml
zNMRk4aujRulgQOjsfvHP6JACUIXosBVokQJlStXLoQs+/e//x2mGDpwRT8/G3XjjTcSvAhdAABk
fL16RY0hHGJy544qSp5y6AYbXbpEocvefVcqW/bI/erWlSpUiMKVq2GffBJd7zD14ovRZa9z8nos
c6i69dboskNZyZJHHqtBgyjcOPx4nZTvF+fPe+ed0eUxY45Md3TgcVB0c4qOHRU7MYuud/UrT54o
pCUNXQ53rmq54hU//L5vf7zQ5dDo26Tk1+oAmFTK0OXP/8470Ti6Quhg+vHHZ7YhCAhd6dGm2A+t
m2YkDVzHCl3x27riVb169RDUQOgCACDDhi5Xnzwd789/lrp2jQ7r0OFI6HIASRq6uneXChSIqlau
ZsXDhkNX48bRZU83rFgxuuyPO5xZkyZSiRJHHsvh5IYbose6/fbka59cIatcObrs6Xm+n0NSQkI0
Zc8dBOfMiUKbpyJ6WqSrbknDjYOhp/kNGyYNH37k8Puuph0rdDkgORwei0OlK2UnCl0+b6xUSXry
SalmTen//i8aPz9HELrOZ40aNVL58uW1e/fuZNcfK3RFP0s/qmDBguri/wKB0AUAQEbUp0/UNMPc
rfB3v4vatMdDV6FC0eX335euvPLIlLq2baOA5cDiCla8a5+nBjpU2YABR0KXq1RFikSXP/ggWv8U
/8d1p07RdD0HJVfAkq59ciCLhy5Pz3PA8+08xc9TEd2B0dWul1+WhgyJwtWp8hRKP8c4B7v47CaH
Kz/XFOeLYU3X3/4WrT8zj4vPHR1mvd7skkukvn2Pvh8IXeebFStWHBW4ThS6bGvsB36tfxBB6AIA
IKPxeY8rWK4seTqc12o5SJnXStWrFzW/8LmOw5ZbprvL4cKF0ZRAhzWHkFy5ooDl+1SrFj2GLztM
ObQ5XLka5fVYbgHv+3g6YLNm0WM1bBgFPU/D8zotN9FwaHHQcbhzhcznFF5z5o/7dr6fm1x4TZYD
nadGuiGIn7MrUUnXdJ0MTzf02jM/v4ceiqY2utoWr5x5PZk7Fyblj/n1uY28G5MkndponkHlgOgm
IiB04dhOFLpA6AIAIMPyZr5uouHgEl9aEf8H9IYNURdBT6PzJsfm/ajcRt3hwR83V3LcUMPT5lxx
cnBzAwpf9uP6/vHb+n7xSpSba7ii5cDkapV5rzA/1syZ0ccd3HzZj+GPuRmGLzsEumlG/Ln5rcOc
m1Z4emGrVlFYSxl+UsN7anmKoJ+rK2t+66mMcX6dSTsjmsOhq1l+Hm7qkbTBhvl5+HU4LILQdb74
KeUPAqEr7fiXpeeC+xcwAABAWnBFytUnV9C8LiwegGh4BkLXmeepgN27d9err76qHj16aJvn3hK6
0jbgxsb81Zw5tSHlYlMAAIBfICEhQe3bt49lqyR7irmK5KmFjzwSNdFwheqXVLlA6MKpOXz4cAhc
kyZNCmFr4sSJ6tmzZ7j+5/zwww+Erl9g7969uv/++5UpUyaVKFlSm/3fJwAAgF/I53BueuZziypV
qiTrNh2k3MAYIHSdWftjP4StWrVKDFneX6tNmzY6kIr/gqxevVq5cuUidJ0E72VWrVq18EsxfhQr
VkzLvOkhAADASVq1apXKlCmT7NzijjvuoKEZCF3pzZdffqlOnTqFKle3bt30VZIpbzNmzAhVmfvu
uy+8jR81atRQhQoVdMUVV4S9uZA6rigm/aUYPwa4sxEAAMBJGjJkyDHPLca4EQdA6Eo/Jk+erIYN
G6p///5q0KBBstC1cOFCNW3aVE2aNEl2NG/eXI8++qguu+wyrXeHH6Ta22+/rQsvvDD6pfjrX6t1
+/Y6dLwd3wEAAE7As5Vee+21xLD1mwsuCGv0AUJXOhKfXhjvXLhjxw61bt06VdML161bx5quUwhe
F110kVp5o8Xvv2dAAADAKenQoYP+329/q+5duzIYIHSlNw5XnlrotUa2YcMGdenSJVWhi+6Fp2aO
97PwJokPPMBgAACAU7Njh+bkzOlFXowFCF3p0fz580O7+F69eoW3C1K5Uzmh6zT44QfpyiulxYsZ
CwAA8Mv5fCx2XqZFixgLELrSK1e6vv3225NqikHoOk3uuUdq0IBxAAAAv5zP4a69NvqHLkDoOncQ
uk4TNy7JkiXaLR4AAIDQBUIXCF1poGRJqVMnxgEAABC6QOgCoStNfPSRlCuXtHs3YwEAAAhdIHSB
0HXa7dsn5c0rsUkyAAAgdIHQBUJXGunWTbr1VomNkgEAAKELhC4QutJAQoKULZs0cSJjAQAACF0g
dIHQlSYaN5YqV2YcAAAAoQuELhC60sSKFdJVV0nff89YAAAAQhcIXYQuQleaePhh6YknGAcAAEDo
AqGL0EXoShMzZkSbJa9dy1gAAABCFwhdhC5CV5qoUEFq2ZJxAAAAhC4QughdhK40MWaMdM010o4d
jAUAACB0gdBF6CJ0nXYHDkg33yy9/TZjAQAACF0gdBG6CF1pom9fqUCBKIABAAAQukDoInThNNu1
S7EBlkaPZiwAAAChC4QuQhfSRJs2UrlyjAMAACB0gdBF6EKaWLcu2iz5228ZCwAAQOgCoYvQhTRR
t65UqxbjAAAACF0gdBG6kCbmz5f+8Q9p+XLGAgAAELpA6CJ0IU3cc4/UqBHjAAAACF0gdBG6kCa+
/FLKmlXavJmxAAAAhC4QughdOO0OHZJuvVXq0oWxAAAAhC4QujKahIQErVq1KhyrV6/Wzp07CV3p
0QcfSHnySHv2MBYAAIDQBUJXRrFt2zY999xz6tixozp37qy2bduqRYsWOuTKCqErfXHYypdPGjyY
sQAAAIQuELoyir1792rZsmWJ77va1bVrVx0+fPhn77tixQrlypWL0HUmeXphsWJSKr4+AACA0AUQ
utKhYcOGadKkSYnvb9++XXPnzj3qmD9/vkaMGKEcOXIQus4kN9JwQ43PP2csAAAAoQuErozGUwo9
zXBzkg55n332WZhCmDNnztjP8bWJhytcmTNn1mWXXaaNGzcyeGeSW8dXrco4AAAAQhcIXRnNunXr
1KlTp2TXefrhptgPsYNV0sPVra+//jqEMSpdZ9jSpdKVV0oLFjAWAACA0AVCV0YyduxYjR49+iTO
/ZfSSONsqVVLqlePcQAAAIQuELoyCk8tbNeundasWZPq+9C98CyaPl266iqXJxkLAABA6AKhKyPw
NEI30Dh48CChK6MoU0Zq3ZpxAAAAhC4Qus5VhK6zbNQoKWdOKZWbWQMAAEIXQOgidOFkHDgg3XST
1LcvYwEAAKGL0AVCF6ELaeKtt6RChaIABgAACF2ELhC6CF04zXbsiH7BjhnDWAAAQOgidIHQRehC
mmjRQipfnnEAAIDQRegCoYvQhTThNv+ZM0szZjAWAAAQuhgLELoIXUgTTz0lPfww4wAAAKGLsQCh
i9CFNDF3rvSPf0jLlzMWAAAQugBCF6ELaeKuu6TGjRkHAAAIXQChi9CFNDFpkpQtm7R1K2MBAACh
CyB0Ebpw2h06JBUtKr3xBmMBAAChCyB0EbqQJgYNkvLmlfbtYywAACB0AYQuQhdOuz17pOuvlz76
iLEAAIDQBRC6CF1IE6+9Jt12m3T4MGMBAAChCyB0Ebpw2m3eLGXPLn31FWMBAAChCyB0EbqQJho2
lKpXZxwAACB0AYQuQhfSxOLF0WbJCxcyFgAAELoAQhehC2miRg3p2WcZBwAACF0AoYvQhTQxZYqU
JYu0YQNjAQAAoQsgdBG6kCbKlJHatWMcAAAgdAGELkIX0sTw4dEv4F27GAsAAAhdAKGL0IXTbv9+
KX9+qV8/xgIAAEIXQOgidCFN9Ool3XKLdOgQYwEAAKELIHSdTRs2bNCQIUM0cOBAbd26ldB1rti+
Pdosefx4xgIAAEIXQOg6W2bOnKkWLVpoxIgR+vzzz7V582ZC17nk5ZelihUZBwAACF0AoetsSEhI
UKtWrfTTTz+d1P3Wr1+vXLlyEboygjVrpCuvlGbPZiwAACB0AYSuM23ChAmaOHGivvnmm1Dp2u7p
aP+xaNEitW3bVm3atAlvkx7PPfecMmfOHPsZ38QgZgS1a0uPPso4AABA6AIIXWda//791bBhQ/Xq
1UuDBw9Wt27dEqte06dPV9WqVY867rnnHpUuXVpXXHGFNm7cyCBmBHPmSFddJa1cyVgAAEDoAghd
Z1LPnj3VqFGjxPeHDh2qqVOn/uz9li9fzvTCjKZKFal5c8YBAABCF0DoOpO+/fZb9enTJ/H9UaNG
afLkyT97P089pJFGBuMOhu5kmIrulAAAgNAFQhdOk/3796tjx44aO3ZsCFvt27dPtq7reOhemAEd
PCgVLix1785YAABA6AIIXWeSQ1a/fv1i5+LdtWLFilTdh9CVQb33npQ/v9M2YwEAAKELIHSlZ4Su
DGrXLilXLmnYMMYCAABCF0DoInQhTXTsKJUqxTgAAEDoAghdhC6k2S/mq6+WpkxhLAAAIHQBhC5C
F9LEs89K997LOAAAQOgCCF2ELqQJ/1K+4gpp8WLGAgAAQhcIXSB0IU240lW/PuMAAAChC4QuELqQ
JrymK0sWia8hAACELhC6QOhCGrn9dum11xgHAAAIXSB0gdCFNDF0aLRv108/MRYAABC6QOgCoQun
3b59Uv780oABjAUAAIQuELpA6EKa6NFDKlpUOnSIsQAAgNAFQhcIXTjttmyRsmeXJkxgLAAAIHSB
0AVCF9JEs2ZSlSqMAwAAhC4QukDoQppYuVLKnFn6/nvGAgAAQhcIXSB0IU08+qj0+OOMAwAAhC4Q
ukDoQpr47ruo2rVmDWMBAAChC4QuELqQJipWlF55hXEAAIDQBUJX+nLo0CGtW7eO0IWMb+zYqJPh
jh2MBQAAhC4Qus6sTp06qWLFiqpcubLuvvtuVahQQXfeeWd4v2TJkqpSpYr2799P6ELG5r26brlF
6tOHsQAAgNAFQteZ9dZbb+n5558P4at06dKqW7euOnfuHN5v2rSpnnjiCe3du5fQhYyvXz+pQAHp
PPonAgAAhC4QutIBTyGMGzFixFEfb9CgQez7fROhCxnfrl3RL+7hwxkLAAAIXSB0nXmeQuiq1yef
fKKEhARt3LhRXbt2Ve7cubV9+3ZCF84N7dpJZcsyDgAAELpA6Do71q9fr2eeeUYFCxZU9uzZwzFu
3Ljz6gtD6DrHuTGM28dPm8ZYAABA6AKh62x+f2/S4sWLE99POgUxo1iyZInat2+vjh07hmPhwoWE
LkTq1ZMeeohxAACA0AVC15nxwQcfaMyYMeHy6NGj1atXL73zzjt69913w+V27drpp59+ynAD7Nf0
xhtvaMWKFeHYuXNnqu63aNEiQte5zgH8qquczBkLAAAIXSB0pb169eqpdevW4bI7FRYqVCi0kPdR
rly50Do+I4auCRMmaPjw4aFqt2XLllTfzxU+Qtd5oFo1qX59xgEAAEIXCF1nlptnHP29vkn79u3L
cAM8efLk0HmxR48eatOmjYYMGZL4sWnTpql8+fIhVPpt/PAeZUWLFtXll19+zLHAOST2/aGsWSXC
NQAAhC4Qus4kV4T69u2rPXv2hEqPq0WHDx/OkAPs1xBvdX/gwIFk67qWL18ewlj37t2THb6uWbNm
ypIly3nVJv+85O/rEiWkLl0YCwAACF0gdJ0ZBw8eDJWhSpUqhRbxbiHv6XmNGjUKH8vo3Ap/7Nix
P3u7devWKVeuXEwvPB8MHizlzi2dR1siAABA6AKh6yxylat///7JrluzZo0uueQSbd68OUMNrgPj
lClTklXp3BBkwYIFP3tfuheeRw4e1O4SJfRAgQJ6o1cvxgMAAEIXCF1pH1QcukaOHKm1a9eGNVFF
ihRRgdgJqafqZSRucf/ee++pVatW6tevn1599dWjAiWhCz/t3atqpUsrU6ZM+vVvfqOePXsyKAAA
ELpA6EpbGzZs0FNPPRVCx1//+tcQupLu15XRLFu2TJMmTdL8+fNTfR9C1/lh27ZtYSqtA1fiEQte
Xal4AQBA6AKh60zwnlY+KTWHrozaTOOXIHSdHxISElSsWLHkoSt2tHnsMQYHAABCFwhdaWf69Omq
VauWateurUceeUTVq1fXzTffnBjACF0414JXmTJlosD1q1/p1XLlFPvie/M6L2hkgAAAIHSB0HV6
7d27V88++2zYIPmOO+5Q06ZN9fjjj6tx48bnRPdCQheOxQ1kvD9bm7Ztoyu+/VaxK6I9vLxp+I4d
DBIAAIQuELpO38nn+++/Hy678198c2A3odh+HrXUJnSdf475T4XRo6UiRaTrr5feeit0OrRhw4ap
ZcuWDBoAAIQuELpOnjv+devWTffcc49mzJihunXr6t5771XOnDlDICN04bzjtYzvvivlzSuVLq0R
7drp/373uzAd0RVgAABA6AKh66S5ouVW617DNXfuXNWrV08TJ048r74whC4clb127dLAMmX0uxRN
N55v0kR7GB4AAAhdIHSB0IVT44mFT7744lGdDm+IHQnjxzNAAAAQukDoAqELp2r37t2ho2c8cOXL
k0fLH3xQypFDKllS6tZNWr6cgQIAgNAFQhcIXfil9u/fr4ceekj58uXTypUroyuXLZNee00qUULK
lk26807JDWk2b2bAAAAgdOF8C12pafvuhhkDBgwI/9XfsGGDPvvss9Bgg9AFHAlem48XqL77TnKD
jRtvjP5A1KwpjRrlMhkDBwAAoQvnWuhyYGjTpo0WLFigFStWqHTp0mGj4+UnmP7kcNWoUaNwWzfS
2Ldvn4YOHapmzZqxTxdwcslMcgOaJ56QcuWS8ueXnn9emjo1sfU8AAAgdCGDh65Zs2aF9u/e8PjO
O+9UjRo1Qhv4Dz/88LiVK1e5+vbtm+y6devW6dJLLz3+f/YJXcCJeXPljz6SqlePph8WLiy1aSMt
XMjYAABA6EJGDl3fffdd2OD4k08+UebMmbV169ZQuXKoOl7o8rSp/v37a8KECbHv702aOXOmypQp
o9y5c4fphoQu4BStXy/16iWVKxcFsLJlpe7dpTVrGBsAAAhdyGihywGrX79+Kl68eKhu7dmzRy1a
tFDnzp1PeL81sZO/2rVr6/rrr9df//pX5c+fPwS48wmhC2eE/3i0by8VKyZlzy5Vq6bYD6u0dStj
AwAAoQsZIXTt2LFD7777bmKHtQMHDoTqlatZqZGQkBBuH8eaLiANTZki1a8fNeDwGrDHH4/WhO3b
x9gAAAhdhC6k19A1f/58FStW7KiQdazw5IrYxx9/HC4PGTJEr732WlgP9vrrr6tjx456+eWX9dNP
PxG6gLS2d680dqz08MNSzpxSwYJSo0bS7NmMDQCA0AWkt9Dldu+eJuhuhA5QPtyF0O3gU2rQoIE6
dOgQLj/11FO69dZbdffdd+uuu+5S5cqVVa1aNUIXcKZt2SL55zX2c6irr5Zuu03q2FFasoSxAQAQ
uoD0ELrcdbBIkSIqX7687rnnHlWtWjWs7+rSpcsJ73esoLF9+/ZUT0skdAFpwNOEX39dKl1aypJF
qlhRcqfRjRsZGwAAoQs4W6HLHQrdAt527tyZeP3GVJykLV68WNOnTw8t5n146iHdC4F04vvvpWbN
pFtukXLkkO6/Xxo+XNq1i7EBABC6gDMZumzOnDmhunX55ZercOHC6tOnzwlvf/jwYb3yyiuhxby7
F+bKlSv2PX6tbrvtNqYXAumN12dOniw9/bSUO7eUN69Ut670xRdswAwAIHQBZyJ0eTNj77H1/PPP
h+YYbhvfvHlzffbZZ8e9j9vKey2Xm3C4suXDYcvv+2OELiCdcjV72DDpgQei9vOugr3yijR3LmMD
ACB0gdCVVqZOnapx48Yddf3AgQOPuzmyK10OZd9//7327t0bDoetH2Lf5L5M6AIygA0bpHfekSpV
ihpwlColvfmmtGoVYwMAIHSB0HU6LVu2TG+//XZY1+WNkr3nVtu2bUOXQoer43H7eE8v9KbIPvLm
zavbb789w08vPJnnT+jCOcOdDr0Bc/HiUtasUpUqUUdENmAGABC6QOg6PXr16qWbbroprM/629/+
pltuuUWrTvDfble1ypYtq759+2ry5Mn64osvwjF48OAM3Ujjm2++Ua1atbR+/XpCF85fs2ZJL74o
FSgQ/fHyXmBjxvgHn7EBABC6QOj6JVzdcnXHAaJ3794aOnTozwYnV8C8/ivl+i0/jh8vI9q1a5e6
du0a1rO5K2NqLF++PDQRIXThnOSf5fHjpcceU+wbXcqXT2rYUPr2W/8SYHwAAIQuELpSy63hW7Zs
qZkzZ+rAgQOpuo9DV6tWrUKnw+rVq4dNkb3H14MPPphhpxe6gYjb37tzY9LQ5dfjcOVpmEmPFStW
aMKECbrmmmsIXTj3bdsmDRokVa0aNeC49VapbVtp0SLGBgBA6AKh6+d4M2NPJXRTjE8//VSTJk0K
oeNEmxw7dLVr107PPPNMCGw+3EK+WbNmGXJ6oTeIftMNBGJ69uwZQlXcxIkTQzt8h6ucOXMmHp5W
eNVVV+nSSy9N1Z5mwDljzRr/oEQbMGfLJpUvL3mbidjPEQAAhC4Qun7GlClTwl5bDhNjx4496ft/
/vnnGW56oTs0vvbaa6Ebo9dytW7dOlT94lzpSlnlotIF/Mf8+VLLllLhwlEDjnvvlYYOlbZvZ2wA
AIQuELri3LXQe3S582C2bNn0xBNPhPDlNU4n4opYpUqVVLFixXCULFlSBQsW1DZPQ8pAPKXSVS4H
L7+tUqVK6OaYGqzpAhL/eyF99ZX07LPR5svXXy/VqRNtwHyCqjkAAIQunBeha82aNWG6nKcLrl27
NlX3cQONf/7zn2rTpo0efvhh9ejRI0wxbN++/QnbzKd327dvD9MkZ8+enarb070QOOYvCGnUqGgD
5hw5pIIFpZdeklL5cwUAAKEL51zo8vS5rSn24vG6rISEhOPex9WxAd7DR9GURIcPa9y4cfhYRuWO
jM8++6yGDRtG6AJOh82bpffflypXjjZgLllS6tLFGwQyNgAAQhfOn9Bl48eP10svvaSmTZvqhRde
UI0aNcLl43E1yw0nypQpo1mzZqlevXrhcp48eUK1KKPyVEO/Nq/zInQBp5mDVufOUfByA45KlaT3
3pP4+QEAELpwroeupUuXhvVcXp/lJhqeLujNkb1f14k4mLj5hCtlK1eujJ1LdQ4dEA+fR/v3ELqA
X+i771waj6Ye+g/kQw9JI0e6zM7YAAAIXTj3QpenB86YMSNcjk+rc2e+wYMHH/c+rgh96w1SU3AD
ip07dxK6AKSOm2xMmiQ99ZRiP0xSgQJRM46vv46acwAAQOjCuRC63Dyjdu3aoXPfxx9/rAYNGuiu
u+7SY489dtz7uMrVoUOHxGqYQ1v+/PnDsfs8+k81oQs4jTw12f/sue++aPphkSJS69bSwoWMDQCA
0IWMHbps9OjR6t69e6hgeZ+q+2InPfO9/85xxKcQLliwQA8++GDY18udCxctWhQeg9AF4JRs2CD1
7i1VqBA14PBGzG+8EW3MDAAAoQsZIXQ5NDloDRo0SAcPHvxFj+EGGlWrVlXevHnVsWPH2Pf5pmSB
jNAF4LRYtEhq2zaqfLkCds89iv3yklJ0XQUAELoIXUhXoctTAOvXr6+ZM2eGRhgTJ07UyJEjtXHj
xlSHtoceeig03fAmyp5uOGrUqFAl+7lNlQldAH4R/0PHa0kbNpTy54/WgHka9Lhx0t69jA8AELoI
XUhfoWvbtm365JNPwmUHpjFjxoTNjfem8sTFUwjnzp171PUTJkxgTReAtOcNmGO/t/TII1H4uvFG
qVEjaeZMxgYACF2MBdJH6PJmyK5uJTV16tRk769ateqEj7F+/XrVrFkzVMj2xE6A3O3wfAsfhC4g
HfA0w4EDow2YPf2weHGpfftoWiIAgNAFnK3Q5ZD03HPPqU6dOuHwZsglS5bUE088Ed6/99571aNH
j+Pe35UuT0+sHDvJ6d+/f7jOreerVauW6moZoQvAaed/Fr35pnT77VKWLFLFilLfvlIqp04DAAhd
IHSdNg5G999/v0qVKqWyZcuqXLlyYXPkMmXKhPe9OXKXLl2Oe/8tW7ZowIABYW1XvGK2ePFi/fGP
f0xsqEHoAnBWzZsnNW8uFS4cVcBiv/M0fLh0Hu0lCACELuAshi43z3BIOp79+/ef8OOudHla4Ucf
faR3331XX331lW644YYQ2HxfQheAdMMdWidPlp5+WsqTR8qdO7r85Zf+Zcb4AAChC0ib0HU6eF2Y
W8WXL19ehQoVCp0MN55nU3gIXUAG4+6qI0dGVa8cOaRbbpGaNZPmzGFsAIDQBUJX+uTOh2vXrtXq
1avDOrF58+aFt4QuAOme/0n07rtSpUrRBsylSkUbMK9cydgAAKELhK6zz2u5+vXrpwIFCoTNkfPl
y6dcuXLptttuC1MXCV0AMhRPp+7QQbFfYtH6L3dCdEfEhIRkN9uwYYM6d+6sffv2MWYAQOgCoStt
uZrlaYWDBg3S7NmzwybLs2bNChsks08XgAzNe315zy/v/eU9wGrWlCZO1OYVK1SiRAllypQpTKc+
wHowACB0gdCVllzp+vDDD7V58+Zk12/fvv28+g8woQs4h/l3mbuzPv64ll1+uYr/+c8hcMWPB2Nh
LOHQIcYJAAhdIHSlXehq2rRpmFpYpUqVsF/XHXfcoerVqzO9EMA5550ePZIFrvgxOb4R89ix0ooV
0nlU6QcAQhcIXWeA1zU4eHk/Lx/uZNimTRumFwI45+w/fFhNmjRJDFv/9V//pXfc9fDFF6NGHPny
SdmzSzfdFK0Hq18/2pR5+nTJvx9i9wcAELpA6DotJkyYwPRCAOesF2Mh6/e//30sT/VN/gFX+Jcs
idrRt2kTrQNzFcx//L0urESJ6Lq2baXRo6PbnkezAgCA0AVC1y80duxYlS5dWrfffns4ihQpohtv
vFHbtm0jdAE4J3lqtZsGpfLGkte9utrl1vSuft1xR9Sgw1Uxv61YUXr2WalPH+mbb6ITBtaJAQCh
C4Qu8xTCBg0aqFu3bnryySfVv3//MN3Q0wwPn0fTaAhdAE6a9zJctkwaMyZaD/bII1ElLF4Vc9v6
GjWkli2lESOiqtjOnYwbABC6cL6Fri1btuj9998Pl6dMmaLvv/8+XK5fv74SUuxrQ+gCgFTYulVy
Fe2996SGDaV77pEKFZKyZpXy54+qYk8/LfXsKX39dXRyQdt6ACB04dwNXa5mvfvuu2F6offpeuaZ
Z1S8ePHQzdBt4zMaT4kcNmxYqNx577HUdmAkdAFIU3v3SmvXesGs1KWL9NhjUpky0vXXR5s4Fy0q
3Xuv5KYeH30kLVjgvTsYNwCELuBcCF22evVqDR8+PGyUvH79evXo0SOEkIzm0KFDGjBggD744APN
mzdPQ4YMCdMk9+/fT+gCkD45WM2dKw0cKL30UlQVu/nmaK1Y7txS2bLSE09Ib7whff65tG5dtO8Y
ABC6gIwTug4ePBj25/rI/1nN4Fy1S9lxsXnz5mEK5c9ZFzuRyZUrF6ELwNnnfxS5KuaQ1a1b2NRZ
5cpJN9wgXXONdMstUrVqUuPG0gcfRKHtPGp8BIDQBWS40OXqkCtbvXr10oIFC0LFx29dJcqomyMf
OHBA48aNU6tWrTRw4MDwGm358uXhtXbv3j28jR89e/YM4SxLliyxn/FNfJcCSJ9cFZs/X/rwQ/9H
KZqOeOutURBzIPN0RU9b9PTFiRM9jSGa1ggAhC4Qus4uV4cef/xx/elPf1LWrFmVLVs2Zc6cWYUL
F87QocvTJevVq6ehQ4cmXj9t2jSVL19e5cqVC2/jR4UKFVS0aFFdfvnlhC4AGe0XnrR+vfTFF9EU
RDfoiP1eC1MTPUXRUxXvuktq1EgaMECaMydq9HES/I84ACB0gdB1Cjy98JtvvtGiRYu0efPmxMMB
xe3kM7qWLVuGNWs/x6+fNV0Azhm7dkUnK/7H0yuvRK3rXRXLkSOqit1+e9TivmNHadw4adWqqAV+
Cm5K5H/K9e7dmzEFQOgCoetkTZ06VX369AkB61zhAJkyKLZr107LvI8OoQvA+S72O1L+HTdtmuQQ
Va9etMlzgQJRO/uCBaUqVaLNnwcM0Ovt2+tXv/qVMmXKpAsuuEC9vfHzecbLhJ1bR46MtmMbP14a
MkQaPJh+JgChC4SuVOjbt6+mT59+Tg3u3r17Q/v7wbG/hpMnT9abb74Z1qrF13SdCN0LAZy3/M8q
/3PKyaJdO6lmTQ3NmTOErZTHGDf1eOedqDrmfR3d8MMbPh8+fE4OzcqVUosW0uLF0po1Uc+Sv/xF
qlvXa6L51gEIXSB0/YxRo0bF/k7uPO7H58yZkyHXdO3YsUPjx49Xv379NMH74aQSoQsAjli+bp1K
lCyZLHBVKFJEazxNsVSpqDoW+50Zpit6w+cSJaTKlaMpi02aRBs/x/7OhE2iPXXRTUDS4QbQ3lLk
008/DeuAR4wYEd767+PW/6x785ukfxZcHPTLjv2pOaGkf16T5tHUZlPfLuVtHfIy6FJrgNCF8zd0
vfXWW8qdO7duvPHG2N/OAomH3/fGyKVif1TPhTVdhC4A+GUSEhLC3wIHrjvuuCP8UyuR/z74pGjh
Qumzz6T+/aW2baNUct99UTMPN/FwQsmZM2rsUaxYFMxq1ZJeeCFqh+/tSjzdcflyydt7nOY5e9t+
ppX+1q1bwpq1pOHSUym91jklTy/87W+lr7468ed0wdAvq2lTad68KHP6shtPOoy1bx/dxpc9ZJ7p
WaeO/y5LrVpF/VDcdNKHh9X3d0Hxk0+iLOuDKhsIXUAGCV3vv/++GjRoEFqlpzyaxv46PPPMM9rl
hdiELgA4b3nGgzeZ95rZk+bU4CC1aFGUVAYNkjp1itaMPfigVLGiVKTIkYrZ9ddLhQtHge3++6V/
/lN67bXofl9+Gc3x8zrkYzT8OJYVK1Yof/78sU9X/7i32bdvWyx0XZwsdF144YVHhS6/jCuvlF58
8cSf0yHJ3fz90hs2jPa1do7Mmzfq9O/qlV/aU09F1992W5RDHaScXX1fL62Lxl56++3oc3sonE1d
OPzzn6Pt2QBCF5ABQpenUZyI/8O59zza34XQBQDJLV26NHSy9XRzhxCvlfV+h6eVN4L21MNYQAqp
wl0rXn89SjePPholElfI3HHx6qujYOYKmvck8z5lTi8uDzntOLW48hb7Pb58wQLlyZMnMUi9kCwt
HdL+A9KoidIDtbbFQlbyStd///d/69tvv032ND1r0p86ad7zn8gHHohyY8mS0uzZUXf+4cOPhCaf
N3pWpZtFDhsWXf/cc9Lzz0eXH35Yat36yGNu3Bh1+vfaMVfJ3OHfb0uXlsaOjapt3oZtyhS+P0Ho
AjJE6Hrvvff0zjvvZNi9uAhdAJC2GjSoq1//+tf6zW9+Ew5fbtq0/ll4JgdjaWdn7CRsXSyNxJLN
p6Ol3j2kl5tKTzwmVbs7lmpiqadAPilbVm28Jody/eH/HdUEpGkswC164lW1rrFABXPu0LWZvoxd
X/aYDUMcNuM+/jiaVpgih4Wim6cKOkS5quVzQ+fDN988chvPwvSkEYey+P86XbVq0CC6XLNm9BhJ
Pfmk5H4lDm/OpC4SOtgldY72LQEIXTj3QpenDs6dOzdxsTChi9AF4NzmGYIOAS4s+Ved1wp53+OZ
M6VJk6KT/Pfei0KD1xrly/fkUWHkhhueCyHDey27X4a3APNtO3SIlmj16BE1N/Q+zJ4C5+qO1y+5
2aELUQ4Q8WlyruJ4nZNnDbp5ordUXLcuem4ONFu3SdtiWWung8u+WO46JO2LIpiOzhyxaw7F0s2u
jTq8/HvVqlX9GGHqT8qSaZbKlNin95ot0o7Xeqtvgyd04YUXJLud1zvPc3lJUQHussukV19N/tni
RbWUHKj+/veo6uVj4MCoOubQ1a9fNKXw7lhGrF07Ck6ulLlQl5TH5o9/jKYjxsPd5ZdHY+4Oil7b
NXUq388gdAEZInSB0AUg44Uln4c4CPiEP2VY8qw8B6CXXpKeeSaaEle9erQVl2fjFS8uFSok5ckj
XXNNtIzKPS5y5YrWHN1yS9SEsEIFqVo1KVu2p48KLrlyPR8Cg5dkeW2SH79q1Wh7r0qVouVYngrn
x3HVxxUazwa86aaoyaH7aXianj+nDy/n8nmVn4efj6fW+a2v8+18e9/vxhujx/Hj+XU4xHjKXtly
UsXY67sj9vnvij3nqrHn9GBtv97xsef7q2TP/dLLr9e02Ud3oHj77bdDJc+38bpmzwA5/J9Skjvo
+3m4MYbDo49//StqfJGQcOzzxLJlpb/9LRr32J+WwGHUy9XcLMPj99hjUdB0M0h/rZL2KPGnfvbZ
6ONx/hpfdVW0nZqXqJ2g+TBA6AIIXYQuAOnhb/mmsF4pfixZsiR0sTvdvJbHM7jdQG/Dhigs+SR8
xgxp4sSoCuSlSO5W55N7hyU3//M6H4cen7T7BD4elvLlOxJQ/NahxYGkaNEohDgseU2RqycOBV43
9PLLUe8K72vsfhSukrja5CpT7KWHrngOD54C5ypM0mlrTz9d56jQ1bDhM6l67e6u57Do6XFe++TQ
6LFwWHB49Of0OdX69VHFzWMT+zKE8ysXmb77LprO57VLn38ebUrs5+6pfn4dDpl9+0YNKBw2/Ro9
hq4a+TVXrz7qqNB1ww2xhKdjd+Xt3bu3XnHZLgWHIT9vr7VyFc6Hx8yv4Xg8hn4tKXtR+To3xfBY
eKx9+HH8/ZGym/6x+pb4vv6aAYQugNBF6AKQ7tWuXVv/8z//o//93/8Nhy+/9lrbY4Yln2w7FLgB
n/eT9/Z/PvGPh6U2baLu516H89BDRypLrva40uMKj6s18c7pruT4PMJhyZWPeFhytcjVIz+O1/s4
OLhxnysjnmbmBgoOIN6P2CfvPvn37HA/TwebtFjj06RJE/31r3/VZZddFg5fbtmyRYb4Gk+cOPyo
wJgtW7bzaisUgNAFQhcIXQDOmlq17j/qhPyaa5qHKpHD0q23RmHJ0/AclmLn6sqSJfr77z2B42HJ
Hc8dlhy23BrclaVmzZKHpU8/PRKWXKVwiHOYS8uwdLq4g+327dvD/lw+fDmjdLUdN26c/vKXv+jP
f/5zOLwXV9GiRbUnle3mARC6QOgCoQvAL+Qpa3nzPnhU6CpRooU6d04elr7+OgpL7pLuv//xsJRy
Gh7SnwMHDoSNkZMeO3fuTFyrBYDQBUIXCF0ATjOHqDvvjBoRXHzxfUeFrnbtmjNIAEDoAqELhC4A
J8PNCNx1zlMBva+uO8J5bdYTTzym3/3ud8mO9ik3SwIAELpA6AKhC8CxeQqgpwm6xbjbfbdoEXWc
i9u8+UctX75cK1asCIcve/oZAIDQBUIXCF0ATsA/vm5i4dbqbnjh7oJkKQAgdIHQBUIXgFPkPZ7c
tt0b/rpNuzevdbMLAAChC4QuELoAnIK5c6N9rdzOvVw5adQoxgQACF0AoYvQBeCUffmlVK2a9I9/
RJsRf/UVYwIAhC6A0EXoAnDKXMkqXz7qRFinjjRnDmMCAIQugNBF6AJwSvbvj9ZoFS0qZc8uvfRS
tFkxAIDQBRC6CF0AToG7Dr75plSwoJQnj/Tqq9LGjYwLABC6AEIXoQvAKVm/XmrZUsqVSypUSHr7
bWnXLsYFAAhdAKGL0AXglPjv6nPPSdmySaVKSUOGSAcPMi4AQOgCCF3p1raT3BGV0AWcHTNmSDVr
Rp0IK1aUJkxgTACA0EXoAqErXVu6dKk6duyo9u3b64033kh1+Fq8eLFy5cqlzZs3M4jAGTB+vFS5
crTHlkPXt98yJgCA//D5mOeZL1rEWIDQld7s3r1brVu31qxZs7Rr1y6NGTNG3bt31+HDh3/2vgsX
LlT27Nm1c+dOBhJII4cOSUOHSrffHrV9r1fPVWbGBQCQ3L6EBH2YNasO0q4WhK70Z+/evVq1alWy
9x3CDhw4cML77dixQ5UrV9ZvfvMbtWnThoEETrPde6V335OK3ibdkE9q2VZaz0xeAMAxHDx4UHUe
f1yZfv1rPeP/zgGErvRt8ODB+uyzzxLfnz59uu6++27ddddd4a2Pe++9V4UKFVKmTJkSj1atWmnH
xo3as2mTdsfecnBwpP7Ys2mjDm1ZJ21boY1rdqtbDylvnsO69opNat9ko9Yv2ijtjd1mW3RbxoyD
g4ODw8fe2HnXj6tXq06dOsnOy+rFgpf/QQ4QutKh4cOHa6jnMSWxaNEitW3bNlSz4kexYsWS/WDH
j47XXKNh116rj3Lm5ODgSMUx5Lqc+iR/Tn16U069cfktuvMPbyrzxZuU4zeTVfvXD2jA1ddq/M05
NSJ37PbXMl4cHBwcHMmP4bHzrgZXX33M87JRo0ZxcgtCV3ozbNgwffTRR6m67Z49e1S9evXEH+pf
/epX6ti+vTbPn6+t8+ZpCwcHxwmPbQvnad/yedq7bJ6++nCe7i06T5f8f2tVvpI0Yvgh7ViyWAeW
zNSOfzNWHBwcHBzHP7bGzr3Wff+9nn766WSBq1GjRvrpp584wQWhKz3NAR4xYkSocsUlJCT8bCMN
B69q1arpggsuUKdOnRhI4CRNnSnVqCVlvVa6P/b2628YEwDAL1e3Xr2wpqtRgwYMBghd6c3atWv1
4IMPqkuXLurcuXNoouHW8QdTscPqDz/8oBw5ctC9EDgJn3wilS8ftX2vU0eaM4cxAQCcugNbtmhE
tmzSihUMBghd6c2hQ4dCZWvNmjXhWL16daoXXrJPF5A6+/dLgwZJt94q5cghvfCCtGwZ4wIAOI18
PnbddezTBULXuebf//537Gf7Ov34I32sgWPZvl3q2VMqVEjKnVtq107auJFxAQCkgU2bpGuv9VQk
xgKELkIXcO7bsEHy9nW5ckWBq08fadcuxgUAQOgCoQuELuCU+O/cP/8peUp9yZLe987NahgXAACh
C4QuELqAUzJjhvTww9JVV0mVKknjxzMmAABCFwhdIHQBp2zCBOmuu6TMmaWHHpK+oe07AIDQBUIX
CF3AqfEWdsOGRdMHHbbq1pUWLmRcAACELhC6QOgCTsnu3VLfvlLhwlFH3ubNpVWrGBcAAKELhC4Q
uoBTkpAgdeki5csXHZ07S1u3Mi4AAEIXCF0gdAGnZOVKqXFjKWdOqVgxqX9/ac8exgUAQOgCoQuE
LuCUzJsnPfVUtF6rTBlp5EjGBABA6AKhC4Qu4JR9/bV0331SlixS9erSF18wJgAAQhcIXSB0Aads
zJhoby2HrUcflWbPZkwAAIQuELpA6AJOyYED0gcfSMWLS9mySQ0bSkuXMi4AAEIXCF0gdAGnZMcO
qUcPqVAh6YYbpDZtpA0bGBcAAKELIHQRuoBT4mDlgHX99VLBglKfPtLOnYwLAIDQBRC6CF3AKVm8
WKpfX8qeXSpRQvrww2hqIQAAhC6A0EXoAk7BrFnSww9Hbd8rVpTGjWNMAACELoDQRegCTtmkSVLV
qlEnwgcekKZNY0wAAIQugNBF6AJOyeHD0scfS6VKRWHr6aelBQsYFwAAoQsgdBG6gFOye7fUr59U
tGj0N6ZZM2nVKsYFAEDoAghdhC7glGzZInXpIuXNK+XJE132dQAAELoIXSB0EbqAU7BypdSkSfT3
xNWt/v2jahcAACB0gdCVIezbt0+rV6/WwYMHCV1IV7w+q27daL3W7bdLI0YwJgAAELpA6MpgPv/8
c3Xt2lUPPvig1q9fT+hCujBlilSjRhS23JEw9m0KAAAIXSB0ZUxr1qxRQkKCOnXqpOXLl6f6fkuX
LiV04bT79FOpUiXp6qulRx6J9twCAACELhC6zgldunTRihUrkl23d+/e2M/wJm3cuDHZ4aD19ddf
K2fOnIQunLIDB6QPPpCKF5eyZZMaNJCWLGFcAAAgdIHQdY7p3LnzUaHrs88+i/38XhvCld/GD1e4
MmfOrEsvvTSEMOCX2LlT6t1bKlRIuv56qVUracMGxgUAAEIXCF3nUejavn275s6de9Qxf/58jRw5
Ujly5KDShZPmYNW2bRS0HLh69YoCGAAAIHSB0HVO69atm9auXZvq2zug5cqVi9CFVFu8OJo6mD27
dNtt0qBB0v79jAsAAIQuELrOcVu3bg0BqmHDhpo8eXKqW8fTvRDHsmfPHjVt2lR16tTR448/Ho4n
n3xS1asvDM0x3CRj7FjGCQAAQhcIXeeRKVOmqEOHDmrevLnatWunXr16adeuXYQu/CKeknrxxRcr
U6ZMyY5y5cZo6lTGBwAAQhcIXUg1QheO5cCBHcqe/epkgeuCCy6IBa4JDA4AAIQuELpA6MKp+vLL
HbrooqND18SJhC4AAAhdIHSB0IVT0qGDdMkl22NB609HTS8cM2YMAwQAAKELhC4QutLel19+qRYt
WqhNmzbhaNmypUaNGpmhX9OaNdIdd0i5cikWrvaqU6eOevHFFxOPxo0bawm7HQMAQOgCoQuErjPh
hRcaHlUFql797gz7ekaMkLJmVew1RL/vAQAAoQuELhC6zqrGjZsfFbquvPIhPfCA9NRT/rjUsaP0
1lvS4MHSZ59Js2dLS5dK69dL27a5Lbt06NDZfR0HDkj160uXXSb16MHXFQAAQhcIXSB0nWWzZkWh
6pJLjg5defI8pJdekp58UqpRQ6pcWSpbVipaVMqbV7rmGilHjmj6Xp48UqFC0ebCFStK99wj1awp
Pfus1Ly51LWr1K+fNHKk9NVX0vz50sqV0saN0o4d0r59J//c169frd69e6tnz57q1atnLGT1iD2/
gbr55gOaM4evLQAAhC4QukDoOktcDRo+XKpQQcqcWXrkEalcuUZHha4aNaoe9/7eMm3rVmn1amnB
Au+rJo0eLQ0YIL35ptSihfTcc1Lt2tJ990WbD5csqVggknLnjqb+eVNi/x7Ol08qXFgqVSpag3X/
/dKjj0rPPy+1ahVVrAYO9Losado0afFiacMG6cMPxxz1nC+66FJt2bKTLzIAAIQu/P/t3Qd81dX9
/3F+/mttq+0PratFVELCsgkgMmTKkCVFloggAiKKoqCigCIqyBSQITJlBYUIyBIMCGFDkCWbyl5h
tIwQQgiQ5P2/n3N780sAIcAlJOT1fDy+zbwBD5DeV875nkN0gei6Od/3+vf3zkjZ7NQHH3gDxsya
NVkNGjTwBFJDd73wwgtuBsmfkpKk+HjplKeJjh3zBpvNSC1cKE2dKo0eLX3xhdSpk/TWW1KzZt4Z
M5s5sxm04sWlkBBvrOXJIz366E+e0PqfVNEVFJTb82vE8ocNAADRBaILRFf62bDBu8zPlgKWKyeN
GOG9ByszsXvF7J4x+33bLNeuXTYD9pNuu+3/pYquQE+RxcYSXQAAEF0gukB03WAJCd77p+rUkXLn
lurVk2bPvrX+GyMifrxoeeGDDz6oU6dYXggAANEFogtE1w1y9Kj3nqpSpaQCBbz3RW3adGv+t65d
u1bVq1dXlSpVVLVqVVWuXFnNmjXTGZsSAwAARBeILhBd/mS7AVpg2fc125TCbsey+6YAAACILhBd
ILqukW1MYUsG69b1LiG0Ld1th7+bfVYWAAAA0QWii+jK1Gyr9mHDvOdl2VlZtknGxo382QMAAKIL
RBeIruti36/at/du927nXQ0c6L2HCwAAgOgC0QWi6zpEREjPP+9dQmhnVs2Y4d2dEAAAgOgC0QWi
6xrFxEhjx3oPBQ4Kkl5/3Xbr488XAAAQXSC6QHRdFzv0t1MnqWBBqWhRqVcvKSqKP1cAAEB0gegC
0XVdFi+WGjeWAgKk6tWl77+Xzp7lzxMAABBdILpAdF2z06elb76RKlaUAgOlFi2klSv5MwQAAETX
rWzatGlq1qyZzp8/z2AQXUTXjbJ3r9Sli/T449ITT0g9ekgHDvBnBwAAiK6sYPfu3SpVqpSee+45
nTt3jgEhuoiua3H69GmdPHlSMTExnuuku86cOafISOnll70bY1SpIn33nTzv588MAAAQXVnN0aNH
VbJkSdWrV4/wIroyn507dyo4OFjR0dE36XeQoKZNX9RDDz2kRx55xHM97Llyen5P37qDjJs1k5Yt
488JAAAQXYSXN7xsxussN/MTXZmF/WX95ZdfVKBAAe3fv9/NON2otbL2ZePiJGu7w4elPXukzZul
JUsSFBLylLJly5bqathwsPscAAAAogsXhhczXkRXptGmTRsFBATojjvuUN68eZUvXz5Nnjz2kp+b
mOhd2mfnYXn+rnsiTdqyRVq+XJo7V5oyRRo9WurfX/r0U6ltW6llS6lJE+9BxTVrSpUrS+XKSU8+
6b03y67SpaV77ql+UXRNmjSWPyAAAJC12JOt4GDOv7kCi62qVavqpZdeIryIrozvmWeeuSh2nnqq
rwsm2xmwQQPbjj3BE0ZnVLBgjCfQjun++w/rj3/c7/nc7Z7rF8+10HOFe67pnmuS5wrTn/4Upnvv
DfN8fpiKFAlThQphqlMnTE2bhql16zB17BimXr3CNHhwmIYOtWWEj130+2jevLkmTpyosLAwLi4u
Lq4bcE2YMMG9nDRpUqq3ubi4btK/Sc81dfhwRT/0kGb16+fezir/7d9++63Gjh2b5u9DU6ZM8TyP
HKw///nPql+/vv5tM4QgujKqOnXqXBQ7OXO20+OPr1GhQnM9L6fpiSfGqVixr1SiRE89+eSHKlXq
LZUp00Rly9ZTuXLPeiKtmsqXr6xKlSqpSpUKnpArr1q1yuu557xX3brlVbt2eT37bHnVrFleNWqU
94RceVWrVl5Vq1ZQ5crldd999+q2225Lddmsm33N8uXLc3FxcXHdgKtChQqe7+tPutUO9tLeZly4
uG7e9ZTn32Dt0qW1+8471bh4cfd2VvleVKZMGRX3/DdfzWNq166tu+++W7fffrtWr17NE3uiK+Oq
VavWRdHVt29Xz0eOe65j/315wnPZJhsxnivWc8V5rnjPZTcv2nSu3QOWkHwlJSUoMdF7JSRc/kpM
THQvN2zYoEWLFmnx4sXustejoqKSP87FxcXF5f/LvsfaNsz58+d3L/mey8V1ky/Pv8HEw4eV9Nhj
Sty61b2dVb4X2UtbJpjWzzdff/21cubMqdmzZ/OknujK2OwnBBdGV79+XzAwAJBF2A+4bAfbAxx+
CGQMx45J//iHtGMHY3EZ48aN09///neFh4czGERXxrd27VoNHTrUbdVu62NnzZqlXbt2MTAAkEXs
27fPndW4106hB3DzsXvhFY0ePVr333+/e94KoivTsJ9uhoSEKD4+nsEAAKILANGV4YPrxx9/ZDCI
rszlX//6l/s/3P/85z8MBgAQXQCIrgxpzJgxBBfRRXQBADIfi62goCDt4TR6gOjKwGwpod3DRXAR
XUQXACDTOXjwoDueg400AKIroz9fXbZsGQNBdBFdAIDMx7Zejo6OTt6CGQDRBaILRBcAAADRBRBd
RBcAAACILhBdILoAAJeQlJTEIABEF4guEF0AgCs5c+aMlixZor59+7rXfaZMmaLWrVvr7bffVtu2
bdWvXz+dP3/efWz27Nn65ptvNH369FRf69ChQxoyZIjmz5/PwAJEl/uesnv3bh0/fjzV+xMSEtxz
ysOHDys2Nva6fo1z586556mbN2++4f899j3Qvl9OmzZNp06dIrpAdAEA0vrc7d9q0qSJ22b59OnT
7n0nT55U+fLlVaJECffyMc+TO9u90Ga3bEvmV155RUePHtV7772ncePGucfYxyy27rrrLhdwAIiu
I0eOqFevXsqdO7dmzJiR/P74+Hh9//337nuJnQN4Pez7Vc2aNd0PiW6kuLg49ezZU+vXr1eDBg30
ySefEF0gugAAaTd+/Hjlz58/Obrsp8/r1q1L/rgdNjp27Fj3+jPPPKMRI0a41y3ASpUqpbNnzyaH
V7FixTRgwAAGFSC6klWvXt39QGbTpk3J77MjKPr37++Xr28/AHrzzTdv6H+DbUVfo0YN93pMTIy2
b99OdIHoAgCknQVVgQIFkqPrQq1atXIHJNtPlHPlyqW5c+e699sTKJsh8x2abD+9Llq0KNEFEF3J
7IcxX3zxhWrVquWeS/qWGtr3DV902Q95Fi5c6JYd2vt/+uknnThxwn2uvb5r1y43qz516lT3Qx5b
2jxy5Eg3+2TatWunt956yx2KbF/TZuJ91qxZo++++05Lly51b9vs25w5c/TLL78oNDQ01bJqY98H
7dcMCwvT1q1b3fvs99GpUycVL17cLS+0JY2ZHdFFdAEAMlB0/ep5Uuf7CXJUVJTuvfderVixIvlj
999/vzZu3Eh0AUTXJVlI2fcEi51y5cq5pYDGZrrsXlFjwRUYGOju77KZ9uDgYC1atEgrV67UAw88
oEGDBmnUqFFumeJnn32mCRMmqGTJkurdu7d7/IcffqgyZcqoT58+7qUti7YgsyWMtux5586dblbe
3l6wYIHuvvtutzywcuXK7vD3lMFl8WZhZZFmv0ZkZKT7WvZr2de2e8d8s/tEF4guAIBfomvo0KFu
eaGxJ0MPPfRQ8k+MN2zYoAcffNA9oSG6AKLrt6LLYsjCxTbbCQgIcLNGNhvlm+myH+DkzZvXbU5h
QWOBZHFkM0p2T6lvuXPdunWTQ8vuHW3UqJF7vX379u7+MGOzUhZnkyZNcp8/efJkF172cbu/zH6N
HDlyuF/TDnxPuROrLbWuUqVK8ts2y+9bUmhfz/f6rYDoIroAAOnMltjYExvfUp2UT5Zatmzpdh/z
RVXp0qU1ceJE97YtwSlUqFByrNnH7Z6ugQMHMqgA0ZUqunzLCletWuVmyG3G6quvvnLv27Jli7uv
1Ga67PuIzSjZ7Jd9T7LvMb7Z9Oeff16DBw92r1t8vfTSS+51W17Ypk2b5F+zdu3aLrBsMyBbrmgb
BtnXNfbDI4sye3kh+zopo2vYsGHu1ze23NDuTbP/HqILRBcA4KrZxhg2g3VhdNlM1htvvJHqJ8G2
zMe3S5j9tNp28/Kxn1DbT6s///xzBhUgupLZMkK7J9THlvlly5YteQdAi66goCD3vca+jzzxxBNu
iZ+9HhISkrwBR/369VNFV9OmTd3r77zzjjvewtjsmMXR8uXL3XNX38Y/9v1t7dq1Lv4effRRt9zx
Qjarbx/zfS+0WLTdXY39sMm+7q2C6CK6AADpyJ4I2U+bbQtku+E8ZWDZcho7ryslexJkM1m2JNGe
/Phmuexx9sSocePGqX6qDSDrRpd9X7BZJlvaZ88lU35/seDq2LGje/3YsWN6/PHH3Q9yvv32Wxc+
tkzZNtCwzXsiIiLchhcVK1ZUly5d3OsdOnRwEWQzWPaDHpuhsl/DNtuwHw4ZWx79pz/9yX2exZNt
nmGfc99997l7tS5kSw9tCWGPHj3c7oS2K6I9xkKuW7du7rmwLZG8FQ6HJ7qILgBAOrInE75lNxfe
0+V7/6Vc6qfEvsdbmN0KN5oDRNf1R9eOHTvcboG2RNB3wLqx+6ksqnwsbiyW7Dmn3YNlywItfOww
dpt1t+WAtqTZZrAs5GwLd9tJ1e4Ns+834eHhbgbNli+mZMFmM/K+DYBsIwz7XDtv61LxZNvB226H
diSGb2dWe59t7GGPuzAeiS4QXQAAAEQXQHQRXQAAACC6QHSB6AIAACC6QHSB6AIAACC6AKKL6AIA
AADR5Re2U6qdp2UbaoDoIroAAABAdPmJ7ShobHfEJ5980j1XvRa2TfytsBsh0ZXB2Ba/M2fOVNeu
XbV161aiCwAAgOjKVOwsroULF17317Et64cMGZIlx5DousHsDIQff/zRHSJn5w2klZ2TQHQBAAAQ
Xf5kZ3fZWVp2BtbkyZPVpk0bd6aXsbP/pk+frnHjxmnChAnubC/7XDs8uX379m5SYP/+/RozZow7
6N386hmTGTNmuIORfWd4WaTZ2V/28tNPP3XPZ+1x1apVU/ny5V3A2e9j8eLF7qwvC7Fb/Tkv0ZVO
pk2bpqVLl6b5821WjOgCAAAguvzJlve9+OKLKly4sIYPH67nnntOefLk0YkTJ9SpUye9//777mBk
W0JoEwcWUiVLltTIkSPdEkM7MPkvf/mLW81lBx/36dNH+/btU4cOHVS5cmX32FKlSqlevXou2Cy0
2rZtq7i4OL377rtq0KCBO2zZVoL17t3bhZ5NTmzatInowuV/WmB/eVNe9pfnQpMmTboouuyEb/vL
WalSJT399NPJl73P/qLnzJnT/aUEAAAA0eUvPXr0UKNGjZLfLlCggMLCwtxz1ZUrV2rNmjXuuejX
X3/tPl6lShU3m2VsI42AgAAdO3ZMXbp00QcffODiKjQ0VM2bN3czXa+88oq7tcZYrNWqVcu93rNn
T7Vo0cK9bjNtNsFgM2oWZOfOnSO68NvWr1+vli1b6rXXXnMv7S/SZ599dtFfnEtFl/1UwKZnL7zG
jh3r/jEEBgYSXQAAAESXX9lzVXvu6mOzT7Yj4cGDBzVgwAD3nLVGjRoaNWqU+7hNCtiqLWMzXBZd
thrL4mrw4MFKSEhwSxF9mjRp4gLL2Ne12TTTrVs3F2Y+Fno241a9enUdOnSI6MJvs5q3v3QWR76X
9hOAC3dluVR0XU5UVJSCg4NZXggAAEB0+T26LJh8bCYqMjJSderUcTNWpmrVqsmvP/XUU5o1a5Z7
3ZYbPvLII26poYVVoUKFXKzZhIMtPYyPj1fTpk1TRZctNTR2f5dvpsv2LzD2+bbK64svviC6cP3s
pwOrVq1K8+ezeyEAAADRdSPYiiqbYbIN32wjC3vbbpmxWSi77cU20ihTpoy798smFF566SXVrVvX
rfBau3atuwXGliHa89QSJUq4mS+LtNGjRys2NtbNktl9XDY5YYFnm2dYpI0fP14FCxZ0z4tt2aFF
mG3EYZ9zNZMTRBcusmXLFlfuVvVvv/22Bg4c6H4aQHQBAAAQXTeDLfOzJX9Llixxewz42I6EU6ZM
0bZt29x5XPZxizF77mqbatjH7faYDRs2aPfu3e4xFlkWUb4t5e1zbDdEey4bHR3toso+3zbqsK81
Z84c91hbpmj3gs2dOzf5axFduGa2sYb9pbVtMvfu3audO3fqzJkzRBcAAADRdVPY5hcNGzbkz5Xo
AtEFAABAdPmbTQj069dPHTt2dDsQgugiuoguAAAAosuPbImfb6fBW32bdqILRBcAAADRBaILRBcA
AAAyWnTZToC+zS5sIwq79uzZc9Hn2V4CnTp1cptYZHT2e7Tzam13xLTYunWrvvzyS7dxx+bNm90M
HtEFogsAAIDoum52H9aIESPcVu62O2C5cuXcOVsWYheyLd5r167tdgrM6GzTuQIFCrit5NNi+vTp
yp49uxsDe95s54Fl5OWSRBfRBQAAgEwSXe3bt9f8+fOT365fv75ef/316/66SUlJfvn9Xc+Mk8Xj
2LFj0/R7tZAMDAxMnsUbPHiwhg4dSnSB6AIAACC6rp0tvbNDi1MeP2TR1bJly0t+vh1gbAcf2+dv
2rTJHUJsZ29ZuH3++efJgWTnaM2aNcu9z143dtZWaGiovvrqK3333XcudGzmzM74mjp1qlq3bu12
QvSxzTnsrC77WJ8+fbRu3Tr3fntpBzDbubW+M8Hsffa1bXng5MmTk0OqZs2aydFlRy2Fh4e7M27t
bC8fW0o5adIk93t9+OGH3UyXsaWUxYsXz7A7MhJdRBcAAAAyQXRZNNWtWzfV+y4XXRY7999/v4uj
yMhI3XHHHS6gLLxslmjFihXu8OKPPvrI3R/Wt29f5c6dW4cPH1a1atVc7Gzfvl0BAQGKiopyj/v9
73+vAQMGqG3btjp+/Hjyr7VmzRo342bxZQcpL1iwwD2fffXVV91SyNGjR7tgtEiqWLGiC7QtW7a4
r22/nrHo+uabb9zvt127di787Gvdc8897nPtMOUPP/zQzW6FhYXpb3/7W3J0nT59WiEhIZoxYwbR
BaILAACA6Lo2L730kl5++eU0R5dttpE/f37Fxsa6DSdy5cqlo0ePuo9ZVE2bNk39+/dXmzZtXNBM
mTLFHZx86NAhLVu2zM2O2czVo48+6uLLIstml3xfI6Xdu3ercOHC7mtZoBkLJLuM3W/l2/Bi8eLF
7nWLwpw5c7rH+qLLovCnn37S888/735PFl0WhTY71qhRIzcjZ+wesJTLC+3rlyxZ0s2yEV0gugAA
AIiua9KkSRM1bdr0itFlM0U282M7/Pmiy0LJostmlWwpn0XXzJkz3VLDzp07p3q8zVZZkNnmFLak
8DHPf/uuXbvcfVQWYClnuFKyX89m4vLkyaPVq1e7JYjNmjVL9Tnx8fEu7oYPH+6+tn2ub+dFi66J
Eydq/PjxLrAu/G8qVqyYW15obPmhRZfFpC+6SpcuTXSB6AIAACC6rp3dn/Xss8+mel+9evX02muv
pXqfb3dDWzIYFBTkQseW4T300EPJzy0rV66sH374wd1T9eCDD7r7rSymLLZsFipHjhwu0OzzLdbs
a9nXtPf7lvSlZFHmi7EOHTq44LJZq7vuusstS7SvM2HCBDd7Zl/D7r2yr28zXfZYU6NGDbds0JY8
2pJC+3z7tWzGy54bW2A2b97cfa4tN7Tlhb6liXFxcW6mzXY1JLpAdAEAABBd18Q2ubAldBYYxpYP
VqhQQVWqVHGxYRHVvXt3d7+VseV7efPm1apVq9w9VHa/lr3ct2+fSpUq5TajOHv2rFu2eN9997mN
KOzeK5sZs/uuGjdu7LZwt5muXr16ua9v92DZ8r8LLV261M3E2de3e75sh0WbfbIZK7uvrGzZsm6p
on1t2+bePte+dr58+dSvXz8XdXbPl923ZjNx9t9hW8IXKlTInTVms282M2Zvv/HGG+ratasLSrt3
zNgSxRIlSlxy6SPRBaILAACA6Eqzjh07avbs2e51W3JnkWEzUHYf1cGDB91SPV+U2f1ONqNkS/Bs
xsj3un3cHpdypz8LGlse6GOfZ5tv2DJFizS7fF/jUoct2w6JNkNlG2r47uny+eWXX9zugj72ePva
9vuw3++BAwfc4+33ZLNlvu3rLSovPCzZfn2bObOljvbfa9FobCmkXRkV0UV0AQAAIJNEl4XPkCFD
XKjAy2LPZug4HBlEFwAAANHlF7ZEz0LDXwcaZ2a2G6LN0F3PocxEF9FFdAEAABBdyOSILqILAAAA
RBeILqILAAAARBeILhBdAAAARBdAdBFdAAAAILpAdGV5tiMN0QUAAEB0gejCDbJ3716FhIS4Q+8A
AABwE3mej/37H/+Q9u1jLEB0Zdx/p6fcKd9XM2vVt29f3X333Vq4cCEDCAAAcBN9N2GC8vzv/2p6
WBiDAaIrI9q0aZO6dOmigQMHupcrV6684mMGDx6s3/3ud8qWLZty5MihyMhIBhIAAOAmmDx5su68
6y73vOwv2bPrhx9+YFBAdGUkCQkJGjRokLZv3+7ePn78uD755JPLLhkcP368+0ed8sr+5z8rtEED
LX7xRS1o1IiLi4uLi4uLi+sGX0saN9YXderotv/5n1TPy26//XZFRETwRBdEV0aRlJSk+Pj4VO/r
0aOHTp486V63+Nq6dWvyZTsWjhgxQn/84x9T/eOuWLas5n/8sdZ89JFWcXFxcXFxcXFx3fBrreea
3rGjHsufP9XzsiJFimjbtm080QXRlZ6OHj2qJUuWJF+LFy/W2rVrlZiYeNHnTpgwQYsWLUp+235K
8thjj6lAgQLupV2PP/64goKCdOedd7p/2DVr1tTJmBgGGgAA4CbYvXu3Cnmen9nzshIlSyoqKopB
AdGV3jZv3qwOHTqoffv2yVf//v11/vz5VJ83ceJEzZo1K9X7zpw54/7hprwOHjyoY8eOafr06cqZ
M6cOHDjAIAMAANxE2zZtUou//1371q5lMEB0ZVR2A2Z4ePhVPWbPnj0qWLCgTpw4wQACAADcTNHR
UkiItHMnYwGiK6OxjTRGjRql0aNHu2WIhw8f1ooVKy66z+tS7P4uDkcGAADIADgcGURXxmXLB22b
+AEDBqhfv37q06eP20gjLi6O6AIAACC6QHTBX2wXQ9tY41KbaxBdAAAARBeILtwERBcAAADRBaIL
RBcAAADRBRBdRBcAAACILhBdILoAAACILhBdILoAAACILoDoIroAAABAdIHoAtEFAABAdIHoAtEF
AABAdBFdILqILgAAABBdILpAdAEAABBdILpAdAEAAIDoAtFFdAEAAIDoAtEFogsAAIDoAoguogsA
kE5mzZql3bt3X/HzNmzYoAULFjBgANEFogtEFwAgrb755hv97ne/0xNPPKEDBw785udt2rRJAQEB
+stf/qI5c+YwcADRBaILRBcA4HLOe67RoaH6wx/+oGzZsrmrWLFi+nX9eu8TucOHvZfn+/2qZcsU
GBiY/Hl33323ZsyYocTERAYSILpAdIHoAoAsLC5OOnpU2rlTWrxYmjBB6t1bevtt7atTR/f8N6JS
Xq0eeECeb/RSgQLuSggOVo3//d+LPi9v3rw6efIkYwwQXSC6QHQBwC3q9GnvE64tW6SICGnsWKlb
N6lVK6lhQ6laNal4ce8TssBAqVAhqUIFqXZtqVkzJXz0kcK6dNGdd96ZHFJPPfWU9qxcKW3dKm3e
7L08r29YuFAFPF/H93kPeMIswvNrJiUl8ecAEF0gukB0AUD6WLZsmX++kC3Zi4mRoqIkW+oXHi59
/bX06adSy5ZSvXpS5cpSsWJSvnzeGamiRaWnn/Z+rEULqXNnafhw2yHD+zUOHvR+zUssB5w8ebL+
+Mc/qkyZMp7nb//+zd/Wtm3bPL9cPt17771abLNmAIguEF0gugAgvXzqCaI77rhDPXv2vPwnnjsn
RUdLe/ZIq1dLM2ZIgwdLHTtKzZtLtWp5Z6OeeMIbVPZkymarLLKef1566y2pa1dp1Cjpp59sdwvp
0CHvrNd1mD9/vqfLDl7x8371PLH7+eef+QMHiC4QXSC6ACB9eBJKnbt0SXWvU6/u3ZVgS/QmTZL6
95fatZOaNJFq1pTKlZMKFpTy5/feN1WqlFSjhvTii9I770iffy59+633/it7EmVPqM6cYaABEF0g
uoguAMhiTpyQNm7UJE8oZbvEZhSzLKrKlpWefVZq2lR6/32pXz9by2frEKXt26Xjx6WzZxlLAEQX
iK5bUUJCglavXq3x48frhx9+0Jmr+Ckq0QUgS7Hvj/v2SXPnSn37epcA2lI/m63Kl0+HPGFV98kn
UwVX48aN9R/bav38ecYPANEFoiurmjlzpvr16+fW8NuhmH369ElzeBFdAG5Zx45Ja9ZIY8ZI770n
1akjeYJKQUHee6zsfqvWrb0bVCxf7s6vUlKSTp86pXr16rngatKkic7ZfVsAQHSB6Mraou0m7hS6
deumXbt2pemxhw4dUnBwMNEFIPOKjfWeWzVzptSjh/d+q0qVks+lUsWK0ksveT/2ww+SfX+8wkYV
MTExGjp0qOLj4xlfAEQXiC78n82bNyssLEz9+/f3PJ/4vycUO3bsUN++fS95tWvXTrlz577stsIA
kCHY9uj2vcp227Pd/myjCtvMwmat8ub1brNus1fvvuv9uG1+YQcJc/YUAKILRBeuxLb0TRlKn3/+
ub799lt3L5ePvT59+nS9/PLLGj16dKrH23bAderUUe3atVNddevWVaVKlfTwww/ryJEjDDSAjMNm
r7Zt827BbluqN24sPfWU98mIXXaGVbNmUq9e3nOvdu+W4uIYNwBEF4guXJu9e/e6e7XsstgaN26c
Zs+enSq6Uurdu7e2bNmSpq+9c+dOlhcCuHlscwrbpMLuqRo2zHtu1T//KRUp4j3XqkQJqW5dqX17
771Za9d679UCAKILILrSS1JSkrtSGjt2rJYsWZKmx2/bto2NNACkj1OnvE8kpkyx04elBg2827Db
duz2JMN2EXzlFalPH2nOHPuJk8Q9VQCILoDoutlstmvq1KluB0PbiXDGjBme5zKfep7bnErT49m9
EIDf2W5/hw5JS5dKgwdLb7zhPTDYZq/s3quSJaX69aUPPvAeHLxhg+0IxLgBANEFoivjOnbsmAsv
20BjzJgxOm4HdKYR0QXgulgsbdokTZwoder0f7NXFleFCknVq0uvvioNGCAtWCBFRXGAMAAQXSC6
shaiC8h6zl/LIb8WSvv3S/PmSf37e0OqWjUpJMS7PLBUKW9wffKJN8DsvtKYGAYbAIguEF0guoCs
xZYily1bVuvXr//tT7LZcvv4N994lwDWqyeVLu2NK5u9euYZ75LBr76SFi3yLiXkAGEAILpAdIHo
ArI62/X0nnvuUbZs2RQUFKRNthPgwYPSTz9JfftKzZt7N7PwzV7ZMsGGDaXOnaXvv7dvGN7NMAAA
RBeILhBdAFL7MTJSd2bP7oLLd+X4wx+0MSBAKlzYe8hwmzbS0KHSsmXe/+P/jWMpAABEF4guEF0A
UvL8n/dPzzyj7CmCy67APHm0dcUK70HEAACiC0QXiC4AV8E2vbDt2m2zi6Ag6bnntLBvX93/4IMu
uOxQdDscHQBAdIHoAtEFIK1OnPDuHPj8897QKldO6tHDey/Wf82bN8/TYdXcwegAAKILRFe6sEOE
7eby8PDwqzrfiugCkCHYVu62jbtt4R4cLBUtKrVtK0VGSklJjA8AEF0gum6ujRs3qnDhwnrwwQeV
K1cuVaxYUcvsBnKiC0BGt2aN1KGDVKKE9/+gmzWTwsOl+HjGBgCILhBd/peUlOSu+P8+2Thx4oSO
HDly2cecO3dO77//vgYNGqSDBw8qOjpamzdv1pAhQ9zsF9EFIMPZsUPq00eqUMG7fLBOHWn8eO+5
WgAAogtE14384lFRUWrbtq3n7+evWrlypfLnz69atWpd9vDPY8eOKSws7KL3jxkzxkUY0QUgw/wf
sOf7kmrUkHLn9p6jNXCgtHcvYwMARBeQftG1Zs0aTZ061b1eunRpffzxx26ma+LEiUpMTLzkY86f
P6+RI0dq8ODBWrFihbu5/K233tILL7ygM2fOEF0Abh7bwn3GDKlRIylfPvvGJs83NmnDBsYGAIgu
4OZE15YtW9xGGAMGDFBISIhbOrhv3z4XVL8VXcZC491331WhQoX0yCOPqEqVKi5CshKiC8gg7CDi
RYukt97yHlZcsKDUqpW0ZAmHFAMA0QXc/OgyU6ZMUYMGDbR8+XI3U9WzZ0+3VPDKf7f/7e7rskCz
+7qyGqILuMk2bpS6dPHOZuXNKzVuLE2bZlurMjYAQHQBGSe6Dh8+rK5du+ro0aPubVs6GJ+GHbx+
+OEHPfzwwypRooT++c9/umi73H1gRBcAv9i3Txo0SHr6ae+GGJ7vPxo50r6ZMTYAQHQRXciY0WWH
fNapU0dn7byaFE6ePPmbj7EliCVLllSPHj3czFhCQoL7OqNGjVJcXBzRBcC/jh2Tvv3Wu+OgzWiV
Ly/16uXdkRAAAKILGT26bLfBunXrqkaNGnr11Vfd9dxzz7klg5djs2OHDh1K9b5Jkya53RCJLgDX
zTblmTNHat7c+3+iRYpI7dt7z9gCAIDoQmaKLrsvq3bt2nrnnXfc2Vu2fXxzz5Mcm7W60Lhx4/Tm
m2+6y5YTlitXLvltizWLt5iYGKILwLVJSpJWrpTnm5E3skJC5PnmIv30EwcXAwCILmTe6ErJdi30
LQ88ffr0RR/v1q2bu3/LAqtVq1Zu98LXX3/dvd2yZUtNsxvYsxCiC/CTbduk7t2lsmW9ywfr1ZMm
TrR1zowNAIDowq0RXRZLefLk0b333ut5vpNXH3300SU307gwxBJSbMWckAW3ZSa6gOtgB6mPGCE9
84w834CkqlWloUOlAwcYGwAA0YVbK7psdqtmzZoaO3astm7d6s7tsqWFP/7442UfN2vWLAUFBXme
M41wG2t8/fXXV3wM0QVkcTZzNWWK1LChd0bLZrY++0zavJmxAQAQXbh1oysyMlIr7R6KC4SGhv7m
4ci2BLFdu3buHi/fksIDBw64g5JPZqHlQEQXkAbnz3sPLm7Z0ntosd2r9fbb0tKl0mUOYAcAgOjC
LRNdFkt2GPKGDRvcmV0///yzmjZtqoEDB/7mYyysZsyY4ZYULlmyxL1v4sSJ+utf/6rjx48TXQCk
X36ROnaUSpaU8uWTmjSxKXL7qQ1jAwAgupC1osvYssDixYvrvvvu0z333KMXXnhB0dHRl33MwoUL
3b1fLVq00FtvvaXs2bOrc+fOmXqgY2Nj1b9/f+3atYvoAq7F7t3y/COSKlaUAgKk2rVt2lz67+Hr
AAAQXciS0WWbY9hsl720ZYZ2T1darVq1Sp9++qnbvfCHH37I9ANts3X23xIREZGmz7cDoYkuZHn2
99/CqmZNKTBQqlRJ6tdPSuMPLwAAILpwy0eXndNlW8HPmzfPxVda2XLEDz74wL1u937ZbNmRI0cy
7SDb7Nbw4cM1c+ZMN4uXFjt37iS6kDXZTqb2gxZbMliggFSihHcp4bp1jA0AgOgC0XUhC6YzZ87o
0KFDWrFihb7//nuFh4frxIkTv/kY207ezuh6++233ZI8s3TpUjVq1Ehnz57NcANo/422w2LK67zd
3J/Cl19+qaioKLcr44IFC5Lfb/e4Pfvss26Hx5RXrVq1VL58eeXMmTNTxyaQZnYshG1+8c470uOP
ew8ufvNNyf69eP5NAQBAdIHo+s3nUd7ztWxHwvHjx6tIkSIKDAzU3Llzf/MxFmRhYWGp3rdx40Z3
P1hGnPVZt26dO7zZlg6+9tpreuWVV/TZZ5+5+DIWm75dGGfPnq3ly5cnP9ZmswYMGODu9brwspm+
3Llzu9lC4Jb1r3/ZyehSqVLebd5tu/dJkzi4GABAdIHoSiuLJJu5KViwoJ588kkXGLaL4eUkJSW5
6OrVq5dbVvjVV1/pkUcecbM/5zLgT7xtJs+WTvqu/fv3u9kp++8wtntjp06d3H97kyZN1LFjxzTN
2NnsYHBwMMsLceuJipIGD/YeWBwU5D3AePhw+0vP2AAAiC4QXVf/3CpKVapUcRthJF7FmTkWMn37
9lW1atX0xBNPqE2bNpddkpiRxcTEuHu6LMjGjBnjZr3SMhbsXohbiv37tRns+vW9oVWunP1EwnaM
YWwAAEQXiK7rYfdnXchmunbs2JHm+LKdDy1SbEniuUx8b4fdl/b666+rT58+RBeyBvv3b0uJX3tN
nr/MUtGi0vvv282MNqXN+AAAiC4QXf4yZMgQ1a9f322E0aBBAz311FNq167dZR8zdepU93kVKlRQ
pUqVVKJECT3++ONXPN8rI7OZLtsyf+/evclLD4ku3JLWrJE6dPBGlsVW8+ZSeLg3wgAAILpAdPnX
5s2b9fzzz6tt27Z68cUX1b17dzVs2FDz58//zcfYzFYHzxO20aNHu8fZjocjRozQoEGD0hQrtwqi
C5nK9u3S559LTz3l3RDDDi4eP967rBAAAKILRNeNYzv32bboZsqUKe6lzfTY7NdvsXu3xo0b516P
jIx0hyqb1q1b6+jRo0QXkFHYcQajR0v//Kf3Pq3KlaVBg+wfOWMDACC6gPSKruPHj7sZrk8++UQR
ERFuiWGxYsXcGVyXM3LkSJUtW9Ztx/7OO++oVKlSKl68uE6dOkV0ATeTnZ03Y4Z3a/d8+aTSpeX5
B24nmjM2AACiC7gZ0WVsiaFt/W7srK7OnTun6cBf32YbtpmGLTG0e6KyEqILGYYd9r1kidSqlVS4
sFSokPfgYnvff8/iAwCA6ALSMbpsZ76vv/5ao0aNuqpt4i0y7ODgZcuWuWWFa9euTV5euGnTJrfV
ut3vRXQB6cRmr2wWy3dwcePG3lkum+0CAIDoAm5edMV6npDZYcB275Zvlmr48OFXPBT53XffVa5c
uVS4cGEVKlQo1WWHBFesWFFxcXFEF3Aj2f1Ydl+W3Z+VJ49Us6b3vq00zE4DAEB0AekUXbat+5w5
c5LftvOp7KDjK52x9avnL/G2bdvcfVsWbilnyeyxGzdudBFHdAF+dvy4NGGCd8dBC60KFaTevaWd
OxkbAACILmTU6PLdw2UsoGwTDR9bImj3eV3J+vXr1a9fP3355Zdp+nyiC7gK9gMMOzvr5Ze9Z2kV
KyZ98IH3jC0AAEB0IWNHV3x8vBo3bqySJUuqdOnSKlq0qAIDA1WmTBn3dkhIiJv5upxhw4Ype/bs
KleunNv9sG7dupo0aRLRBVwPmz22IxzatvUeXBwcLLVsKc2bJ509y/gAAEB0IbNEl913Zdu82/X+
+++rXbt2+uCDD9zrdrVo0cIddny5aLPt4X1ndRlbVmhne9kW9EQXcJW2bZN69JDKlvUuH6xfX/ru
O+nkScYGAACiC5kxuiyQrhQKhw4d+s2P2b1ctqzwwiWFKXcvzAohQnThuhw8KA0dKlWvLgUGSlWr
et++zL89AABAdCGTRNf1SkpK0meffeaCo169eqpfv76qVavmlijaMsOqniePdngy0YWszP4NtGnT
JvWxDNHR0uTJ0gsveLd4L1NG6tZN2rqVAQMAgOgC0ZVanz593LLE7t27u6tHjx764osv3Ou2VHHq
1KlEF7KsMWPG6Pbbb1e2bNn0+htvKGHxYu9hxXaPVpEidv6CtGyZ9x4uAABAdIHoupSzV7ipPyts
HU904UJJnmvoyJG6/fe/d8Hlu5p5rtjnnpNmzrSbKhkoAACILhBdILpwLWze6v033kgVXHaVLl9e
x69wDh4AACC6QHSB6MLlxMdLX36pxEKF9L7n8gVXhQoV9G/+jgAAQHSB6ALRheswYYL3XK3ixSU7
r86OZXj3XVWqVElHjx5lfAAAILpAdIHoQlrYUQkLFiz4v3fMnSuVLy8VKCANGnTRAcZZ4d5GAACI
LhBdILrgF926dXPLBe974AEt+eYbqVkzKSBA+ugjidksAACILhBdILpwbWy2qlOnTqk2xrjfc4WX
KKGkHTsYIAAAiC4QXSC6cD0OHz6sXLlyXbQj4ZsdO7ot4gEAANEFogtEF67TL+vWKaBAgeTgevHF
FxVz6hQDAwAA0QWiC1eSmJio/fv3e/59/uquY8eOEV24pA0tWijwttv0wksvXfFwcAAAQHSB6MJ/
7dixQ82bN9eAAQPUu3dvrVy5kujCxbZvl/Lk0Z5Zs3Tm/HnGAwAAogtEF9Jq48aNGjt27DU9dteu
XQoODia6soK2baWGDRkHAACILhBduFqbNm3Shx9+qGnTpik0NFR79+5N9fG4uDi3/PDC68CBA1q4
cKEKFChAdGWFb+JBQdLy5YwFAABEF4guXMgCaeLEiclXWFiY5s2b5+7lMhZMQ4cO1dKlSzV37lx1
7txZhw4dSn58RESE59/vYy6u7KXvsmWFtqNdjhw5dOTIEQb6Vtanj1SxIuMAAADRBaILl7J161b1
6NFD3bt3dy+7du2qMWPGKCEh4ZKfv3jxYn333XfJb8fGxmrbtm0XXXYv2OzZs5U/f35mum5lcXFS
SIg0eTJjAQAA0QWiC1crKSkpecbLZ8mSJZowYUKaHr97927u6brV2d+FokUldisEAIDoAtGFq2fB
NW7cOP34448unGwGq1OnTm6DjLRg98Jb/i+IVLq0NHgwY1u7NJwAAAxoSURBVAEAANEFogvXyjbE
sHu6bLt4u9asWZPmxxJdt7iICClfPun4ccYCAACiC0QXrte5c+eu+jFE1y2uTh3po48YBwAAiC4Q
XbhZiK5b2MaN0qOP2o17jAUAAEQXiC4QXfC711+XWrRgHAAAILpAdIHogt8dOCAFBEjr1jEWAAAQ
XSC6QHTB7z79VKpRg3EAAIDoAtEFogt+d/KklD+/9NNPjAUAAEQXiC4QXfC7ESOkkiWlhATGAgAA
ogtEF4gu+JUdG1CsmDR2LGMBAADRBaILRBf8buZMKSREio1lLAAAILpAdIHogt9VrSr16ME4AABA
dIHoAtEFv/v5Z+828QcPMhYAABBdILpAdMHvmjaV2rRhHAAAILpAdIHogt/t2CE9+qi0eTNjAQAA
0QWiC0QX/K59e6l+fcYBAACiC0QXiC743bFjUp480tKljAUAAEQXiC4QXfC7/v2lChWkpCTGAgAA
ogtEF4gu+NWZM95zuSZNYiwAACC6QHSB6ILfhYV5oys+nrEAAIDoAtEFogt+lZgolSsnDRjAWAAA
QHQBRBfRBb9bvNi7gYZtpAEAAIguEF0MAdEFP3vuOalDB8YBAACiCyC6iC743caN3sOQd+1iLAAA
ILoAoovogt+9+abUtCnjAAAA0QUQXenp8OHDmjBhgoYMGaI9e/YQXbeqqCgpIEBauZKxAACA6AKI
rvSyefNmde7cWeHh4Vq9erUOHTpEdN2qunWTatRgHAAAILoAoiu9nD59Wj179tSJEyeu+rFRUVEK
Dg4mujKLmBjvN+NZsxgLAACILoDoSi9r167V5MmTtWLFCo0bN067d+9O9fG9e/dq5MiRF12jRo1S
165dFRgY6Pk3/m8GMjPw/LmpWDHp3DnGAgAAogsguvxl06ZN+vjjj1Ndw4YNU0JCgvv43Llz9dpr
r7n3zZ49W71793b3d/lERkaqSpUqqly5snvpu6pWrapSpUopZ86cRFdmYH/exYt7wwsAABBdANHl
P3Z/1o8//ph8zZo1S8uWLVNiYqL7uIVWixYtkj9/1apVmjRpUpq+9q+ef9Tc05VJhIdL+fJ5lxgC
AACiCyC60s/+/fv1+eefJ7/9888/a8qUKWl67Pbt24muzKJqValrV8YBAACiCyC6bobQ0FB3RURE
qHv37qmWF14OuxdmEmvWSLly2bQnYwEAANEFEF03Q1JSktsufvTo0dqxY0eaH0d0ZRLNmkmtWjEO
AAAQXQDRldkQXZnAzp3So4/aYWyMBQAARBdAdBFd8LsPPpDq1WMcAAAgugCii+iC3x09KuXJI82f
z1gAAEB0AUQX0QW/GzhQKlfObtpjLAAAILoAoovogl/Fx0tFikhhYYwFAABEF0B0EV3wOzvgumBB
KS6OsQAAgOgCiC6iC35lywkrVpT692csAAAgugCii+iC3y1ZIgUGSvy5AABAdAFEF9GFG+D556X3
3mMcAAAgugCii+jCDfhDkXLl8h6KDAAAiC6A6CK64GetW0uNGzMOAAAQXQDRRXTB7w4d8s5yrVrF
WAAAQHQBRBfRBb/r2VOqVo1xAACA6AKILqILfhcb6/1GO306YwEAANEFEF1EF/wuNFQqVkw6f56x
AACA6AKILqILfpWQIJUuLQ0fzlgAAEB0MRYguogu+F14uJQ/vxQdzVgAAEB0MRYguogu+F3NmlKX
LowDAABEF9EFoovogt/98ouUO7e0fz9jAQAA0UV0gegiuuB3r7witWzJOAAAQHQRXSC6iC743d69
3sOQN2xgLAAAILqILhBdRBf8rmNH6dlnGQcAAEB0gegiuuB3J05IQUHSvHmMBQAAILpAdGVkCQkJ
Gjx4sHr06KG+ffuqT58++uKLL3TmzBmiKyMbOlQqW1ZKTGQsAAAA0QWiKyM7f/68Zs6cqZ07d2r/
/v3asWOHOnTooFOnTl3xsb96/lETXTfB2bNSkSLS+PGMBQAAILpAdGU2u3bt0ogRI9L0ufv27VNw
cDDRld6mTJFn4KW4OMYCAAAQXSC6MoJz587pxIkTydfx48cVExOjpKSkiz53/PjxioyMTH579erV
euGFF9SgQYNUV8OGDVW9enU9/PDDnn/j/2aQ04v9mVWuLPXpw1gAAACiC0RXRrF+/Xq1bNlSr732
mnvZokULffbZZy7GUrKlhr1791Z0dHTy++y+rU8//VSffPKJe+m7unTpolatWikgIIDoSk9Ll3oP
Qz5yhLEAAABEF4iujCKtM1179+7VwIED0/x1Dx8+rJCQEJYXpqcXXpDef59xAAAARBeIrsxo0qRJ
mncVW5Cze2E6s2+iAQHSjh2MBQAAILpAdGVGoaGhVxVQRFc6e+cdqVEjxgEAABBdILoyK7un62oQ
XenI7uEKDJSWL2csAAAA0QWiK6sgutKR7Vb49NOMAwAAILpAdBFd8LvTp73nck2bxlgAAACiC0QX
0QW/GzdOKlrUtqFkLAAAANEFoovogl8lJEilS0tDhzIWAACA6ALRRXTB7+bOlfLmlU6cYCwAAADR
BaKL6ILf1a4tffIJ4wAAAIguEF1EF/xu/XopVy5p3z7GAgAAEF0guogu+F3LltKrrzIOAACA6ALR
RXQRXX63f78UECCtW8dYAAAAogtEF9FFdPmd3cdVsybjAAAAiC4QXUQX0eV30dFSgQLenQsBAACI
LhBdRBfR5WfDhnnP5kpMZCwAAADRBaKL6CK6/OrcOaloUSk0lLEAAABEF4guoovo8rsZM6TgYCk2
lrEAAABEF4guoovo8rvKlaWePRkHAABAdIHoAtHld8uXS7lzS4cPMxYAAIDoAtEFosvvXnxRevtt
xgEAABBdILpAdPnd9u3So49KW7cyFgAAgOgC0QWiy+/ee09q2JBxAAAARBeILhBdfmfjFxgoLVvG
WAAAAKILRBeILr/r21cqX15KSmIsAAAA0QWiC0SXX8XFec/l+v57xgIAABBdILpuZbGxsVqzZo32
799PdKWTBPufCROkwoWls2cZEAAAcO1iYpQQEiLt2cNYgOjKiKKiotSrVy8NHTpUPXv21KJFi4iu
G2zDhg0q//TTmmv3coWGMiAAAOC6LFm4UOX/+letiohgMEB0ZURffvml1q1b516Pj49Xly5dFBMT
c8XH7dy5k+i6Bps3b1ZQUJCyZcum+zzXgvBwBgUAAFyzyMhI/T1HDvfc4pFcubR27VoGBURXRjNs
2DBt2bLFvZ6UlKTevXsnR9e5c+d0/PhxHTt2zL1Mef3888967LHHiK6rsH79ej300EPum6Lv+svd
d2vevHkMDgAAuGpLlizRX//611TPLe6//36tXLmSwQHRlZ6OHDmiOXPmJF+zZ8/W8uXLlZiY6D5u
0fTGG2+ob9++at26tRYuXJj82AULFig4ONjNaKW87H25cuXSXXfdpcOHDzPI1xFd2bNn1/z58xkc
AABwTdF17733pnpu8be//U2rVq1icEB0paetW7fq448/Tr46deqkr776SufPn3cfnzt3rgYPHuyW
vU2fPl2DBg1K/lh0dLTbYOPCy6atIyIi9NFHH+nUqVMM8lWwcc6TJ4/7pvhAjhxavHgxgwIAAK7Z
ihUrlOO/ywvth+K+20YAoisD6dGjh06cOJHq7aNHjzIwN9CGX35Rxb/9TfMnTmQwAADAdVu6dKkq
VKjgfjgOEF0Z0NSpU90Ml93HtWnTJg0YMMBtqIEb6Px5JZYsKa1ezVgAAAC/8N06AhBdGZBtlhEa
Guo20LDg2rdvH4Nyo9mSzOLFpWXLGAsAAAAQXVmnA7g3i+gCAAAA0QUQXQAAAADRBRBdAAAAILoA
ogsAAAAgukB0AQAAAEQXQHQBAACA6AIyiLg46cknpchIxgIAAABEF+BvCadPa2RIiKJXrGAwAAAA
QHQB/pSUlKRWrVop2223qXadOoqNjWVQAAAAQHQB/hAdHa2WLVsqW7ZsyVetWrV08OBBBgcAAABE
F3C9IiIiUgWX7woNDWVwAAAAQHQB1+v8+fPq3bt3quBq27at4mxjDQAAAIDoAvzDwuv222/Xu+++
y2AAAACA6AJuhEWLFikxMZGBAAAAANEFAAAAAEQXAAAAAIDoAgAAAACiCwAAAACILgAAAAAA0QUA
AAAARBcAAAAAEF0AAAAAAKILAAAAAIguAAAAAADRBQAAAABEFwAAAAAQXQAAAAAAogsAAAAAiC4A
AAAAILoAAAAAAEQXAAAAABBdAAAAAHAL+//O0YfEHlqdmwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Billede2.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis of seven trials on tranexamic acid versus placebo or no intervention. Outcome measure is bleeding. Analysis was performed with alpha 5% and power 80%. Model-based heterogeneity correction was 53%, relative risk reduction 30% and control group incidence 10%. Graph shows the Z-curve, which is the cumulative result of analysis with trials added according to year of publication. Horizontal line represents 'traditional' 5% level of significance, and inward sloping red line shows trial sequential monitoring boundary. Vertical line represents required information size. Analysis shows that the Z-curve does not cross the trial sequential monitoring boundary, and the total number of participants (N = 1651) is 95% of required information size (N = 1734). The meta-analysis therefore remains inconclusive.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAyYAAAJOCAYAAABC5xOxAACAAElEQVR42uzdB5yU1d32ceKbvHme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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-07-01 14:55:26 +0100" MODIFIED_BY="Karin L Dearness">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>CENTRAL July 2014 </B>
</P>
<P>#1 stomach or antrum or antral or pyloric or pylorus or gastri* or epigastr* or duodenal or duodenum or gastro-duodenal or gastroduodenal or oeso*ag* or esp*ag* or upper GI or UGI or upper gastrointestinal</P>
<P>#2 h*emorrhag* or bleed* or re-bleed* or rebleed*</P>
<P>#3 (#1 AND #2)</P>
<P>#4 MeSH descriptor Gastrointestinal Hemorrhage explode all trees</P>
<P>#5 Gastrointestinal Hemorrhage</P>
<P>#6 h*ematemesis</P>
<P>#7 (#3 OR #4 OR #5)</P>
<P>#8 tranexamic acid or amchafibrin or anvitoff or cyklokapron or Espercil or exacyl or lysteda or spotof or t-amcha or tranhexamic acid or transamin or Transcam or ugurol</P>
<P>#9 (#7 AND #6)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-07-01 14:55:13 +0100" MODIFIED_BY="Karin L Dearness">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Ovid MEDLINE 1950 to July 2014 </B>
</P>
<P>1. (stomach or antrum or antral or pyloric or pylorus or gastri$ or epigastr$ or duodenal or duodenum or gastro-duodenal or gastroduodenal or oeso*ag* or esp*ag* or "upper GI" or UGI or "upper gastrointestinal ").mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>2. (h*emorrhag$ or bleed$ or re-bleed$ or rebleed$).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>3. 1 and 2</P>
<P>4. exp Gastrointestinal Hemorrhage/</P>
<P>5. h*ematemesis.mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>6. or/3-5</P>
<P>7. ("tranexamic acid" or amchafibrin or anvitoff or cyklokapron or Espercil or exacyl or lysteda or spotof or t-amcha or "tranhexamic acid" or transamin or Transcam or ugurol).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>8. 6 and 7</P>
<P>9. randomized controlled trial.pt.</P>
<P>10. controlled clinical trial.pt.</P>
<P>11. randomized.ab.</P>
<P>12. placebo.ab.</P>
<P>13. drug therapy.fs.</P>
<P>14. randomly.ab.</P>
<P>15. trial.ab.</P>
<P>16. groups.ab.</P>
<P>17. or/9-16</P>
<P>18. exp animals/ not humans.sh.</P>
<P>19. 17 not 18</P>
<P>20. 8 and 19</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-29 08:21:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-07-01 14:55:34 +0100" MODIFIED_BY="Karin L Dearness">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 08:21:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>EMBASE 1980 to July 2014 </B>
</P>
<P>1. (stomach or antrum or antral or pyloric or pylorus or gastri$ or epigastr$ or duodenal or duodenum or gastro-duodenal or gastroduodenal or oeso*ag* or esp*ag* or "upper GI" or UGI).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>2. (h*emorrhag$ or bleed$ or re-bleed$ or rebleed$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>3. 1 and 2</P>
<P>4. gastrointestinal hemorrhage/</P>
<P>5. duodenum bleeding/ or stomach hemorrhage/ or upper gastrointestinal bleeding/</P>
<P>6. h*ematemesis.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>7. or/3-6</P>
<P>8. ("tranexamic acid" or amchafibrin or anvitoff or cyklokapron or Espercil or exacyl or lysteda or spotof or t-amcha or "tranhexamic acid" or transamin or Transcam or ugurol).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>9. 7 and 8</P>
<P>10. Clinical trial/</P>
<P>11. Randomized controlled trial/</P>
<P>12. Randomization/</P>
<P>13. Single-Blind Method/</P>
<P>14. Double-Blind Method/</P>
<P>15. Cross-Over Studies/</P>
<P>16. Random Allocation/</P>
<P>17. Placebo/</P>
<P>18. Randomi?ed controlled trial$.tw.</P>
<P>19. Rct.tw.</P>
<P>20. Random allocation.tw.</P>
<P>21. Randomly allocated.tw.</P>
<P>22. Allocated randomly.tw.</P>
<P>23. (allocated adj2 random).tw.</P>
<P>24. Single blind$.tw.</P>
<P>25. Double blind$.tw.</P>
<P>26. ((treble or triple) adj blind$).tw.</P>
<P>27. Placebo$.tw.</P>
<P>28. Prospective study/</P>
<P>29. or/10-28</P>
<P>30. Case study/</P>
<P>31. Case report.tw.</P>
<P>32. Abstract report/ or letter/</P>
<P>33. or/30-32</P>
<P>34. 29 not 33</P>
<P>35. 9 and 34</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-07-29 07:45:00 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-07-01 14:56:52 +0100" MODIFIED_BY="Karin L Dearness">Science Citation Index search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-29 07:45:00 +0100" MODIFIED_BY="[Empty name]">
<P># 7 #6 AND #5</P>
<P># 6 TS=(random* or blind* or placebo* or meta-analysis)</P>
<P># 5 #4 AND #3</P>
<P># 4 TS=(tranexamic acid)</P>
<P># 3 #2 AND #1</P>
<P># 2 TS=(oeso*ag* or eso*ag* or stomach or gastric or ventricular or duodenum)</P>
<P># 1 TS=(bleeding or hemorrhage or haemorrhage or re-bleeding or (recurren* and (bleed* or haemorrhage or hemorrhage)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-08-07 13:29:59 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-07-30 10:47:19 +0100" MODIFIED_BY="[Empty name]">International Clinical Trials Registry Platform (ICTRP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-08-07 13:29:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>ICTRP July 2014</B>
</P>
<P>(bleeding OR "BLEEDING" OR "Blood Loss" OR "EXTRAVASATION BLOOD" OR "HAEMORRHAGE NOS" OR "HEM" OR "hemorrhage" OR "HEMORRHAGE (NOS)" OR "HEMORRHAGE NOS" OR "Hemorrhage, unspecified" OR "Hemorrhages" OR "Loss of blood" tranexamic acid OR "Acid, Tranexamic" OR "AMCA" OR "AMCHA" OR "Cyclokapron" OR "Cyklokapron" OR "t-AMCHA" OR "TRANEXAMIC ACID" OR "trans-4-(Aminomethyl)cyclohexanecarboxylic Acid" AND (tranexamic acid OR "Acid, Tranexamic" OR "AMCA" OR "AMCHA" OR "Cyclokapron" OR "Cyklokapron" OR "t-AMCHA" OR "TRANEXAMIC ACID" OR). "trans-4-(Aminomethyl)cyclohexanecarboxylic Acid")).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-07-24 14:02:12 +0100" MODIFIED_BY="[Empty name]">Search results</TITLE>
<APPENDIX_BODY MODIFIED="2014-11-05 14:51:38 +0000" MODIFIED_BY="[Empty name]">
<P>Eighty records were identified by initial electronic searches of the following databases.</P>
<UL>
<LI>CENTRAL: 10 citations.</LI>
<LI>MEDLINE: 22 citations.</LI>
<LI>EMBASE: 62 citations.</LI>
<LI>Science Citation Index: 6 citations.</LI>
</UL>
<P>Thirty-seven additional records were identified in the search update performed July 2014 (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 randomised trials included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 randomised trials (described in 10 references) included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;15 records retrieved for further assessment of eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;122 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;121 hits identified through database searching (84 hits in the original and 37 hits in the updated search)&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;One additional record identified through other sources&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;107 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;One ongoing trial and 4 full-text articles (three trials on cetrexate or patients without upper gastrointestinal bleeding and one observational study) excluded.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>